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1.0 Introduction  
As military technology advances, modern warfare has caused more devastating injuries to 
soldiers on the battlefield. In parallel with the advancements in modern warfare, the survival rate 
of critically wounded soldiers has improved with better trauma wound care (Devore, 2011). As 
more soldiers survive their combat wounds, they must face the consequences of devastating 
functional and morphological skeletal muscle tissue damage. During the most recent military 
operations, Operation Iraqi Freedom and Operation Enduring Freedom, an estimated 82% of the 
soldiers injured on the battlefield suffered from at least one musculoskeletal extremity wound 
(Devore, 2011). These combat wounds can cause volumetric muscle loss (VML) where severe 
muscle damage results in inadequate functional recovery. Furthermore, there are many more 
causes of VML other than wound trauma, such as accidents including car crashes, sports injuries, 
and burns (Eckardt, 2003). 
Skeletal muscle accounts for 40% of the adult human body’s mass, and as robust as it is 
in terms of responding to physiological changes, can be damaged by an injury which can affect 
its ability to remodel, repair, and regenerate (Yin, 2013). Skeletal muscle is composed of 
myofibers, neurons, vasculature networks, and connective tissue (Yin, 2013).  The innate skeletal 
muscle regeneration capacity is directed by satellite cells (SCs) or skeletal muscle stem cells 
(Yoseph, 2015). Quiescent SCs become activated during injury to reconstruct muscle tissue 
(Tedesco, 2010).  However, when skeletal muscle is damaged significantly, native SCs and their 
microenvironment are compromised, hindering the body’s natural ability to direct regeneration 
(Yoseph, 2015). 
Current solutions for the treatment of VML consist of autologous tissue transfers from 
other healthy regions of the patient’s body to the injury site. Despite being the most common 
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treatment method, these grafts can result in failure, scar tissue formation and necrosis (Eckardt, 
2003). For these wounds to be treated more effectively and consistently an alternative solution 
must be developed. 
Myofibers are the structural and functional element of skeletal muscle, and each one is 
encased by a basement membrane where SCs reside (Sanes, 2003). VML results in the 
destruction of the basement membrane, causing the wound site to lose the necessary cues 
provided naturally by this layer (Yin, 2013).  The lack of basement membrane impairs muscle 
regeneration since SCs no longer have guides or cues that promote migration and alignment 
(Tedesco, 2010). Additionally, the lack of muscle tissue is coupled with a lack of structural 
support for cellular growth at the wound site.   
SCs are considered the initial guides that trigger muscle regeneration. Researchers have 
investigated how the niche, or biological environment of SCs may guide their performance 
(Yoseph, 2015). The SC microenvironment consists of extracellular matrix (ECM), vascular and 
neural networks, growth factors (GFs), and cytokines (Yoseph, 2015). By understanding their 
niche, tissue engineers may be able to develop therapies to successfully treat VML. The goal of 
these tissue engineered strategies is to provide auxiliary cues, often using natural chemicals, to 
signal the body to regenerate the damaged or missing muscle tissue.   
Biomimetic scaffolds are engineered to mimic the endogenous SC niche to induce the 
activation of SCs from surrounding tissue for muscle regeneration at the wound site. (Bae, 2012; 
Cezar, 2015; Yin, 2013). By implanting an engineered scaffold, it can act as a source of nutrients 
and delivery vehicle for GFs, provide topographical cues for cellular alignment, as well as 
provide temporary structural support at the injury site (Ahmed, 2008; Cornwell, 2007). Another 
11 
 
benefit of tissue engineered scaffolds is its 3D structure that has been shown to induce cell 
differentiation, similar when in native ECM (Chen, 2015). 
A promising material for biomimetic scaffolds is fibrin, the polymerized product of the 
glycoprotein fibrinogen and the enzyme thrombin (Cornwell, 2007). Fibrin is advantageous 
because of its modular and tunable capabilities (Grasman, 2012; Grasman, 2015). Fibrin is also 
an important factor in wound healing and tissue repair (Cornwell, 2007). Fibrin's matrix 
facilitates tissue regeneration by promoting migration, adhesion, and proliferation of cells while 
directing cell signaling via integrin-based mechanisms (Clark, 2001). For instance, fibrin 
microthreads, fibrin extruded into long thin threads, have been used for the restoration of VML 
defects in the skeletal muscle of mouse models (Page, 2011).The fibrin microthreads were 
created because they are similar to the hierarchical cable-like structure of skeletal muscle fibers 
(Grasman, 2015; Page, 2011). GFs can be incorporated into fibrin to facilitate controlled release 
to enhance skeletal muscle regeneration (Grasman, 2015) Although fibrin has advantageous 
properties, some limitations include rapid scaffold degradation and the GF release is still too 
rapid and not able to sustain its release for effective skeletal muscle regeneration (Grasman, 
2015) 
The goal of the project was to make progress towards the development of a fibrin-based 
scaffold to treat VML in a clinical setting. Specifically, the project aims were to create a platform 
technology using a fibrin composite scaffold that will release growth factors in a controlled 
manner while being user friendly, easy to handle and providing structural support. Finally, it will 
allow for further development by future MQP groups to expand, layer or potentially stack the 
composite for a full-thickness model. 
The project involved designing, developing and testing a tissue engineered scaffold for 
the regeneration of skeletal muscle tissue. A series of Gantt charts, Appendix A, were used to 
12 
 
track the team’s progress. The design team worked with the clients and users to develop a set of 
objectives and constraints for the scaffold. From the initial set of objectives, the design team 
interviewed clients and users and reviewed current literature to refine and expand the objectives 
to encompass the project goals. A list of constraints were utilized, Appendix B, in order to limit 
the project’s scope. Additionally, the team defined sub-objectives for each of the main 
objectives. The sub-objectives were defined to further clarify the important aspects for the 
project. 
Once the objectives were finalized, the clients, users and designers conducted comparison 
analysis to determine the most important scaffold properties. It was determined that developing a 
scaffold that promoted myogenesis, was reproducible, had robust properties, and was user 
friendly were the most important features for the scope of the project. The design team then used 
these prioritized objectives to develop a series of needs, or requirements of the scaffold, which 
were translated into the five primary scaffold functions: 
1. Fabricated with over 90% success and require under 2 hours user labor 
2.  Promotes cellular viability without significant difference between composite and 
positive control 
3. Slows degradation to preserve partial structural integrity for two weeks 
4. Promotes nuclear alignment along fibrin threads at angles <10 degrees relative to 
the thread 
5. Releases 10 ng of FGF-2 over a period of two weeks 
After functions were developed to satisfy the needs, different possible solutions were 
researched to carry out the functions, known as means. The means were then ranked based on the 
priority objectives to see which would be the best at accomplishing their specific function. Once 
the means were ranked, a series of feasible designs were created by identifying the highest 
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ranked combinations of means for each function. After doing an analysis of all the possible 
designs, a final design of a fibrin film with fibrin microthreads, controlled release of FGF-2 
loaded to the surface using heparin immobilization, and chemically crosslinked was evaluated to 
have the highest success rate. 
Once the final design was selected, experimentation was conducted to optimize the 
design. Initially, feasibility studies were performed to test different steps of the protocol and try 
to maximize the number of usable scaffolds during production and reduce user labor time. These 
tests were successful and allowed the design team to move forward with validating that it was 
user friendly, easy to handle and required little user labor. The scaffold was analyzed for release 
of FGF-2 using an ELISA (Peprotech) to monitor release kinetics of the GF from the scaffold. 
Additionally, an aresazurin assay was used to characterize cell viability, Hoechst stain to allow 
for visualization of cellular alignment along the threads and a protocol was developed to analysis 
the degraded area of scaffold over time to study crosslinking efficacy.  
Through these experiments, the team was able to conclude that the scaffold allows for 
controlled release of FGF-2 over 14 days with and without heparin immobilization to the surface. 
The scaffold was able to promote cellular viability just as well as a positive control tissue culture 
plate without a significant difference. The incorporation of fibrin microthreads increased cellular 
preference for alignment compared to cells placed on a film scaffold. Finally, chemical 
crosslinking of the composite preserved 94% of the composite area after 14 days with cells 
seeded on the scaffolds and left in media. Overall, the composite scaffold is a successful 
structurally supportive, user friendly scaffold that delays degradation and releases growth factor 
for two weeks while promoting cellular viability and alignment.  
The major aim of this project was to create a functional composite scaffold that can be 
developed into  a full-thickness scaffold in the future. Further characterization and modification 
14 
 
of the scaffold components are required before moving forward with creating a functional 
composite scaffold. For instance, the experiments that would need to be completed, is a 
functional assay of the composite loaded with growth factor and cells to quantify cell 
differentiation and observe myotube formation, as well as long-term experiments to test the 
scaffold over the 3-6 week long repair phase. Once the components are optimized, future work 
with the fibrin-based scaffold could focus on the creation of a full-thickness scaffold. The 
scaffold will also need to be further characterized and tested in-vivo. Although this scaffold is for 
skeletal muscle regeneration after traumatic injury, in the future, it may be possible extended to 
other skeletal muscle loss such as aging, disease, or inactivity.  
2.0 Literature Review  
The literature review includes an overview of volumetric muscle loss (VML), including 
the causes, prognosis, and current treatment methods. By identifying insufficiencies in the 
current treatments, the need for a tissue engineered scaffold becomes clear. The properties and 
natural regeneration of skeletal muscle tissue were also reviewed to further understand and 
identify important aspects of the process. By further understanding the process of skeletal muscle 
regeneration, endogenous cues can be incorporate into a tissue engineered scaffold to improve 
regenerative capabilities. This chapter is a review of current technologies in research that explore 
scaffolds as a solution along with their advantages and disadvantages.  
2.1 Volumetric Muscle Loss (VML) 
Each year, VML injuries that occur as a result of combat injuries, car accidents, sports 
injuries, tumor ablation procedures, and reconstructive surgeries affect 5.8 million Americans 
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and account for 20 billion dollars in health care expenses (ASPS, 2015). This type of injury is 
characterized by extensive musculoskeletal damage that hinders functional regeneration. VML 
injuries usually involve the loss of 20% or more volume of muscle in a particular area of the 
body (Turner, 2013). The majority of combat wounds are extremity injuries, 53% of which 
involve VML (Owens, 2008). Additionally, 64% of all soldiers who are considered unfit for 
continued duty are those with VML (Owens, 2008; Masini, 2009). Although these injuries are 
not always life-threatening, they can severely impact the quality of life of patients. Chronic pain 
for the remainder of a patient's life often occurs due to the large-scale loss of the muscle tissue. 
Significant loss of muscle tissue results in limited functional regeneration and the formation of 
nonfunctional scar tissue. The destruction of the basement membrane, which normally contains 
GFs, SCs, and other biochemical cues, results in inhibited regeneration (Turner, 2012). 
2.1.1 Current Treatment Methods for VML 
If VML injuries are acute, physical therapy may be sufficient (Dziki, 2016). However, in most 
cases surgical intervention is required. The current gold standard for the treatment of VML is autologous 
tissue transfer, in which several studies have been performed with in vivo models and in vitro models. 
This is a surgical procedure in which muscle tissue is removed from a healthy area and grafted 
onto the site of the injury (Eckardt, 2003). This procedure has many limitations because it is 
complicated, time consuming, and does not consistently achieve functional muscle regeneration 
(Äärimaa, 2004). Additionally, 10% of these surgeries result in infection or tissue necrosis 
(Eckardt, 2003). Many patients with a tissue graft experience chronic pain for years after the 
surgery, which in some cases can be so severe that patients request amputation (Huh, 2011). 
To understand how debilitating VML injuries are, in vivo models were used to study the 
viability of tissue grafts in repairing muscle function. In a study of quadricep grafts in rats, 
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significant loss of muscle function was observed, with the injured legs exhibiting 55% less 
strength than the uninjured control legs, four weeks after the injury (Li, 2014). Extensive fibrosis 
was observed that resulted in scar tissue formation. Muscle contractility measurements showed 
an extreme reduction in strength. In Figure 1, the control images show that collagen fibers are 
not present in healthy muscle tissue.  The lack of organization of the extracellular matrix (ECM) 
due to the orientation of the autograft inhibited functional recovery of the muscle, which is 
consistent with much of the literature that suggests that structural alignment is necessary for 
functional recovery. In addition, peripheral nerve damage caused severely hindered muscle 
function, highlighting the importance of innervation in muscle regeneration (Li, 2014). 
  
Figure 1: Histologic sections showing collagen fibers within regenerated muscle tissue stained using hemtatoxylin and eosin 
(H&E) and Masson’s Trichrome. (Li, 2014). 
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 Garg et al. performed a study in a rat “open fracture” model with VML. Male Lewis rats 
were divided into four experimental groups: Sham-operated, Osteotomy, VML injury, and 
Osteotomy + VML injury (Garg, 2015). The sham group was uninjured, the Osteotomy group 
had a piece of the tibia surgically removed, the VML injury group had tibialis anterior (TA) 
muscle injury, and the Osteotomy + VML injury group had both. Persistent functional deficits 
were found as well as increased stiffness due to scar tissue formation in the groups with VML. It 
was shown that VML resulted in weak repair tissue that persisted even after bone healing. The 
maximal force was significantly decreased in the Osteotomy + VML injury group and the VML 
injury group only compared to the Osteotomy only group and the uninjured sham. It was also 
found that the severity of muscle functional deficits was dependent on the length of the muscle 
and the joint angle (Garg, 2015). This study among many others shows that VML is a severely 
debilitating injury that requires either physical therapy, which does not correct muscle deficit, or 
surgical muscle transfers, which lack in restored function, indicating a need for a better and more 
reproducible way of treating VML  (Dziki, 2016; Garg, 2015). 
2.1.2 Clinical Need 
Although current studies have furthered the understanding of VML, they have not 
resulted in a standardized or consistent strategy to address VML or restored muscle function (Li, 
2014). Moderate success has been achieved but the persistence of functional deficits in the 
injured area highlight the need for an improved treatment of VML that promotes functional 
regeneration of muscle tissue.  
In addition to the lack of functional muscle or healing occurring with physical therapy or 
orthotics, there are many limitations as mentioned above with the current treatment strategies. 
Current autologous transfer procedures involve the possibility for donor site morbidity and may 
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not provide an environment that is favorable for tissue reconstruction or angiogenesis (Dziki, 
2016).  Due to the numerous adverse effects of these currents treatments for VML, they result in 
muscle function deficiency weakness and overall reduced quality of life. Because of the inability 
of current VML solutions to restore skeletal muscle function, there exists a need for a solution 
that is induces muscle regeneration. 
2.2 Skeletal Muscle  
In order to assess the best solutions for VML, there needs to be an understanding of the 
structure and functions of native skeletal muscle, and more importantly, how the natural repair 
process takes place. A treatment method will need to mimic and function similarly to the highly 
aligned, innervated, and vascularized native tissue in order to signal the appropriate biochemical 
and biophysical cues for regeneration. An emphasis will be placed on recreating the processes 
and environment that occur during the repair phase of native muscle regeneration. 
2.2.1 Structure and Properties  
Skeletal muscle consists of highly innervated, and vascularized myofibrils that are 
aligned for contraction. The somatic motor neurons innervate the tissue branch to affect a 
number of muscle fibers. For skeletal muscle contraction to occur there needs to be an action 
potential signaled to the somatic motor neuron which controls several individual muscle fibers. 
These muscle fibers are multinucleated because of fusion between the myoblast cells. Resting 
directly above the myofibers are the motor units that consists of a somatic motor neuron and 
neuromuscular junctions to the myofibers, which facilitates contraction. These motor units are 
the endings to axons that originate from the spinal cord and are controlled by the central nervous 
system. Because a somatic motor neuron can stimulate many muscle fibers at once, it allows 
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contraction of the entire muscle to occur synchronously. This is also facilitated by the alignment 
of the muscle fibers and ability to contract in the same longitudinal direction (Fox, 1996). 
Surrounding the muscle fibers is the ECM made up of structural proteins including 
collagen (type I-IV) and elastin, and specialized proteins including fibronectin, various laminins 
and integrins, and proteoglycans. Within muscle tissue, a basement membrane encases each 
myofiber and provides structural support. The basement membrane, or basal lamina, is mainly 
composed of collagen and laminin proteins which are cross-linked together in a network of 
glycoproteins and proteoglycans (Sanes, 2003). Heparin sulfate proteoglycans modulate growth 
factor activity and protect them from denaturation and proteolytic degradation. They also 
collaborate with other components of the ECM to define the structure of the basement membrane 
(Sarrazin, 2011).  
Another important property of muscle tissue is vascularization. Within the ECM, the 
vasculature providing oxygen and nutrients to the muscle fibers and other cells located within the 
tissue. Compared to tissue such as bone, muscle tissue is highly vascularized (Sanes, 2003). 
Overall, it is important that muscle tissue consists of highly aligned myofibers that are innervated 
and vascularized to function properly.  
Another important component of skeletal muscle are the SCs beneath the basal lamina. 
SCs serve as myogenic precursors for muscle growth and repair. Specifically, SCs that express 
the transcription factor paired box 7 (Pax7) are required for skeletal muscle regeneration in 
response to injury (Cezar, 2015). SCs exhibit properties similar to archetypal stem cells and are 
essential in forming the basal origin of adult muscle regeneration. (Collins, 2005). The 
mechanism of how SCs function is shown in Figure 2. SCs are dormant until injury occur, at 
which point they are activated by growth factors such as HGF and FGF-2 to initiate muscle 
regeneration (Collins, 2005). SCs guide myogenic regulatory factors (MRF) such as MyoD, 
20 
 
Myf5, Myogenin, and MR4 which further promote SC proliferation. The proliferation of SCs is 
followed by differentiation and fusion to form multinucleated myofibers that allow for highly 
functional skeletal muscle (Yoseph, 2015). 
 
 
Figure 2: Satellite cell specification during the its development and activation, proliferation, and differentiation during a muscle 
injury (Yoseph, 2015) 
Numerous studies have since revealed that the proliferation and differentiation of SCs 
during muscle regeneration is profoundly influenced by innervation, vasculature, GFs, hormones, 
nutrition, and the extent of the injury (Bae, 2012; Yoseph, 2015). By mimicking the biological 
environment or niche, SCs can function better and effectively regenerate injured muscle tissue. 
2.2.2 Skeletal Muscle Regeneration  
Skeletal muscle has the innate capability of natural repair, which requires a complex, 
stepwise process and the coordination of a variety of cell types. However, this process, as 
described below, can only occur naturally in response to minor muscle damage from injuries 
such as small lacerations, contusions or sports-related tears (Cezar, 2015). When extensive 
damage has occurred due to severe trauma from vehicular accidents and combat injuries, factors 
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such as poor cell migration, and rapid death hinder the natural process. The three sequential, 
overlapping main phases of muscle regeneration are the inflammatory phase, the repair phase, 
and the remodeling phase (Cezar, 2015).  
During the inflammatory phase, the body breaks down and removes damaged tissue. 
Plasma membrane dissolution resulting from muscle fiber necrosis activates the complement 
cascade. Inflammation occurs as neutrophils migrate to the injury site within two hours to 
degrade damaged myofibers after necrosis has taken place (Tidball, 2010). The peak neutrophil 
concentration occurs between six and twenty-four hours. Myeloperoxidase (MPO) is released by 
these neutrophils and induces damage of the muscle membrane. Through the production of free 
radicals, neutrophils target the damaged debris from the membrane for phagocytosis (Nguyen, 
2005). Necrotic myofibers are engulfed via phagocytosis by pro-inflammatory M1 macrophages, 
which become the primary cell type at the injury site within two days (Tidball, 2010). Anti-
inflammatory M2 macrophages begin to replace M1 macrophages over the next three to seven 
days and increase myoblast proliferation and differentiation through the secretion of interleukin 
10 (IL-10), preparing the injury site for the next stage of regeneration, the repair phase (Deng, 
2012).  
The repair phase has a duration of three to four weeks and is characterized by satellite 
cell activation, proliferation, and migration, and is further broken down into two sub-phases. The 
first sub-phase is the recruitment and proliferation of SCs, which is triggered by the release of 
various growth factors such as hepatocyte growth factor (HGF), the only GF that brings SCs 
back into the cell cycle, from the ECM of muscle fibers, which triggers stimulation of satellite 
cell proliferation and chemotaxis (Tatsumi, 2004). Other GFs that are involved in signaling 
proliferation are insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor 
(VEGF), fibroblast growth factor-2 (FGF-2), fibroblast growth factor-6 (FGF-6), and platelet-
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derived growth factor (PDGF) (Tatsumi, 2004). These GFs are also present in the second sub-
phase, the differentiation phase (Ciciliot, 2010). As SCs proliferate, they typically migrate in a 
longitudinal direction along the myofibers (Charge, 2004). When SCs activate and reenter the 
cell cycle, they express myogenic factor 5 (Myf5), commit to myogenic differentiation, then 
express myogenic differentiation factor-1 (MyoD) (Cooper, 1999). A major issue in VML is that 
the basal lamina is ruptured, and the SCs lack the guidance to direct this cell migration and 
myogenic differentiation (Jarvinen, 2005). 
 The second subphase of the repair phase, the differentiation phase, is characterized by the 
differentiation of SCs into mature muscle fibers. Myogenesis occurs as myoblasts produce 
myogenin and begin to fuse together to form myofibers (Cornelison, 1997). Myogenesis is 
stimulated by IGF1 and IGF2 (Menetrey, 2000). IGF1 and IGF2 stimulate the proliferation and 
differentiation of myoblasts, which promote myofiber formation as more myoblasts are able to 
fuse together. Due to increased availability of insulin-like growth factor receptor-1 (IGRF1) in 
skeletal muscle, IGF1 has more of an influence in skeletal muscle regeneration than IGF2 
(Smith, 1999). The significance of IGF1 in regeneration has been determined by neutralizing 
IGF1, which inhibited regeneration (Lefaucheur, 1995). Furthermore, IGF1 has been injected 
into aged rats, to enable the restoration of satellite cells to proliferate (Chakravarthy, 2000). 
Temporal expression of another growth factor, HGF, for 48-72 hours in the proliferation phase 
has been shown to  inhibit the differentiation phase (O’Reilly, 2008).  For functional 
regeneration, vascularization and innervation must occur simultaneously to the process of 
myogenesis. IGF1 has been shown to induce sprouting of nerves during the repair phase, which 
is crucial for functional muscle contractility. At the same time, HGF and IGF2 promote 
angiogenesis through paracrine signaling (Christov, 2007).  Another factor that has been shown 
to be crucial for angiogenesis, which is crucial for skeletal muscle regeneration, is FGF-2 (Kim, 
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2010). FGF-2 has also been shown to facilitate myogenesis by recruiting additional satellite cells 
from the quiescent stage, thus increasing the number of proliferating satellite cells (Yablonka-
Reuvini, 1997).￼ 
 The final stage of skeletal muscle regeneration has the longest duration, on the order of 
three to six months, called the remodeling phase. Once myofibers are formed in the repair phase, 
they are able to further mature during the remodeling phase, as they fuse with the existing 
muscle at the site of the injury (Turner, 2012). Infiltration of fibroblasts, which can start as early 
as the inflammatory phase, continues into the remodeling phase and replaces damaged 
connective tissue. Fibroblastic infiltration is crucial for regeneration, but too much fibroblastic 
activity leads to increased collagen deposition, which remodels into non-functional scar tissue 
(Jarvinen, 2005). This is often seen in large injuries such as VML, whereas smaller injuries are 
typically able to recover without the formation of scar tissue. The destruction of the basal lamina 
by VML is another reason for increased scar tissue formation because the loss of biochemical 
signaling for satellite cell infiltration results in much higher fibroblast infiltration and a lack of 
myoblast formation and is shown in Figure 3 (Jarvinen, 2005).  
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Figure 3: Segments B, C, and D in the figure show the proliferation of satellite cells, their fusion into immature myofibers, and 
their fusion with existing healthy fibers. Segments E, F, and G show the inhibition of this process due to fibroblast infiltration and 
collagen formation, which occurs in VML as a result of destruction of the basal lamina. (Grasman, 2015). 
 
 Throughout the entire process of muscle regeneration, there is a delicate balance between 
formation of healthy tissue and scar tissue that is determined by the relative infiltration of 
satellite cells and fibroblasts. VML injuries inhibit the full capacity of the innate repair process. 
In order to promote this process, intervention is necessary to assist the natural repair process. 
2.3 Tissue Engineering Scaffolds 
 Tissue engineering has emerged as a promising solutions for the treatment of VML. 
Tissue engineering technology encompasses the use of tissue substitutes known as scaffolds for 
the functional reconstruction of damaged skeletal muscle. Scaffolds can be made from many 
different materials or combinations of materials, which can be modified for various applications. 
Benefits of using tissue engineered scaffolds include (Bian, 2008): 
1. The ability to engineer custom tissue architecture for precise structural repair at the injury 
site. 
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2. The ability to precondition tissue implants to specific mechanically or metabolically 
demanding environments. 
3. The ability to deliver molecules or cells upon implantation. 
4. The ability to guide cellular functions. 
When designing a scaffold, it is imperative to ensure that the microenvironment created 
by the scaffold incorporates cues that help signal the SCs to direct the body’s natural 
regeneration. Some of the cues that help signal SCs and help them function are shown in Figure 
4. For scaffolds to direct skeletal muscle regeneration it is imperative that they facilitate cell 
alignment, promote skeletal muscle formation, and stimulate vascularization and innervation 
(Grasman, 2015). Cell alignment is one of the most influential factors in regeneration. Other 
strategies to promote regeneration include the incorporation of GFs and peptide sequences within 
the materials of scaffolds (Grasman, 2015). These strategies involve incorporating cues that 
mimic the SC niche. 
 
Figure 4: Biophysical and Biochemical cues which make up the synthetic niche for satellite cells for regeneration (Cezar, 2015). 
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2.3.1 Current Scaffold Technology 
 There are many factors to consider when developing an effective scaffold to promote the 
regeneration of skeletal muscle. The generally accepted considerations are biocompatibility, 
promotion of native tissue infiltration, promotion of cell alignment, 3D organization, and 
biodegradability (de la Puente, 2014). Both synthetic and natural materials have been 
investigated for use in tissue scaffolds. A major issue with synthetic polymers such as Polylactic 
Acid (PLA) and Polyglycolic acid (PGA) is that the mechanism by which they degrade forms 
acidic byproducts that increase pH (Sung, 2004). This can be harmful to the native tissue around 
the implanted scaffold and lead to scaffold failure (Sung, 2004). Natural materials such as fibrin 
breakdown through known mechanisms in the body (Page, 2011). Some of the current natural 
scaffold materials that are being researched include fibrin, alginate, decellularized extracellular 
matrix, and collagen (Borselli, 2010). 
2.3.1.1 Cellular and Acellular Scaffolds 
 Current research into implantable scaffolds for the regeneration of VML is divided into 
two categories: cellular and acellular scaffolds. Cellular scaffolds are seeded with cells before 
implantation, while acellular scaffolds are devoid of cells upon implantation. Cellular scaffolds 
allow the seeded cells to incorporate with the native tissue, while acellular scaffolds require host 
cells to migrate into the scaffold (Burg, 2000). Scaffolds with seeded autologous cells may 
decrease the amount of foreign body response produced but can be very costly and time 
consuming due to the culture time needed (de la Puente, 2014). An additional limitation of 
cellular scaffolds is the size of the implant due to oxygen diffusion limitations (Corona, 2016). 
Acellular scaffolds provide an off the shelf treatment option for VML. The scaffold can be 
manufactured and packaged without needing to provide a strictly controlled sterile environment 
27 
 
or worry about cell apoptosis on the scaffold (Badylak, 2016). Fibrin, alginate, decellularized 
extracellular matrix, and collagen scaffolds can all be manufactured with or without cells upon 
implantation. 
2.3.1.2 Fibrin Scaffolds 
Fibrin is produced by the polymerization of fibrinogen and thrombin, which forms 
naturally in the body in response to tissue damage, to create a protein mesh that acts as a support 
in blood clot formation. Because fibrin is produced in the body, it allows the scaffolds to be more 
readily accepted by the body. Cells bind readily to fibrin, and the scaffold can also be loaded 
with GFs (de la Puente, 2011). This allows fibrin to be used as a scaffold for drug delivery to the 
surrounding tissue. Fibrin scaffolds allow for the proliferation of cells throughout the scaffold, 
are degradable, and are eventually replaced by extracellular matrix that is produced by the native 
cells (Huang, 2005).  Fibrin scaffolds can be produced in many forms such as gels and threads 
(Proulx, 2011). 
Huang et al. studied the formation of functional muscle in vivo through the use of fibrin 
gels (Huang, 2005). Myoblasts were isolated from the left tibialis anterior muscle of rats,  seeded 
into well plates, and after five days of cell culture, seeded onto a fibrin gel. After two days, 
myotube formation was observed, after five days the contraction of the gel was almost finalized, 
and after eight days the engineered structure was electrically stimulated. Upon stimulation, the 
engineered muscle produced length-tension trends that were characteristic of skeletal muscle. 
The engineered muscle, however, was only able to produce a fraction of the force that skeletal 
muscle is able to produce and the myotubes formed were only about a tenth of the size of native 
skeletal muscle (Huang, 2005). 
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Page et al. studied the regeneration of muscle defects through the use of fibrin 
microthreads seeded with adult human muscle-derived cells from discarded muscle flap tissue 
(Page, 2011). The fibrin threads were formed by mixing fibrinogen and thrombin and extruding 
the polymerized fibrin into threads (Page, 2011). Muscle defects were created in mice, and fibrin 
threads seeded with adult human muscle cells were placed into the wound. The alignment of the 
fibrin threads is thought to mimic the alignment in native muscle tissue. It was found that the 
fibrin microthreads were able to promote native muscle regeneration, cell migration, and reduce 
the amount of scar tissue formation. Tetanic intermittent and maximum force measurements 
were performed on uninjured mice, untreated injured mice, and fibrin thread treated injured 
mice. In the treated mice, almost 100% of native muscle strength was regained, while in 
untreated mice only 50% strength was achieved. Upon dissection and analysis of cell types in the 
affected region, it was found that the majority of the cells involved with the regeneration process 
were native muscle cells and not the exogenous cells that were implanted. This suggests that 
acellular microthreads may allow for the possibility of aided muscle regeneration (Page, 2011).  
2.3.1.3 Alginate Hydrogels 
 Naturally-derived alginate is a polysaccharide that is extracted from brown algae. The 
structure of the polysaccharide is a copolymer of guluronate and mannuronate (Lee, 2012). It is a 
lightly cross linked hydrogel that without surface modifications does not allow for cell 
infiltration and degrades through passive dissolution. This means that natural biological 
mechanisms such as phagocytosis and enzymatic cleavage do not facilitate degradation of 
alginate hydrogel. Therefore, modifications are needed to allow for controlled and predictable 
degradation. For this reason, alginate is predominantly used as a scaffold for GF delivery to 
target tissues, and a biocompatible structure for nanoparticles (Stilhano, 2016). 
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 Borselli et al. studied the muscle regeneration effects of alginate gels loaded with 
angiogenic and myogenic GFs (Borselli, 2010). Hind limb ischemia was induced in mice and 
different test group materials were injected into the injury site. The various test groups evaluated 
were alginate gel, alginate gel loaded with VEGF, alginate gel loaded with IGF, alginate gel 
loaded with both VEGF and IGF, bolus injections, and a control group. The study found that 
alginate gel provided a suitable vehicle for drug delivery to the targeted muscle tissue. The test 
group that consisted of alginate loaded with VEGF and IGF produced muscle fiber diameters 
closest to that of native muscle. This test group also produced muscle regeneration that exhibited 
the maximum amount of strength produced across all test groups during a tetanic force test 
(Borselli, 2010). 
 Wang et al. developed a shape memory alginate scaffold that allows for minimally 
invasive cell and GF delivery. A modified, crosslinked alginate scaffold was produced to act as 
synthetic extracellular matrix. The scaffold was dehydrated and then rehydrated with a 
suspension of cells, GFs, or both. The seeded cells were found to proliferate and migrate through 
and out of the scaffold in clusters. The scaffold’s surface properties were also found to be 
suitable for cell migration and proliferation. The degradation rate was determined to be 
beneficial for muscle regeneration as the degradation rate closely matched the rate of 
regeneration in damaged skeletal muscle. Although these tests were all done in vitro, they 
provide promising results for the use of alginate memory scaffolds in future research (Wang, 
2012). 
2.3.1.4 Decellularized Extracellular Matrix 
Decellularized ECM scaffolds are tissues harvested from mammalian origin and then 
decellularized (Wolf, 2012). They are comprised of collagen, elastin, laminin and 
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glycosaminoglycans, all of which naturally provide structure and support for cellular growth 
(Corona, 2016). The decellularized ECM not only provides structure, but also provides other 
factors that are responsible for triggering and controlling a range of cellular reactions, including 
VEGF, FGF-2, and cytokines (Gentile, 2014). All of these factors and biochemical cues allow 
the scaffold to assist in the migration and proliferation of target cells (Wolf, 2015). This is 
essential because of the scaffold’s acellular nature. ECM scaffolds are also degradable, allowing 
the native tissue to replace the scaffold entirely as the macrophages break it down. The density of 
the scaffold is the determining factor for the degradation rate. Generally less dense ECM 
degrades in 60-90 days, while denser ECM degrades fully in 12-24 months (Badylak, 2016). 
 ECM can also be produced in a variety of formats. The major ones are 2D ECM sheets, 
powders, tube shapes, thermally responsive hydrogels, and whole decellularized organs. The 
format most used for VML research is whole decellularization of organ or tissue samples. This is 
mainly due to the mechanical properties of the whole decellularized tissue and the fact that the 
tissue maintains its native architecture (Crapo, 2011).  
 Many studies have been performed on the effectiveness of porcine urinary bladder ECM 
scaffolds as a treatment method for VML. Sicari et al. performed a study that consisted of ECM 
scaffold implantations into both rat and human patients with lower extremity VML. The study 
observed that in both cases, perivascular stems cells and initial formation of skeletal muscle in 
the affected area were present. In the human study, increased functionality was observed that was 
not achieved through physical therapy alone (Sicari, 2014). Clinical studies have been done to 
explore the ability of biologic scaffolds to be used as a surgical treatment for VML by providing 
a microenvironment that triggers a healing response. A murine model of VML was used to 
evaluate the spatial and temporal presence of skeletal muscle cells during tissue remodeling at 
the site of the skeletal muscle injury (Sicari, 2014). To create VML in the mouse model, an 
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excisional defect was made in the quadriceps of the hind limb. Untreated injuries were evaluated 
as a negative control six months after the injury and showed no signs of skeletal muscle 
formation. Mice that were treated with an ECM scaffold exhibited striated muscle cells six 
months after the injury. After these encouraging results in mice, clinical studies were done in 
five human patients who had experienced VML and exhausted all other treatment options. An 
acellular scaffold composed of porcine urinary bladder ECM was surgically implanted after 
removing scar tissue that had developed at the injury site. After surgery, each patient was put 
into a physical therapy program to promote functional recovery. Images were taken both before 
the surgery and six months post-surgery. Magnetic resonance imaging (MRI) showed formation 
of dense tissue after six months. Desmin and MHC positive cells were found, which are 
indicative of actively regenerating skeletal muscle cells. Additionally, postsurgical function was 
examined. Three out of five of the patients had 20% or greater improvement in muscle strength. 
The other two patients were considered nonresponders because although they reported an 
increased quality of life, functional deficits remained as they had lack of active movement 
(Sicari, 2014). 
 Corona et al. performed a similar study with less promising results (Corona, 2013). This 
study tested the use of ECM scaffolds on rats that had induced VML in both hind limbs, while 
only treating one with the scaffold. The study monitored the growth of muscle fibers and found 
that after six months, there was no indication that any mature muscle fibers were able to form 
across the muscle gap for the treated leg or the untreated leg. Fibrous masses were observed in 
both legs; however, the leg that was treated developed fibrous tissue to a lesser degree. 
Functionality increased but it was determined that this could not be due to muscle regeneration 
since muscle fibers were not formed (Corona, 2013).   
 More recently, Dziki et al. performed a cohort study with 13 patients implanted with 
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porcine ECM scaffolds (Dziki, 2016). At 24-28 weeks post-op a statistically significant average 
increase in strength of 37.3% was observed when compared to pre-op values. Also at 24-28 
weeks, 12 out of the 13 participants were reported to have increased range of motion and 
functionality (Dziki, 2016). These varying results show that there is potential for an increase in 
muscle regeneration through the use of ECM scaffolds, but the exact mechanism of action may 
not fully be identified yet. 
2.3.1.5 Collagen Scaffolds 
 Collagen scaffolds are another type of scaffold made from natural materials found in 
mammalian tissue. Collagen is found naturally in bone, cartilage, and skin, providing structure to 
all of these tissue types. Collagen can be harvested from skin, tendon and cartilage and fabricated 
into collagen mesh, porous scaffolds, and sponges (Gómez-Guillén, 2011). These scaffolds are 
predominantly seeded with cells before implantation. For this reason, many scaffolds are 
fabricated with specific geometries to promote cell alignment for skeletal muscle formation. This 
is done through the creation of grooves and pores in the scaffold structure (Chen, 2015). 
Collagen is a degradable material that upon implantation would eventually be replaced by ECM 
which is secreted by the native cells in the region. Similar to decellularized ECM scaffold, the 
degradation rate for the collagen scaffolds are dependent on the density of the scaffold and the 
ease at which macrophages can penetrate the material (Kroehne, 2008). 
 Experimental studies done on the viability and effectiveness of collagen scaffolds at 
promoting cell alignment have provided promising results. Choi et al. conducted a study on the 
ability to produce self-aligned skeletal muscle through the use of electrospun collagen nanofiber 
meshes (Choi, 2008). The study used collagen fibers mixed in a 1:1 ratio with PCL and then 
electrospun to create a mesh. PCL is a biodegradable, flexible polyester polymer. The study 
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aimed to determine if the orientation of the electrospun mesh could influence the organization, 
proliferation and differentiation of seeded human skeletal muscle cells. It was found that mesh 
orientation had no effect on cell adhesion and proliferation, but the formation of myotubes was 
more consistently aligned in the organized mesh compared to that of the randomly oriented fiber 
control group. This increased alignment can potentially improve the muscle function and 
maturation of myofibers in the body (Choi, 2008). 
 Chen et al. performed a study that tested whether or not the geometry of a collagen 
scaffold influences the alignment of skeletal muscle myoblasts (Chen, 2015). In this study, lines 
of water were printed onto a liquid nitrogen cooled plate. The frozen lines that were produced 
provided a mold to cast the collagen matrix. This allowed for the production of a collagen 
scaffold that had clearly defined grooves. Rat skeletal muscle myoblasts were seeded onto the 
scaffold and cultured for 7-12 days. The grooved collagen scaffolds increased cell alignment. 
However, there was no observable difference observed in myogenic gene expression (Chen, 
2015). 
 In a study by Kroehne et al., C2C12 myogenic cells were seeded onto collagen sponges 
and implanted into rat skeletal muscle tissue (Kroehne, 2008). Isometric contraction 
measurements were done before and after implantation. Between 14-50 days after implantation, 
the scaffold and surrounding muscle were analyzed. The implant region was observed to be 
redder in color than the surrounding tissue, which was determined to be due to an increase in 
vascularization. The force measurements were determined to be 5-20% of undamaged skeletal 
muscle tissue tetanic tension values. It was also determined that there were large regions of the 
scaffold where endogenous cells had not infiltrated. This means that the formation of muscle 
fibers was not supported by the host cells (Kroehne, 2008).   
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2.3.2 Biophysical and Biochemical Cues in Scaffolds 
By incorporating cues that naturally occur during muscle regeneration into scaffolds, it is 
possible to induce a biomimetic microenvironment at the injury site to facilitate muscle 
regeneration. As mentioned, the cues can be either biochemical or biophysical (Cezar, 2015). 
Biophysical cues are considered as adhesive and mechanical signals, presented by material 
carriers that dramatically affect cell survival and ultimately participate in regeneration (Cezar, 
2015). Whereas biochemical cues are considered as growth factors, cytokines, and signaling 
ligands that signal host cells (Cezar, 2015). The creation of an ideal synthetic niche for SCs has 
seen clinical success for improving survival, engraftment, and fate control of delivered cells. 
Incorporating a variety of cues is difficult; therefore a few key cues deemed imperative for 
adhesive, mechanical, and soluble microenvironment cues are chosen in particular (Cezar, 2015).  
2.3.2.1 Biophysical Cues – Surface topography 
 Biophysical cues such as adhesive signals incorporated into scaffolds are crucial for an 
effective scaffold. Topography, the surface features of scaffolds, will greatly affect cell behavior 
by facilitating cell alignment as well as differentiation and gene expression. Patterns on the 
surface of the scaffold have been studied with great success (Gilbert, 2010). Patterning can be 
incorporated in two-dimensional (2D) or three-dimensional (3D) and has been shown to guide 
alignment of muscle myoblasts and myotubes which lead to the formation of pre-patterned cell 
sheets. Issues with 2D microprinting include limited thickness which can lead to less alignment 
of myotubes, also harvesting the cell sheets is cumbersome. 3D microprinting has seen greater 
success of alignment of myotubes due to greater thickness and processability (Chen, 2015). 
Getting cells to adhere to the scaffold via the guidance is an obstacle that must be 
overcome to maximize effectiveness. Cell types that are known to be adherent to a positive 
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control or tissue culture plate, may not adhere to the biomaterial surface. The surface of scaffolds 
can be altered at a nanoscale to greatly influence cell contact guidance. Small features on the 
nanoscale level like columns, protrusions, pits and nodes were shown to promote cell adhesion. 
Janson et al. was able to prove the importance of nanotopography by performing a study to show 
that increasing the size of the small features results in a decrease in cell adhesion (Janson, 2015).  
Chen et al. investigated how 3D porous collagen scaffolds fabricated via 3D 
microprinting affected cell behavior (Chen, 2015). The microgrooves were concave to imitate the 
basement membrane for engineering skeletal muscle tissue. Microgrooves on the scaffolds were 
shown to promote cell alignment once the activated SCs adhered to the microgrooves. 
Afterwards, the SCs divided to produce SC-derived myoblasts that further proliferated before 
differentiation further and fusing to form myotubes. These then matured further into myofibers 
(Chen, 2015). 
2.3.2.2 Biophysical Cues – RGD Ligand 
The incorporation of adhesive cues that mimic natural binding in the satellite niche has 
been researched in skeletal muscle regeneration. For instance, by covalently modifying alginate 
hydrogel scaffolds with RGD-containing cell adhesion ligands it mimicked adhesive cues for 
myoblast cells (Roweley, 1999). RGD is a tripeptide, Arginine-Glycine-Aspartic acid, which is 
the sequence found in proteins. The binding of integrins to the RGD ligands mediates both cell-
cell and cell-substratum interactions (D’Souza, 1991). Rowley et al. were able to to get 
myoblasts to adhere to RGD-modified alginate surfaces (Roweley, 2002). The adherence of 
myoblasts allowed for further proliferation, and the fusion into multinucleated myofibrils 
(Rowley, 1999). In vitro RGD density, affinity, and nanoscale distribution were shown to 
regulate skeletal myoblast proliferation and differentiation (Boontheekul, 2008; Rowley, 2002). 
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2.3.2.3 Biophysical Cues – Porosity 
When regeneration occurs, fibroblast activity leads to scar tissue formation. Ideally 
fibroblastic activity should be controlled to ensure proper collagen deposition. Fibroblasts 
deposit collagen which eventually forms into scar tissue and inhibits the full recovery of 
functional skeletal muscle tissue. Typically, pores that range in the size of 5-15 µm favor 
fibroblast ingrowth (Annabi, 2010). By incorporating pores and controlling the sizes, the 
fibroblastic activity can be greatly optimized.  
Another benefit of porous scaffolds is that without an intrinsic vascular system, the 
maximum thickness of engineered tissue is approximately 150-200 µm (Annabi, 2010). This 
maximum thickness can be attributed to the insufficient oxygen and nutrient transport within the 
deeper areas of the biomaterial (Annabi, 2010). Therefore, scaffolds are generally highly porous 
with interconnected pore networks to facilitate nutrient and oxygen diffusion as well as waste 
removal. Open porous and interconnected networks are essential for cell nutrition, proliferation, 
and migration for tissue vascularization and formation of new tissue.  
The porous surface may also help improve the mechanical stability of the implant by 
mechanical interlocking between the scaffolds and surrounding tissue (Loh, 2013). As a result, 
the porosity and pore size of the scaffold should be taken into account for the intended 
application. The pore size needs to be large enough to allow the release of GF and endogenous 
SCs to infiltrate the scaffold but still allow for necessary mechanical stability (Loh, 2013). 
Incorporating porosity into a scaffold is a delicate balance as the degree of porosity will have a 
substantial effect on the mechanical properties, specifically with the decrease in scaffold 
elasticity or stiffness. It is imperative to not alter the scaffold elasticity because it has been 
shown to induce cellular differentiation (Engler, 2006; Gilbert, 2010). 
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2.3.2.4 Biophysical Cues – Scaffold Elasticity 
The mechanical properties of scaffolds also impact their success in muscle regeneration. 
Mimicking native muscle tissue elastic modulus, has been shown to induce cellular 
differentiation (Engler, 2006; Gilbert, 2010). The elastic modulus of native skeletal muscle tissue 
ranges from 8-17 kPa when at rest (Engler, 2006). When skeletal muscle is in contraction, the 
elastic modulus can be as high as 11,200 kPa (Caiozzo, 2002).  Engler et al. were able to 
determine that SCs commit to the different lineages of muscle cells based on matrix elasticity 
(Engler, 2006). By having a scaffold with a similar elastic modulus, better SC engraftment and 
niche repopulation in vivo occurs. Matrix elasticity is another concern, and it has been shown to 
help regulate SCs self-renewal in culture. Gilbert et al. were able to culture SCs on soft hydrogel 
substrates that mimicked the elasticity of muscle 12 kPa (Gilbert, 2010).  Great success was 
shown in regulating SCs to self-renew in vitro and extensively contributed to muscle 
regeneration when the hydrogels with SCs were implanted into mice. (Gilbert, 2010). The self-
renewing proliferation of SCs is multifunctional and maintains the cell population, but also 
provides numerous myogenic cells. The myogenic cells proliferate, differentiate, fuse and lead to 
new myofiber formation that have functional contractility (Yin, 2013).  
2.3.2.5 Biophysical Cues – Degradation 
In addition to the scaffold providing stability, the scaffold degradation should match the 
timing of the regeneration process. The ideal mechanism of healing would allow for the 
synchronization of scaffold degradation with the replacement of native tissue, which makes the 
resorption rate of the scaffold important (Sung, 2004). For a muscle scaffold, the scaffold should 
be fully degraded at the end of the repair phase (Turner, 2011). By following the timeline of the 
repair phase – three to six weeks – it allows for the scaffold to provide support for the wound site 
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while new myofibers repopulate (Sung, 2004). By degrading within this timeframe, it allows for 
the the replacement by natural tissue produced from cells (Sung, 2004). 
 There are many factors that affect degradation such as hydrophobicity, molecular weight, 
crystallinity and many in vivo processes that need to be considered. Typically, degradable 
polymers will break down or erode by surface erosion, bulk erosion or a combination of the two 
(Ulery, 2011). Surface erosion is characterized by the rate of polymer degradation being much 
greater than the rate at which water diffuses into the bulk of the material leading to it degrade 
almost entirely at its surface (Ulery, 2011). Bulk erosion is the opposite, water diffusion is much 
faster than degradation leading to degradation occurring throughout the bulk of the material 
(Ulery, 2011). These two distinctions are important in determining which material is best for a 
desired application.  
The degradation products of the biomaterial scaffold are also an important consideration. 
Some materials may produce toxic byproducts, which can be detrimental to the surrounding 
tissue. For instance, polymers like PLA and PGA degrade by hydrolysis of the ester bonds, 
which produces acidic byproducts (Sung, 2004). The acidic byproducts make a more acidic 
environment which can lead to tissue necrosis (Sung, 2004).  
2.3.2.6 Biochemical Cues – Growth Factors 
The aforementioned cues are just some of the biophysical cues that scientists have 
successfully incorporated into scaffolds. Although incorporating physical cues is important, the 
incorporation of chemical cues paired with physical cues allows for greater effectivity.  
 Biochemical cues help the body signal and facilitate muscle regeneration. Biochemical 
cues can be membrane proteins, intracellular proteins or extracellular factors such as GFs. 
Within the body are a plethora of biochemical cues that naturally occur; Table 1 lists some of the 
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currently known cues. These cues are important to regeneration of tissue because they signal for 
cellular activity.  
Table 1: List of the many biochemical cues natural in the body and their function (Horsley, 2004). 
 
There has been clinical success with incorporating GFs into tissue engineering constructs 
to enhance muscle regeneration (Borselii, 2010, Cezar, 2015). For a scaffold, GFs are used to 
either replace the GF population that would naturally occur or supplement the surrounding tissue. 
The GFs’ intended function for this application is to activate the removal of damaged tissue and 
synthesis of new muscle fibers which ultimately helps to restore functional contractile properties. 
Many GFs are present in the body and not all of them have been characterized. Table 2 is a 
summary of the current characterized GFs and their actions are shown. 
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Table 2: Some of the GFs currently being researched with success and the actions they perform (Whitaker, 2001). 
 
 Vascular endothelial growth factor (VEGF) has been proven to initiate blood vessel 
formation, or angiogenesis to return normal levels of tissue perfusion within three weeks in the 
thigh and leg muscles of ischemic rabbit hind limbs (Borselli, 2010). VEGF plays a role in 
myogenesis by helping improve muscle contractility (Bae, 2012). Another feature of VEGF is its 
ability to protect tissue from hypoxia and tissue necrosis, making VEGF a desirable and 
multifunctional GF (Sahni, 2000). 
Fibroblast growth factor 2 (FGF-2) is a GF that helps facilitate myogenesis, angiogenesis, 
and innervation (Bae, 2012). This multifunctional GF requires prolonged exposure to cells to 
sustain vessel maturation for angiogenesis. The presence of FGF-2 has been shown to increase 
endothelial cell migration and proliferation (Bae, 2012). FGF-2 helps enhance myogenesis 
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because its natural function in the body is to stimulate SC proliferation (Bae, 2012). The 
requirement of prolonged exposure presents an issue for delivery, since FGF-2 acts as an 
inhibitor for the next step of the differentiation phase (Velleman, 2008). 
 Nerve growth factor (NGF) helps facilitate innervation of the newly formed muscle 
tissue, axonal growth, cell survival as well as angiogenesis and skeletal muscle fiber remodeling 
(Whitaker, 2001). NGF belongs to the neurotrophin family which functions to enhance 
peripheral nerve regeneration (Sakiyama-Elbert, 2000). Diao et al. was able to transfect NGF and 
show that it promoted NGF and VEGF protein expression which further facilitated angiogenesis 
and type I muscle fiber expression (Diao, 2016). In vivo, NGF has been added to nerve guide 
tubes, leading to a limited increase in nerve regeneration, highlighting the need for a delivery 
system to release NGF (Sakiyama-Elbert, 2000). Maintaining NGF release over a long duration 
is difficult and requires a delivery system that provides prolonged release. Sakiyama-Elbert et al., 
were able to develop a heparin-containing fibrin-based matrix to enhance neurite extension by 
controlling the rate at which NGF was delivered (Sakiyama-Elbert, 2000). 
Insulin-like growth factor 1 (IGF1) is another multifunctional GF that has been studied 
with great interest. Its ability to protect cells from apoptosis and to mute the inflammatory 
response has led to IGF1 being heavily researched (Borselli, 2010). This GF is active during all 
stages of regeneration, and it leads to the activation and proliferation of SCs, therefore enhancing 
muscle fiber regeneration to form highly functional muscle tissue (Borselli, 2010). 
Current research has focused on multifunctional GFs and their combined delivery effects 
is summarized in Figure 5. For instance, the combined delivery of VEGF and IGF1 led to 
parallel myogenesis, angiogenesis, and as a result innervation (Borselli, 2010). As SC activation 
and proliferation are stimulated, the presence of IGF1 mutes the inflammatory response, and 
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protects the cells from apoptosis. Borselli et al. were able to get highly functional muscle tissue 
to form by combining the temporal and spatial delivery of VEGF and IGF1 (Borselli, 2010).      
 
  
Figure 5: Current clinically successful GFs, showing that some are multifunctional 
Native GF release is time and location sensitive since and they have short half-lives and 
do not act in an endocrine fashion (Lee, 2011). Direct injection of GFs may lead to severe side 
effects due to the abnormally high initial concentration (Lee, 2011).  It is vital that the release of 
the GFs from a tissue engineered scaffold is controlled and models that of natural muscle tissue. 
The spatial and temporal complexity of endogenous GF release provides a significant new drug 
delivery challenge of mimicking endogenous release profiles.  
2.3.3 Controlling the Release of Growth Factors   
As mentioned previously, the biochemical cues, specifically GFs, involved in the 
regeneration of muscle tissue are very important to ensure the regeneration of functional skeletal 
muscle tissue. Due to the way in which these GFs react with the wound site, it is also important 
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that these factors are only released during certain phases, and also that a proper dosage is 
delivered throughout the healing process (Drury, 2003). 
In addition to releasing these biochemical cues over an extended period, it is often 
desired to control the spatial distribution of drugs release. For certain GFs, such as the VEGF, 
delivery of a large amount to a single area can be very toxic towards the patient and possibly 
cause further issues, such as the development of tumors (Drury, 2003). In addition to facilitating 
the transport of drugs to a certain area and avoiding toxicity, being able to control the release 
profiles of these drugs will in turn increase their effectiveness and require less chemicals. 
In order to mimic natural GF delivery to cells in-vivo engineers have developed different 
methods using polymers and other materials, which can control the release of GFs or other drugs 
at a wound site (Uhrich, 1999; Yamamato, 2001).The methods developed have been categorized 
into either temporal or distribution control, each have been successful under specific conditions 
(Uhrich, 1999). The temporal release of a drug, as seen in Figure 6, is defined as a type of release 
that is controlled via the properties of a polymer. For example, the release profile of the drug can 
be limited by the degradation of the polymer, delayed dissolution, or by the drug’s ability to 
diffuse through the polymer’s membrane. Alternatively, controlled drug release known as 
distribution control consists of the placement of the drug directly at the site and is beneficial for 
the treatment of tumors. This method is focused on the targeted-area application of the drug, as 
well as the sustained release (temporal release) of the compound.  
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Figure 6: Temporal drug release mechanisms. (Uhrich, 1999) 
GFs  have a very short half-life and therefore if not protected, will degrade quickly 
(Yamamato, 2001). This raises problems for the regeneration of muscle tissue, as certain GFs, 
such as FGF-2, required prolonged exposure to the cells during this process to achieve full 
maturation (Bae, 2012). 
An early example of the controlled release of GFs was achieved by Yamamoto et al. in 
2001 using a gelatinous hydrogel. In this study, a series of GFs relevant to regenerative medicine 
were selected - FGF-2, TGF-β1, BMP-2, and VEGF - and were sorbed into the hydrogels 
(Yamamoto, 2001). This approach of GF controlled release used the degradation of the hydrogel 
to control the release rate. For the in vitro experiment, the hydrogels were placed into varying 
ionic PBS solution baths. The GF concentration within the ionic solution was recorded each hour 
(Figure 7). It is evident that the amount of GF released throughout the experiment was dependent 
on the ionic solution strength, except in BMP-2 which was relatively constant. The release rate 
of the growth factors depended on its affinity to the hydrogel, making this a more effective 
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method of control for certain factors, such as FGF-2 and TGF-β1, than others, such as BMP-2 
(Yamamoto, 2001).    
  
Figure 7: Release profile of GFs FGF-2 (○), TGF-β1 (●), BMP-2 (△), and VEGF (▲) from a gelatinous hydrogel into PBS. 
(Yamamato et al., 2001). 
         In addition to the release profiles from the gelatin hydrogels, Yamamato et al. observed 
the absorption of the GFs into the gel. It was determined that BMP-2 and VEGF absorbed less 
into the gel than their counterparts, FGF-2 and TGF-β1. This was predicted to be due to the 
differences in chemical structure and charge (Yamamato, 2001). Therefore, there are a limited 
amount of compatible GFs and delivery vehicle combinations. 
         As well as using an entire scaffold as the delivery vehicle, studies have been performed 
using polymeric systems to delay the release rate of growth factors. These polymeric systems can 
encapsulate the desired protein or drug and due to either electrostatic interactions or pore size 
limitations the molecules will be encapsulated for longer, temporarily inhibiting the activity. In 
the study performed by Gu et al., VEGF was encapsulated into alginate microbeads in the 
presence of CaCl2 and the release rate was observed over two weeks (Gu, 2004). The objective 
of the study was to determine the most efficient method of encapsulating VEGF to delay its 
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release. The alginate bead compositions were altering, both with and without CaCl2, and 
additionally different mediums, PBS and BSA, were used as the bulk liquid. It was determined 
that in order to sustain the release of the VEGF from the alginate beads, the electrostatic 
interactions would need to be overcome, and CaCl2 was used to do so at varying concentrations. 
It was observed that in the presence of 0.1 M CaCl2 and when placed in a PBS bath, the alginate 
microbeads were capable of sustaining a release rate of 6 ng/ml/day for over two weeks, which 
opens up possibilities for this technology to be incorporated into various tissue engineering 
constructs (Gu, 2004).  
Controlled release studies have also been performed by altering the composition of a 
composite scaffold to create more affinity, resulting in an extended release time. In a study 
performed by Jeon et al., fibrin gels with varying fibrinogen (9.4-188.6 mg/ml), thrombin (3.3-
66.66 mg/ml) and heparin (0-166.7 µg/mL) compositions were loaded with FGF-2 and the 
release kinetics were observed (Jeon, 2005). The goal of this study was to determine to what 
degree the release kinetics could be controlled in such a gel. In this study, it was observed that 
increasing the concentration of fibrinogen in the gel would extend the release through diffusion 
of FGF-2 out of the gel. In addition to increased fibrinogen concentrations, the addition of 
heparin to ionically bond the FGF-2 was also utilized to extend the release kinetics. The best 
combination observed was using 188.6 mg/ml of fibrinogen, 166.7 mg/ml of thrombin and 166.7 
µg of heparin, which resulted in approximately 55% cumulative release over 14 days (Figure 8).   
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Figure 8: Cumulative release of FGF-2 from fibrin gels prepared at different fibrinogen concentrations (Group V, fibrinogen, 9.4 
mg/ml (○); Group II, fibrinogen, 94.3 mg/ml (●); Group VI, fibrinogen, 188.6 mg/ml (▼)) with thrombin (NIH U/ml) in the 
presence of heparin (166.7 µg). The values represent the mean ± S.D. (n = 5). (Jeon, 2005). 
2.4 Summary and Need 
 As discussed, there is a need for a technology that promotes functional skeletal muscle 
regeneration for VML patients. Currently, autologous tissue transfer is insufficient in 
regenerating functional muscle and the surgery often results in graft failure. There are many 
tissue-engineered scaffolds that have been explored as a solution for functional tissue 
regeneration in applications such as VML and others. While many make strides towards a viable 
solution, there is still a need for a scaffold that both mitigates foreign body response and scar 
tissue formation as well as can provide structural support and promote myogenesis for functional 
muscle regeneration.  
 One solution that has been explored in Pins’ lab is the use of fibrin microthreads as a 
scaffold that can be implanted directly into the wound bed (Grasman, 2015). This scaffold 
showed promise in its ability to regenerate functional muscle without scar tissue formation, but is 
lacking in its ability to serve as a vehicle for controlled growth factor release. The growth factor 
loaded to the fibrin microthreads was released after only three days which is not sufficient to 
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provide release throughout the three to six week long repair phase (Grasman, 2015). Because of 
this, a need exists to develop a scaffold that is capable of controlled growth factor release 
throughout the repair phase. The following sections will detail how the project design addressed 
the concern.  
3.0 Project Strategy 
 The project strategy chapter outlines the engineering design process and how it was 
applied to the project for designing a composite scaffold for skeletal muscle regeneration. To do 
this, the design team compiled the information from the initial client statement, client interviews, 
project objectives, constraints and the revised client statement. Processes and insight on the 
process were utilized from two sources that outline design process approach: Engineering 
Design: A Project Based Introduction by Clive L. Dym and Patrick Littleand Biodesign: The 
Process of Innovating Medical Technologies by Paul G. Yock, Stefanos Zenios and Josh 
Makower (Dym & Little, 2000; Yock, 2015).  
3.1 Stakeholders  
 To create a successful design, the team needed to consider all of the stakeholders in the 
project which include the design team, the clients, and users. The clients’ opinions are very 
important as they are the ones funding the project, the users are the ones that will need to utilize 
the device and the design team are the ones who must be able to apply the design process and 
find a feasible solution. The design team considers the constraints they have created while trying 
to satisfy the clients’ and users’ objectives.  
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 The clients for this project include Dr. George D. Pins and Dr. Jeannine M. Coburn, and 
Meagan Carnes and Joanna Santos are the users. The design team includes Alexandra Burr, 
Anthony Campagna, Janine Fatal, James Lin and Elizabeth van Zyl. The project objective was 
given to the team by Dr. George D. Pins and Dr. Jeannine M. Coburn because of the need for 
aligned myogenesis and vascularization to occur in a tissue engineered construct that graduate 
students Meagan Carnes and Joanna Santos are creating as a solution for volumetric muscle loss. 
The need exists for a composite scaffold to be created because even though fibrin microthreads 
have shown to be successful in promoting functional muscle regeneration from implantation in a 
wound site (Grasman, 2015) the microthreads alone are difficult to handle and degrade too 
quickly to be an appropriate vehicle for the growth factor delivery necessary to impact 
regeneration. The goal is to provide these users with a reproducible composite scaffold that 
promotes functional skeletal muscle regeneration through the release of growth factors for at 
least two weeks.  
3.2 Initial Client Statement  
The initial client statement given to the team was: 
“Design and characterize an implantable composite fibrin scaffold with controlled release of 
growth factors to promote regeneration of skeletal muscle tissue.” 
 
To best accomplish this goal, the team would need to combine a successful composite 
scaffold fabrication technique with a GF loading method. The team needed to identify and 
prioritize a set of design objectives and constraints. The objectives and constraints then needed 
further refining throughout the process as the stakeholders’ needs were more critically examined. 
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This led to a final set of objectives and constraints which allowed the team to plan a 
comprehensive project strategy and design process. 
 As previously mentioned, there have been attempts to create a scaffold in Pins’ lab, but 
there is need to create a composite that is able to release the growth factor throughout the repair 
phase, as well as be more user friendly and easy to handle, as expressed by the stakeholders. The 
current method for fibrin microthread bundles have been noted as being difficult to work with by 
users.  
3.3 Constraints 
 To  complete the project for MQP requirements in a lab at WPI, there are certain criteria 
that have to be met. Some of the potential criteria were identified as constraints because they 
would limit the ability for the project to continue. The constraints and definitions can be found in 
Table 3. 
Table 3: Project constraints 
Constraint Definition  
Money Budget of $1300 
Time Must be finished by April 20th 2017 
Availability Materials must be available for Pins lab 
Materials Must not be cytotoxic or harm users   
Sterility Must be able to be sterilized by well-known techniques 
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 The constraints provided the team with working limitations. They must be met to create 
the composite scaffold. First, the team had a budget through WPI of $1300. Additionally, the 
team had until April 20th, 2017, project presentation day, to complete the project. The materials 
involved in the composite fabrication must be available to the members of design team and the 
users. Furthermore, the materials used for the scaffold must not be cytotoxic or harmful to the 
users during fabrication. Finally, for the in vitro studies, the team needs to make sure the 
fabrication process includes a method of sterilization that users are familiar with or are well-
known and can be learned. 
3.4 Objectives  
The team initially developed a list of objectives and constraints based on the initial client 
statement. The team’s initial objectives and constraints were also developed to encompass the 
needs and wants of the stakeholders. After user and client interviews, the team altered the set of 
objectives and constraints based on their priorities and timeline to guide the project goals and 
determine success.  
The initial objectives were evaluated after the team received feedback from the users and 
clients. The team would focus on growth factor release for skeletal muscle regeneration so the 
objectives were broadened to reflect this potential. Therefore, instead of trying to achieve all 
three goals of angiogenesis, innervation and myogenesis, myogenesis would be considered the 
most important for this project. Additionally, the design team and the clients discussed the 
importance of  a scaffold that provides structural support and is easier to handle that fibrin 
microthreads. Users expressed the difficulty of working with microthread bundles and the 
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limited ability to alter controlled release of growth factors from them.  This mindset was used to 
strengthen and broaden our revised objectives which are outlined in the tree in Figure 9. 
 
Figure 9: Project objective and sub-objective tree 
The eight high-level objectives are user friendly, reproducible composite fabrication, 
robust scaffold properties, promote myogenesis, promote angiogenesis, promote innervation, 
cost efficient, and minimize environmental impact. These main objectives are defined as in Table 
4 and are broken down further into sub-objectives which are defined in Tables 4-11.  
Table 4: Main objective definitions 
Composite 
Vascular 
Scaffold 
User Friendly
Minimal 
Preparation 
Time
"off the shelf" 
Design
Modular 
Capabilities 
Easy to  
Handle
Reproducible 
Composite 
Fabrication
Consistent 
Scaffold 
Properties
Can achieve 
consistent 
functionality 
Robust Scaffold  
Properties 
Physiologically 
Relevant 
Degradation 
Implantable 
Material
Promotes Cell 
Alignment
Physiologically 
relevent stiffness 
and strength
Promote 
Myogenesis
Cell Migration
Cell 
Proliferation
Promote 
Angiogenesis
Sprouting of 
Existing Blood 
Vessels
Maturation of 
Blood Vessels
Promote 
Innervation
Differentiatio
n of new 
nerve cells
Infiltration of 
existing nerve 
cells
Cost Efficient
Can be 
purchased 
sustainably
Fabrication 
equipment is 
inexpensive  
Minimize 
Environmental 
Impact
Minimize 
Organic 
solvent use
Minimize 
waste 
production
Initial Objective Definition 
User Friendly Must be easy to use, easy to handle and have the potential for adapting to 
user needs (layers, size, etc) 
Reproducible 
Composite Fabrication 
Needs to be able to be continually produced at the same quality level and  
easy to fabricate  
Robust Scaffold 
Properties 
Needs to promote alignment as well as degrade and provide structural 
stability for the time span equivalent to the repair phase 
Promote Myogenesis Needs to promote processes involved with muscle regeneration 
Promote Angiogenesis Needs to promote processes involved with vascular regeneration  
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Table 5: Sub-objective definitions: user friendly 
 
Table 6: Sub-objective definitions: cost efficient 
 
  
Promote Innervation Needs to promote processes involved with nerve regeneration  
Cost Efficient Must cost a reasonable amount for the benefits it provides and can be 
produced with inexpensive equipment  
Minimize 
Environmental Impact 
Must considerably and reduce environmental impact through material 
selection and fabrication method 
Sub-objective Definitions: User Friendly 
Minimal Preparation Time Fabrication protocol needs to be simple and convenient for user 
“off the shelf’ Design Some components are storable for later use and ready for 
incorporation into the composite 
Easy to Handle The scaffold must be easy to work with and allow user to perform 
experiments with it 
Modular Capabilities Protocol can easily be adapted to change size or number of layers in 
the composite 
Sub-Objective Definitions: Cost Efficient 
Consumables can be 
purchased sustainably  
Materials required are available to the lab and are affordable for 
purchase over time, disposables and consumables are cheap 
Fabrication equipment is 
inexpensive 
Equipment required to produce scaffold is inexpensive and capable of 
being purchased by the user or is already available to the user  
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Table 7: Sub-objective definitions: robust scaffold mechanical properties 
 
Table 8: Sub-objective definitions: reproducible composite fabrication 
 
Table 9: Sub-objective definitions: promote myogenesis 
 
Table 10: Sub-objective definitions: promote angiogenesis 
 
 
Table 11: Sub-objective definitions: promote innervation 
 
Sub-Objective Definitions: Robust Scaffold Properties 
Promotes Cell Alignment Includes structural components that help to promote cell alignment  
Physiological Relevant 
Degradation 
Composite will degrade in vivo during the time span of the repair 
phase and function throughout it  
Physiological Relevant 
Stiffness and Strength 
Stiffness and strength of composite is comparable to native muscle 
tissue  
Sub-Objective Definitions: Reproducible Composite Fabrication 
**Precision** Consistent 
Scaffold Properties 
Thickness, incorporation, volume and other properties remain 
consistent each time it the scaffold is produced by following 
protocols  
**Accuracy** Can achieve 
consistent functionality  
Performance and success in achieving various objectives remains 
consistent. Accurate in the ability to achieve target goals  
Sub-Objective Definitions: Promote Myogenesis 
Cell Migration Composite signals fibroblasts to the area to differentiate to myoblasts 
Cell Proliferation  Composite is inductive and promotes cell proliferation in the area  
Sub-Objective Definitions: Promote Angiogenesis 
Sprouting of existing blood 
vessels 
Composite signals existing blood vessels from the healthy tissue to 
sprout to the scaffold site 
Maturation of blood vessels Blood vessels surrounding the impacted tissue mature and develop  
Sub-Objective Definitions: Promote Innervation 
Differentiation of new nerve cells New nerve bundles develop at the site 
Infiltration of existing nerve cells Existing nerve endings growth and infiltrate the site  
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3.5 Quantitative Analysis of Objectives 
To determine the most important objectives to drive the design specifications, a pairwise 
comparison was completed by the clients, users and design team. To complete the pairwise 
comparison charts, the stakeholders were asked which objective is preferable when placed next 
to another, causing them to prioritize. A score of "1" indicated that the objective in the column of 
the chart had priority over the objective in the row of the chart, a score of 0.5 indicated that were 
equal in priority, and a score of 0 indicated that the objective in the column of the chart had less 
of a priority than the objective in the row of the chart. Once the chart was complete, the scores in 
each row were added up to reach a score for each objective. The pairwise comparison charts for 
each stakeholder can be found in Appendix C. The design team completed the chart as a group.  
The scores of the two clients and the two users were averaged for each objective to be 
used in the final scoring. An example of a summary table showing the averages for the clients, 
users, and design team is shown in Table 12 and a comprehensive table showing the summary of 
scores for all of the sub-objectives is found in Appendix D. Next, the objectives were weighted 
based on the total scores for each, using the equation in Table 12. The average of the clients’ 
responses were multiplied by 0.4 as were the average of the users’ responses. The design team’s 
responses were multiplied by 0.2 in order to give more weight to the clients and users. An 
example of the final weighted objectives using the equation below is used in Table 13 for the 
main objectives and the remainder can be found in Appendix E.  
 
𝑊𝑒𝑖𝑔ℎ𝑡 = [(0.4 ∗ 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑢𝑠𝑒𝑟𝑠) + (0.04 ∗ 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑐𝑙𝑖𝑒𝑛𝑡𝑠) + (0.20 ∗ 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑑𝑒𝑠𝑖𝑔𝑛 𝑡𝑒𝑎𝑚) 
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Table 12: Scores of main objectives by category 
 
Table 13: Weights of main objectives 
 
 
 
 
 
 
 
 
 
 Clients  Users Design Team Total  
User Friendly 3.75 3.75 2.5 10 
Reproducible Composite 
Fabrication 
5.25 6 6.5 17.75 
Robust Scaffold Properties 5 5.75 6.5 17.25 
Promote Myogenesis 9 5 4.5 18.5 
Promote Angiogenesis 2.25 4 4.5 10.75 
Promote Innervation 1.25 2 1 4.25 
Cost Efficient 4.25 0.75 1.5 6.5 
Minimize Environmental 
Impact 
1.5 0.25 0.5 2.25 
Main Objectives Weight 
Promote Myogenesis 6.5 
Reproducible Composite Fabrication 5.8 
Robust Scaffold Properties 5.6 
User Friendly 3.5 
Promote Angiogenesis 3.4 
Cost Efficient 2.3 
Promote Innervation 1.5 
Minimize Environmental Impact 0.8 
57 
 
This shows that the main objectives the team focused on are for the scaffold to promote myogenesis, have 
reproducible composite fabrication, robust scaffold properties, and be user friendly. 
3.6 Functions and Specifications 
Specific functions were identified to determine whether or not the scaffold would be 
successful in achieving the objectives. For the first two objectives, user friendly and reproducible 
fabrication, a singular function was developed to optimize fabrication. The next objective, robust 
scaffold properties, was achieved by ensuring the scaffold promoted viability and prolonged 
degradation. Finally, to promote myogenesis, the functions that needed to be achieved were 
cellular alignment and controlled release throughout the repair timespan.  
3.6.1 Function 1: Fabricated with over 90% success and require under 2 hours user 
labor   
 For two of the main objectives, user friendly and reproducible composite 
fabrication, the sub objectives included being easy to handle and reproduce along with being a 
supportive functional layer that could be modified for full-thickness solutions. To ensure this, the 
scaffold would need to be fabricated with 90% success and require under two hours user labor. 
This means that when scaffold are fabricated this way, 90% of them must be viable for 
experiments, without holes or incomplete incorporation with the frame. The composite needs to 
be much easier to handle and store than fibrin microthreads. To do this, the team would need to 
use the Pins’ Lab protocols for fibrin microthreads and films and combine them while testing 
different variations for a composite scaffold. This could include altering different steps in the 
process or how the user interacts with the scaffold. Some variations that will be included are 
whether or not coating the material the gel is cast on is necessary, the best way to organize the 
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threads, the rinse times and volumes of water used for baths and which patterned surface shall be 
used. A similar approach would need to be done to ensure it could be fabricated in under two 
hours. A series of experiments needs to be completed that records the time taken for each step as 
well as the viability of the scaffolds using a particular method. This can be denoted by the 
number of usable scaffolds per batch which is typically five scaffolds per one mililiter 
polymerized fibrin.  
3.6.2 Function 2: Promotes Cellular Viability 
Primarily, the fibrin composite needs to not only be biocompatible, but must promote 
cellular growth. The composite needs to provide a stable environment for the cells with potential 
for muscle differentiation. The cell type to be used for the entirety of the experiments are C2C12 
murine myoblasts because it is a relevant muscle progenitor cell line. The first step in doing that 
is providing an environment, with  the composite that allows survival to be maintained. In 
addition, it must allow for cellular proliferation and adhesion onto the scaffold. The composite 
will maintain this stable environment for the duration of testing incubation which is simulated to 
be four days, as this should be sufficient to see multiple population doublings and be an indicator 
of long-term viability (Burattini, 2004).To test this, a viability assay can be performed using 
resazurin to show proliferation compared to a positive control after incubation. If the cellular 
viability is not compromised during this incubation period, it indicates that the scaffold is 
achieving this function. Similar results should be achieved when incubation time is extended to 
the entire three-week time span.   
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3.6.3 Function 3: Prolongs Degradation to Preserve Partial Structural Integrity for 
Two Weeks 
Spatiotemporal degradation is necessary for treating VML to allow the native muscle 
fibers to integrate into the scaffold and eventually replace it. To successfully allow for tissue 
integration the scaffold should degrade slowly through the repair phase which takes three to four 
weeks (Tatsumi, 2004). This means that the time that the scaffold remains in the affected area 
should be equal to the time it takes to synthesize mature muscle tissue (Yannas, 2005). In order 
to accomplish this, the scaffold may need to be crosslinked to fortify the fibrin composite 
network to slow the degradation process (Page, 2011). In order to test that the scaffold is capable 
of remaining structurally intact for this time period, cells can be seeded on the surface and 
degradation can be measured by imaging the scaffolds at time points and identifying the 
degraded areas of the scaffold and quantifying them through imageJ.  This will be used as a 
marker appropriate for measuring structural integrity. For exact quantification of this function, 
research and experiments would need to be conducted to test whether the composites degrade 
through bulk or surface degradation but that is outside the scope of this project due to time 
constraints. .Newly created, and nondegraded scaffolds should be used to determine the 
degradation. Additionally, the same number of cells seeded on the surface are used across all 
experiments. The analysis will compare the percent area remaining of the scaffold and the team 
will mark success based on the percent area remaining after two weeks.  
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3.6.4 Function 4: Promotes Nuclear Alignment Along Fibrin Threads at Angles 
<10 Degrees Relative to the Thread 
 For the proper regeneration of functional muscle tissue, the scaffold needs to 
promote cellular alignment which will lead to the formation of myotubules (Bettadapur, 2016). 
As sub functions, the scaffold needs to allow for cellular signaling, migration, alignment and 
infiltration into and around the composite. In order to evaluate the success of this function, the 
C2C12 cells used will be fluorescently tagged using Hoechst, which stains the cell nucleus. 
Using a fluorescent microscope, these samples will be imaged at regions on the composite 
containing a thread for reference. Success will be achieved if the composite significantly 
improves cellular alignment compared to a plain film. This can be done by using imageJ to make 
the nuclei ellipsoidal and quantify how frequently the angles they are at align in response to a 
topographical cue such as the fibrin microthreads incorporated in the composite. Through 
histograms, the angles can be binned at intervals of 10 degrees and less than 10 degrees will be 
considered highly aligned cell nuclei. Therefore, the composite should significantly increase the 
frequency of nuclei aligned less than 10 degrees relative to the thread compared to a control 
scaffold. Significance can be quantified using an unpaired t-test between the <10 degree 
frequencies for each group. 
3.6.5 Function 5: Releases 10 ng of FGF-2 over a period of two weeks 
For the specific scope of the project, the design team and clients chose basic fibroblast 
growth factor (FGF-2) due to its ability to signal myogenesis, angiogenesis and innervation. 
While promoting myogenesis is the main objective for this function, it is advantageous to show 
proof-of-concept experiments with a growth factor that could be used in the future to promote all 
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three processes involved in regeneration. However, like other growth factors, FGF-2 has a short 
half-life (Lazarous, 1995). Therefore, if delivered in a bolus manner, such as an injection, the 
benefits and cues from the factor will not be as effective. For the specific scaffold being 
developed, a controlled release method must be utilized to allow for FGF-2 release over time to 
increase cellular activity. In order to determine the efficiency of the scaffold, release profiles can 
be used to monitor time versus amount of FGF-2 released from the scaffold. In order to 
accomplish this, an ELISA specific to the detection of FGF-2 is used. Samples will be compared 
to known standards in order to determine concentrations over time. To use concentrations that 
are relevant to the current research being done, the scaffold should be capable of releasing at 
least 10 ng of FGF-2 after being loaded (Makridakis, 2010). A successful growth factor release 
rate should sustain the release of the FGF-2 loaded into or bound to each scaffold throughout the 
desired release period, at least two weeks to match the repair phase.  
3.7 Engineering Standards 
Strict standards must be followed to ensure safety and functionality of the device. 
International Organization of Standardization (ISO) is a governing body that ensures that 
products are safe, reliable, and of good quality. The standard 10993-5:2009 is for assessing the 
biocompatibility of medical devices and materials, specifically, the cytotoxicity assessment in 
vitro. This standard is applicable for the device since it is designed to be implanted and in vitro 
experiments will be conducted. In the cell viability assay which will be done for the 
corresponding function, the results will also allow us to conclude that there are not cytotoxic to 
the cells if they sufficiently allow for proliferation that is comparative to a positive control.  
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American Society of Testing and Materials (ASTM) has formulated a standard guide for 
characterization and testing of biomaterial scaffolds used in tissue engineered medical products 
called ASTM F2150. The standard is a resource of currently available test methods for the 
characterization of the compositional and structural aspect of the scaffold. The test methods 
guide characterization of bulk physical, chemical, mechanical, and surface properties of a 
scaffold by describing test methods to determine, tensile, flexure, compressive, density, 
molecular weight, pore size and other characteristics. Degradation is a vital aspect of the scaffold 
and F2150 references F1635 which is a test method for characterizing degradation profiles of 
natural polymers such as fibrin. The standard also referenced ISO 10993 for additional guidance 
in the profiling of degradation. Specifically 10993-13 explains a test method for real-time 
degradation test in a simulated environment.  
Since the device is designed to release FGF-2, drug release must follow strict standards. 
However based on ASTM F2211-13 there is currently no standard for the characterization and 
sourcing of GFs and methods for their assay. Also based on the ASTM F211 there is currently a 
need for guidance for development of in vitro assays to measure release of therapeutic proteins 
from matrices. The general consensus for evaluating drug release involve the following three 
methods sample and separate (SS), continuous flow (CF), dialysis membrane (DM) (D’Souza, 
2014). The three methods are advantageous due to the ability to evaluate nano-sized dosage 
forms which is ideal for GFs (D’Souza, 2014). For the SS method entails having the drug 
delivery system be introduced into release media that is maintained at constant physiological 
conditions.  The drug release can then be quantified by sampling the release media. The SS 
method provides a direct approach to monitor drug release that is the most simple. CF method 
monitors drug release by using an IV or flow-through cell apparatus. The method allows for drug 
release to occur as a result of buffer or media being constantly circulated through a column 
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containing the drug delivery system. The eluent can be collected and monitored to create a 
release profile. DM is considered the most versatile and popular of the three methods (D’Souza, 
2014). This method involves physically separating the drug delivery system by using a dialysis 
membrane. The drug delivery system is introduced to a dialysis bag containing release media 
that is subsequently sealed and placed in a larger vessel containing release media. The drug will 
release and diffuse through the dialysis membrane to the outer compartment where it is sampled 
for analysis to create a release profile (D’souza, 2014).  
Before any medical device can be implanted, it is vital that it is sterilized following the 
standard ISO 11737 to mitigate infection and other complications. This standard evaluates the 
amount of microorganisms that may be present, tests the sterility, and validates the sterilization 
process.  
3.8 Revised Client Statement 
From the weighted objectives and further specification from the clients and user, the team 
developed a revised client statement: 
“Design, develop, and characterize a composite fibrin scaffold composed of a 
patterned fibrin film with fibrin threads to provide topographical cues for 
cellular alignment that will guide myotube formation and myogenesis in an easily 
reproducible manner. The fabrication should be user friendly, and the composite 
should promote proliferation through the controlled release of FGF-2 to the 
scaffold by adsorbing heparin and prolonging scaffold degradation in vitro for 
two weeks by chemically crosslinking with EDC/NHS solution.”  
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 This revised client statement will be used to ensure that the clients' and users' wants and 
needs are met with the various design specifications determined by the design team. 
4.0 The Design Process  
 Once the team completely understood the background of the project and stakeholder’s 
expectations, a project strategy was developed. This project strategy outlined a plan of action for 
the work needed to accomplish the project goals, starting with an analysis of the client, user, and 
designer’s priorities, developing a series of functions, and determining means which would be 
capable of accomplishing these functions. Once all possibilities were determined, the success-
rate of said means were then evaluated in terms of specifications, which lead to the final design.  
4.1 Needs Analysis 
As outlined in Chapter 3.5, all objectives were ranked based on their importance to the success of 
the project by the clients, Professor Pins and Professor Coburn, the users, Meagan Carnes and 
Joanna Santos, and the design team. The objectives are listed in order of importance based on 
percentage of the total points in Table 14. 
Table 14: Ranked objectives by percentage 
 
 
 
 
 
Objective   Percentage 
Promote Myogenesis 38% 
Reproducible Composite 
Fabrication 
34% 
Robust Scaffold Properties 33% 
User Friendly 20% 
Promote Angiogenesis 20% 
Cost Efficient 13% 
Promote Innervation 9% 
Minimize Environmental Impact 5% 
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Once the main objectives were prioritized, the needs and wants of the project were 
developed. A need was defined as something that the stakeholders felt were integral to the 
success of the project. Based on the way in which the objectives were ranked, as seen in Table 
13, the design team determined which objectives would be translated to needs. The top four 
ranked objectives, to Promote Myogenesis, to allow for Reproducible composite fabrication, 
to include Robust scaffold properties, and to create something User friendly. All the needs, 
which were determined by the design team in collaboration with the client’s and user’s rankings, 
were ultimately used to generate the functions of the scaffold.  
A want was defined as something which was desired to be included, but would not be 
absolutely necessary. All of these lowly ranked objectives would improve the final, but without 
them, the team still would have created a successful product. Similarly, based on the way in 
which the objectives were ranked, as seen in Table 14, the design team determined which 
objectives would be translated to wants. The bottom four ranked objectives, to Promote 
angiogenesis, create a Cost efficient scaffold, to Promote innervation, and to Minimize 
environmental impact. 
4.2 Design Alternatives  
 For each of the functions that the design group identified, a list of design alternatives 
(means) was identified. Means are different ways in which the scaffold material and modification 
options could fulfill each functional requirement. Each means was then compared to the list of 
constraints. If the means did not pass our constraints test then that specific means was no longer 
considered a viable option. Appendix B: Constraints Test for Developed Mean shows a list of 
our means and whether or not they passed the constraints test. Once it was determined whether 
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or not the means passed the constraint test, each means was looked into further and a list of pros 
and cons was developed for each. Table 15 shows the list of means for each function that passed 
the constraints test.  
Table 15: Means for each function 
Promotes cellular 
viability 
Prolongs degradation 
to preserve partial 
structural integrity  
Promotes nuclear 
alignment  
Releases FGF-2 over a 
period of two weeks 
Fibrin Film Chemical Crosslinking Fibrin Microthreads Diffusion 
Fibrin Gel UV Crosslinking Patterned Surface Degradation 
Fibrin Microthreads Protease Inhibitors Microthreads with 
Peptide Ligands 
Polymer Encapsulation 
Fibrin Gel with 
Microthreads 
- Patterned Surface with 
Microthreads 
Immobilization using 
heparin 
Fibrin Film with 
Microthreads 
- Patterned Surface with 
Peptide Ligands 
 
 
4.2.1 Fabrication Optimization Means 
 The means for fabrication optimization were approached in a slightly different manner than 
the means for the following functions. Where listing multiple options for each function is possible 
for functions 2-5, the optimization means only include binary options. Therefore, they were just 
listed and tests during scaffold fabrication. The variables tested and adjusted during fabrication 
were the alignment method – manual alignment or using the vacuum alignment device, coating 
the casting platform – either coated according to the protocol used in Pins’ lab or left uncoated, 
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and finally the rinse duration and volume for the rinses after casting – ranging from 5 – 10 minutes 
and 15 mL to 25 mL per scaffold.  
4.2.2 Cellular Survival Means 
Fibrin Gel 
 Fibrin gel is made of the proteins fibrinogen and thrombin, which are crucial in the blood 
clotting cascade. Fibrin gels are easy to produce, can have growth factors incorporated into their 
three-dimensional matrix, and have been shown to promote healing in several different wound 
types including skeletal muscle (Ye, 2000). Fibrin gels are often used within biomaterials to 
promote wound healing because the polymerization mechanism of fibrin allows controlled 
gelation times. Fibrin gels are characterized by their nonlinear elasticity, soft compliance at small 
strains, and their ability to stiffen to resist deformation (Janmey, 2009). The pros and cons of 
fibrin gel are outlined in Table 16. 
Table 16: Pros and cons for fibrin gel to promote cellular survival 
Pros Cons 
1. Easy to produce  1. Cells are unable to adhere and move 
through the fibrin gel 
2. The fibrin gel drug delivery system maintains 
the biological activity of FGF-2 
2. Mechanical properties are weak for 
functional replacement of load-bearing 
skeletal muscle tissue 
3. Parameters such as crosslinking density and 
fibrin concentration can be controlled in a gel to 
control the release of FGF-2 
3. Degrades rapidly in vivo 
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Fibrin Film 
Fibrin film is similar to the first mean as it is easy to produce and acts as a natural 
reservoir for the binding and release of growth factors (Ye, 2000). The dehydration of a fibrin gel 
into a film makes the network of fibrin tighter and increases the degradation time(Ye, 2000). 
Fibrin films have been found to enhance cell proliferation and promote an organized cell 
response to a biomaterial (Campbell, 2005). The mechanical properties of fibrin films make it 
possible to use patterned arrays of growth factors on its surface, which can be used to seed cells 
(Campbell, 2005). Table 17 outlines the pros and cons of using fibrin film.   
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Table 17: Pros and cons for fibrin film to promote cellular survival 
Pros Cons 
1. Easy to produce 1. Fragile and brittle  
2. Cells are able to move through the fibrin film 2. Limited information about long-term 
success when used solely 
3. Fibrin acts as a natural reservoir for the binding 
and release of certain GFs including FGF-2 
3. Stiffness modulates deeply adhesion, 
proliferation, and differentiation  
Fibrin Microthreads 
Fibrin microthreads have been shown to promote ingrowth of new muscle tissue when 
implanted in a skeletal muscle deficit (Page, 2011). Fibrin microthreads are 155–165 µm in 
diameter, which is a proper diameter to promote longitudinal growth and alignment of cells 
(Page, 2011). It is possible to modify their mechanical strength and degradation rate in order to 
achieve the optimum functionality for the specific application (Page, 2011). Fibrin microthreads 
can act as a delivery vehicle for cell implantation by allowing cell seeding and alignment (Page, 
2011). On the downside, fibrin microthreads have a time consuming preparation time and can 
degrade rapidly in vivo (Page, 2011). Pros and cons for the use of fibrin microthreads are 
outlined in   
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Table 18.  
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Table 18: pros and cons for fibrin microthreads to promote cellular survival 
Pros Cons 
1. Have been shown to direct aligned muscle 
regeneration 
1. Long preparation time 
2. Reduce the deposition of collagen in wounds, 
reducing scar formation 
2. Degrade rapidly in vivo if not 
crosslinked  
3. Promote ingrowth of new muscle tissue  3. Lacks user friendliness due to being 
hard to handle 
 
Composite of Fibrin Gel with Microthreads 
 Fibrin gel with microthreads is beneficial because the microthreads can compensate for 
the weak mechanical properties of the fibrin gel.  Fibrin microthreads, when compared to fibrin 
gel scaffolds (UTS - 6.5 ± 2.0 kPa), have shown significantly more strength with ultimate tensile 
strengths (UTS) of up to 4.5 ± 1.8 MPa (Cornwell, 2007). Strategically combining fibrin 
microthreads with a gel provides mechanical properties similar to native tissue (Chroback, 2016). 
This suggests that using the gel and microthreads together will make the scaffold more robust 
and conducive to the development of organized and aligned tissue. Although gels with fibrin 
threads provide a microenvironment that mimics natural physiologic conditions, their strength is 
usually in the single kilopascal range, which may fall short of that of natural skeletal muscle 
tissue (Cornwell, 2007). Table 19 shows the pros and cons for using fibrin gel with microthreads. 
Table 19: Pros and cons for fibrin gel with microthreads to promote cellular survival 
Pros Cons 
1. Microthreads enhance mechanical properties 1. Long preparation 
time 
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2. Microthreads make scaffold conducive to tissue regeneration tissue 
regeneration 
 
3. Gel acts as reservoir for growth factors  
 
 
Composite Fibrin Film with Microthreads 
 Fibrin film with microthreads is similar to the fourth mean because the microthreads 
improve the mechanical properties and increase the rigidity. This concept has not been evaluated 
before, but has the potential to combine the pros of the fibrin film and the fibrin microthreads, as 
previously described. While the microthreads enhance the mechanical properties and promote 
alignment, the film could potentially acts as a reservoir for growth factors and allows the cells to 
move throughout it (Ye, 2000) The pros and cons are outlined in Table 20.  
 
Table 20: Pros and cons for fibrin film to promote cellular survival 
Pros Cons 
1. Microthreads enhance mechanical properties 1. Long preparation time 
2. Microthreads make scaffold conducive to tissue regeneration 2. Fragile and brittle 
3. Better mechanical properties than gel with microthreads 
 
4.2.3 Prolong Degradation Means 
Due to the nature of VML, the natural biochemical cues such as growth factors that signal 
for cellular processes are absent from the wound site. For a scaffold to be effective in treating 
VML, the scaffold must remain intact long enough through the repair phase to effectively release 
growth factors. Additionally, the scaffold should degrade in a timeframe that is both 
physiologically relevant but additionally promotes regeneration by closely matching the time for 
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tissue growth (Sung, 2004). In essence, the scaffold ideally should degrade while simultaneously 
be replaced with new skeletal muscle tissue. Methods to slow down degradation include 
chemical crosslinking, physical crosslinking, and the incorporation of protease inhibitors 
(Grasman, 2012; Cornwell, 2007; Thomson, 2013). 
Chemical Crosslinking through EDC/NHS 
The chemical crosslinking strategy currently being used in Pins lab is 1-ethyl-3-3(3-
dimethylaminopropyl) carbodiimide and N-hydoxysulfosuccinimide (NHS) (EDC/NHS) which 
has been developed for the use with fibrin microthreads (Grasman, 2012). Using these two 
agents in a neutral buffer has been shown to effectively crosslink fibrin because it tightens the 
molecular network, and therefore slows down the degradation rate (Grasman, 2012). The pros 
and cons of EDC/NHS crosslinking are outlined in Table 21.  
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Table 21: Pros and cons of chemical crosslinking to allow for isomorphous degradation 
Pros Cons 
1. Inexpensive 1. Time Consuming 
2. Been shown to tether GFs to the surface of 
scaffolds 
2. May not be suitable for all applications 
needed 
3. Fibrin integrity remains intact 3. Changes mechanical properties 
4. Possibility for tunable mechanical properties  
 
Physical Crosslinking through UV Radiation 
 The second means is a strategy that involves UV radiation to crosslink the composite, or 
components of it. The fibrin is subjected to a short burst of UV rays to reinforce the fibrin 
network and reduce the degradation rate (Cornwell, 2007). UV crosslinking has also been shown 
to attenuate fibroblast proliferation (Cornwell, 2007). The pros and cons of UV crosslinking is 
outlined in Table 22. 
Table 22: Pros and cons of UV crosslinking to allow for isomorphous degradation 
Pros Cons 
1. Faster procedure 1.  May damage certain constructs 
2. Can assure treatment is the same each time 2. May not be suitable for all applications 
needed 
3. Been shown to tether GFs to the surface of 
scaffolds 
3. Free radical formation 
4. Increases mechanical properties 4. Alters cell-matrix interactions  
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Protease Inhibitors 
 The third means is a strategy that plays a role in the natural activity of fibrin. By adding 
protease inhibitors, such as aprotinin, and incorporating them into the network slowed 
degradation occurs (Smith, 2007; Thomson, 2013). Aprotinin is a small protein that can diffuse 
out from the network to allow fibrinolysis to occur (Smith, 2007). By chemically conjugating a 
protease inhibitors to fibrinogen, it will inhibit the plasmin-mediated fibrin degradation and slow 
the process (Smith, 2007; Thomson, 2013). Additionally, the concentration of aprotinin can 
directly tune the degradation rate, which makes it easy to fine tune the scaffold to reach a desired 
degradation rate (Smith, 2007; Thomson, 2013). Table 23 outlines the pros and cons for the use 
of protease inhibitors for prolonged degradation. 
Table 23: Pros and cons of protease inhibitors to allow for isomorphous degradation 
Pros Cons 
1. Would be harmless in a fibrin scaffold in 
small enough doses 
1. May not increase mechanical properties 
2. Could easily modify to change degradation 
time 
2. Process may be time consuming 
3. Best mimics natural processes 
 
4.2.4 Promote Aligned Myogenesis Means 
For a scaffold to be effective in treating VML, the host cells need to be aligned to form 
functional muscle tissue. Due to the nature of VML, the natural cues that would promote 
alignment are absent from the wound site. Specific addition or modification to scaffold surfaces 
and composition are able to cue cellular alignment (Cezar, 2015). These methods include the use 
of fibrin microthreads, patterned surfaces, fibrin microthreads with peptide ligands, fibrin 
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microthreads with patterned surfaces, and patterned surfaces with peptide ligands (Chen, 2015, 
Cornwell, 2007).  
 
Fibrin Microthreads 
The first means to promote aligned myogenesis is through the use of fibrin microthreads.  
The thread-like structure provides an aligned surface for cells to adhere to and fuse together to 
form functional myofibers (Page, 2011). The fibrin itself also contains biochemical cues, along 
with the aligned thread structure, promotes tissue regeneration by allowing the cells to form an 
aligned matrix which mimics native tissue architecture (Cornwell, 2007). Pros and cons for the 
use of microthreads are outlined in Table 24. 
Table 24: Pros and cons for fibrin microthreads to promote aligned myogenesis 
Pros Cons 
1. Promotes cellular alignment 1. Adds additional fabrication time to the 
scaffold 
2. Fabrication protocol is already 
established 
2. Brittle 
3. Easy to make reproducibly 3. Difficult to handle 
 
Patterned Surface 
For the second means, patterned surfaces with grooves and channels provide indentations 
on the micro-scale for cells to migrate along as well as align in (Chen, 2015). Cells that have the 
intrinsic potential for cellular alignment have shown alignment when confined in 
microarchitectures such as grooves and channels on the surface of scaffolds ranging in groove 
widths of several nanometers to 100 micrometers (Chen, 2015). The use of these 
77 
 
microarchitectures provides a 3D structure that is favorable for cellular alignment (Aubin, 2010; 
Chen, 2015). An outline of the pros and cons for using a patterned surface can be found in Table 
25.  
Table 25: Pros and cons for patterned surfaces to promote aligned myogenesis 
Pros Cons 
1. Easy to create rigid grid on scaffold 1. Heterogeneous distribution depending on 
difficult to control and manufacture 
concentration of patterned grooves 
2. Modification beyond conventional patterns 
allow for more design flexibility 
2. Custom wafers for patterns can have a high 
initial cost 
3. Reduced fabrication time 3. Patterns may not work with all scaffold 
types 
 
Fibrin Microthreads and Peptide Ligands 
The third means to promote cellular alignment are through the use of microthreads and 
peptide ligands. Fibrin microthreads on their own have already shown potential for cellular 
alignment by providing a 3D architecture close to that of native tissue (Cornwell, 2010). Peptide 
ligands have the ability to mimic the adhesive cues of myoblasts (Gribova, 2014). By applying 
the peptide ligands to the thread, the peptide is able to increase cellular adhesion. The increased 
cellular adhesion to the aligned fiber promotes cellular fusion into multinucleated myofibrils 
(Rowley, 1999). Fibronectin is an essential part of the basement membrane of muscle fibers in 
vivo (Sanes, 1982). Therefore by incorporating a fibronectin-derived amino acid sequence, like 
RGD peptide has been shown to be a potential cue to increase cellular alignment (Sengupta, 
2012). The pros and cons of this option are outlined in Table 26.  
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Table 26: Pros and cons for fibrin microthreads and peptide ligands to promote aligned myogenesis 
Pros Cons 
1. Peptides would provide additional cues 
for alignment 
1. Sterilization procedure may need to change 
from current methods 
2. Inexpensive to add to the current 
microthread fabrication procedure 
2. Has the potential to detach/denature and be 
ineffective 
3. Minimizes the risk of immune reactivity 
or pathogen transfer when compared to 
xenografts or cadaveric protein sources  
3. Increased prep-time required 
 
Fibrin Microthreads and Patterned Surface 
 For the fourth means, fibrin microthreads with the addition of patterned surfaces may 
allow for additional alignment due to an increase in topographical cues along with the chemical 
cues from the fibrin microthreads. Both the use of fibrin threads and patterned surface 
individually have shown increased possibility for cellular alignment due to their 3D structures 
(Cornwell, 20010 Aubin, 2010). Together there may be an increase in cellular alignment due to 
an increase in topographical and structural cues. The pros and cons of fibrin microthreads and 
patterned surfaces are outlined in Table 27. 
Table 27: Pros and cons for fibrin microthreads and patterned surfaces to promote aligned myogenesis 
Pros Cons 
1. Increased alignment possibilities 1. Increased fabrication time 
2. Allows for increased design flexibility 2. Pattern may not work with all scaffold types 
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Patterned Surface and Peptide Ligands 
The fifth means for promoting aligned myogenesis is through the use of patterned 
surfaces and peptide ligands. Topographically the patterned surface would promote alignment 
and migration by providing a preferred 3D structure for the cells to align in (Aubin, 2010). With 
the addition of peptide ligands, the scaffold would be able to provide chemical cues for cellular 
alignment by mimicking the adhesive cues for myoblasts (Rowley, 1999). Table 28 outlines the 
pros and cons for the use of patterned surface and peptide ligands. 
Table 28: Pros and cons for patterned surfaces and peptide ligands to promote aligned myogenesis 
Pros Cons 
1. Peptides would provide additional cues for 
alignment 
1. Sterilization procedure may be more 
difficult 
2. Inexpensive to add to patterned surfaces 2. May detach/ denature and be ineffective in 
the patterns 
3. Minimize risk of immune reaction 3. Increase prep-time is required 
4.2.5 Controlled Release Means 
In order to properly simulate the same niche as natural regeneration, a controlled release 
of relevant GFs must be developed from the scaffold. The scaffold must be fabricated in such a 
way that allows for growth factor loading, specifically FGF-2, and to support sustained release of 
this growth factor throughout the repair phase, about 3-4 weeks (Tatsumi, 2004). In order to 
accomplish this within a fibrin scaffold, there are a variety of methods previously used, each 
having their own advantages and disadvantages, such as diffusion, degradation driven, 
immobilization using heparin, polymer encapsulation, and finally stimuli driven release (Section 
2.3.3).  
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Diffusion 
 Diffusion driven controlled release utilizes the pores of a specific material in order 
control the release of an agent, or growth factor. In the case of the fibrin scaffold developed, a 
monolithic or matrix device would be used (Fan, 2012). This method of controlled release would 
be accomplished by soaking the fibrin scaffold in a saturated bath of growth factors and allowing 
the system to come to equilibrium. This method could also be accomplished by bulk loading of 
the FGF-2 with the solutions used to create the scaffold. The scaffold could then be placed in the 
desired environment and the concentration gradient would drive the growth factor out of the 
scaffold. In order to alter the pores of the scaffold, salts or similar dissolvable materials could be 
used during the fabrication of the scaffold. A schematic outlining this mechanism can be found 
in Figure 10 and the pros and cons of using diffusion as a mechanism for controlled release in 
Table 29.  
 
Figure 10: Diffusion drive release of FGF-2  
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Table 29: Pros and cons for diffusion to allow for controlled release 
Pros Cons 
1. Allows transport of nutrients and GF 
within scaffold and with surrounding tissue 
1. Heterogeneous distribution depending on 
difficult to control concentration gradient 
2. Pore size can be altered to control what is 
released using inexpensive salts 
 
 
Degradation-driven 
 A degradation-driven system utilizes the scaffold degradation to control the release of the 
active agent, or growth factor. Simplifying the degradation of the scaffold down to only surface 
degradation will allow for an easier understanding of this method of release. For this method, the 
growth factor would be fully incorporated within the scaffold. If the scaffold is loaded with the 
growth factor, similarly to the monolithic method above, the growth factor will be dispersed 
throughout the entire scaffold. Assuming that the growth factor is too small to diffuse out of the 
scaffold through the pores, the growth factor will be released as the material of the scaffold 
erodes. However, bulk degradation as well as surface degradation is frequently observed, making 
the analytical predictions of this system more complex (Fan, 2000) Figure 11 outlines the 
mechanism by which degradation driven systems allow for controlled release and Table 30 
outlines the pros and cons of this method  
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Figure 11: Degradation induced FGF-2 release 
Table 30: Pros and cons of a degradation driven system to allow for controlled release 
Pros Cons 
1. No additional material needed 
in scaffold 
1. Scaffold may degrade too quickly 
 
2. Heterogeneous degradation resulting in different release 
profiles across scaffold 
 
Immobilization using heparin 
 Certain growth factors, including FGF-2, have an affinity to the glycosaminoglycan 
carbohydrate known as heparin. Heparin can ionically bind to the growth factors, temporarily 
sequestering the factor into the scaffold (Hudalla, 2011). Until disassociation or competitive 
ionic interaction is able to cleave the heparin-growth factor ionic bond, the growth factor will 
remain inside the scaffold’s matrix. This method would be incorporated by EDC/NHS 
crosslinking the scaffold with heparin. The growth factor, in solution, would be placed onto the 
scaffold, allowing the development of the ionic bond between the growth factor and the heparin 
molecules. The growth factor would remain immobilized until the bond was cleaved, releasing 
the growth factor into the surroundings. The immobilization of FGF-2 through the use of heparin 
is characterized in Figure 12 the pros and cons of this method are outlined in Table 31.  
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Figure 12: Immobilization of FGF-2 using heparin 
 
Table 31: Pros and cons of immobilization using heparin to allow for controlled release 
Pros Cons 
1. Extensive control over release profile 1. Not all GFs have affinity to heparin 
2. Can use any GF with affinity to heparin 
 
 
Polymer encapsulation 
 In this work, polymer encapsulation is referring specifically to the incorporation of 
polymeric beads, encapsulating the growth factor, into the scaffold to delay the release. Polymer 
encapsulation controlled release use alternate polymers, such as alginate, to encapsulate the 
growth factor. The encapsulation of the growth factor inside of these beads will be able to delay 
the release of the growth factor based on the degradation rate of the polymer in the system. As 
these polymer beads degrade, the growth factor will be released into the scaffold, which will 
allow for diffusion out of the scaffold due to the concentration gradient in the system. Before the 
polymer beads have degraded, the growth factor will be unable to diffuse out of the scaffold due 
to the additional mass. Altering the compositions of the polymer beads will allow for control of 
the release rate (Fan, 2012). A schematic depicting the mechanism of encapsulation to allow for 
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controlled releases is shown in Figure 13 and the pros and cons for this method are outline in 
Table 32.  
 
Figure 13: Polymer encapsulation for controlled release 
 
Table 32: Pros and cons of polymer encapsulation to allow for controlled release 
Pros Cons 
1. Different polymers have different 
degradation times 
1. Potentially expensive, synthetic polymers can 
exhibit poor cell adhesion 
 
2. Possibly complex and time consuming 
4.3 Means Evaluation 
After the pros and cons for each means was thoroughly investigated, the team did a 
means evaluation through the use of a matrix found in Appendix F: Means Evaluation Matrix. In 
the matrix, each means was ranked based on how it contributed towards each of our main and 
sub-objectives. The mean is highlighted in red if it was later determined to not fit within the 
constraint and it is green if it is top-ranked. Each sub-objective had a 1 to 4 ranking system with 
a list of ranking quantifiers. A four was considered the highest ranking, while a one was the 
lowest. If a particular function had no corresponding contribution to a certain sub-function, then 
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that section was blacked out in the matrix. Only the means that passed the constraints test were 
scored in this matrix. Each design team member filled out the matrix and then results were 
discussed until there was a consensus on each ranking. Each means was ranked independent of 
the other means and was based only upon how well it accomplished the prioritized objectives.  
Through this analysis, as seen in Table 33, it was determined that to accomplish function 
2, cellular survival, the most efficient means would be fibrin gel with microthreads and fibrin 
film with microthreads. For function 3, the degradation of the scaffold, all three means ranked 
very similarly, so to further determine their performance experimental procedures were needed. 
For function 4, promoting myogensis, the highest ranked means were fibrin microthreads and a 
patterned scaffold with fibrin microthreads. Finally, for function 5, the controlled realease of 
FGF-2, degradation, and immobilization using heparin scored the highest. The means for 
function 1, fabrication success, were not ranked in the same manner due to the need for 
experimental testing to determine their performance.  
Table 33: Summary of means evaluation 
Function Means Overall Score 
2 
Fibrin film 36 
Fibrin gel 35 
Fibrin microthreads 33 
Fibrin gel with microthreads 38 
Fibrin film with microthreads 39 
3 
Protease Inhibitors 31 
UV Crosslinking 33 
Chemical Crosslinking* 31 
4 
 
 
Fibrin microthreads 39 
Patterened surface 34 
Microthreads + peptide  34 
Patterned +microthread 39 
 
5 
 
Diffusion  21 
Degradation 26 
Immobilization using heparin* 27 
Polymer encapsulation 20 
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4.4 Feasible designs 
After all of the rankings were completed each means’ total score was tallied. This helped 
the group to identify the most promising feasible means for each function. Morphology charts 
were developed for the means that ranked the highest in each function. The morphology charts 
for the highest ranking feasible means are shown in Table 34 – 37. 
The highest ranked means were combined to create 5 feasible designs. The team 
developed visual prototypes depicting what the design would look like (Figures 14-18). Each has 
a top and front view of the composite with green representing the conjugation method of FGF-2 
and yellow representing the crosslinking method for the scaffold. Fibrin microthreads are shown 
in blue, gels are depicted as light gray and films are depicted as dark gray.   
 
 
 
Figure 14 Film with Microthreads, FGF-2 immobilized using heparin and EDC/NHS crosslinking 
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Table 34: Morphology chart 1 
 
Figure 15: Film with microthreads, FGF-2 incorporated and released with degradation and UV crosslinked 
Table 35: Morphology chart 2 
 
  
Means 1 2 3 4 5 
Allows cellular 
survival through a 
form factor of a 
fibrin scaffold 
Fibrin Film Fibrin gel Fibrin 
Microthreads 
Fibrin gel with Micro 
threads 
Fibrin film with 
microthreads 
Promotes 
endogenous aligned 
myogenesis 
Fibrin Micro 
threads 
Patterned 
Surface 
Micro threads 
and peptides 
Patterned surface and 
microthreads 
Patterned 
surface and 
peptides 
Release FGF-2 
throughout 
regeneration phase 
Diffusion Degradation Polymer 
Encapsulation 
Immobilization using 
Heparin 
- 
Spatiotemporal 
degradation 
“Isomorphous 
degradation” 
Chemical 
Crosslinking 
UV 
Crosslinking 
Protease 
Inhibitors 
- - 
Means 1 2 3 4 5 
Allows cellular survival 
through a form factor 
of a fibrin scaffold 
Fibrin Film Fibrin gel Fibrin 
Microthreads 
Fibrin gel with 
Micro threads 
Fibrin film with 
microthreads 
Promotes endogenous 
aligned myogenesis 
Fibrin Micro 
threads 
Patterned 
Surface 
Micro threads 
and peptides 
Patterned 
surface and 
microthreads 
Patterned surface 
and peptides 
Release FGF-2 
throughout 
regeneration phase 
Diffusion Degradation Polymer 
Encapsulation 
Immobilization 
using Heparin 
- 
Spatiotemporal 
degradation 
“Isomorphous 
degradation” 
Chemical 
Crosslinking 
UV 
Crosslinking 
Protease 
Inhibitors 
- - 
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Figure 16: Gel with microthreads, FGF-2 immobilized using heparin and EDC/NHS crosslinked 
 
Table 35: Morphology chart 3 
Means 1 2 3 4 5 
Allows cellular survival 
through a form factor of a 
fibrin scaffold 
Fibrin Film Fibrin gel Fibrin 
Microthreads 
Fibrin gel with 
Micro threads 
Fibrin film 
with 
microthreads 
Promotes endogenous 
aligned myogenesis 
Fibrin Micro 
threads 
Patterned 
Surface 
Micro threads 
and peptides 
Patterned 
surface and 
microthreads 
Patterned 
surface and 
peptides 
Release FGF-2 throughout 
regeneration phase 
Diffusion Degradation Polymer 
Encapsulation 
Immobilization 
using Heparin 
- 
Spatiotemporal 
degradation “Isomorphous 
degradation” 
Chemical 
Crosslinking 
UV 
Crosslinking 
Protease 
Inhibitors 
- - 
 
  
89 
 
 
Figure 17: Gel with microthreads, FGF-2 released with degradation and UV crosslinked 
Table 36: Morphology chart 4 
Means 1 2 3 4 5 
Allows cellular 
survival through a 
form factor of a 
fibrin scaffold 
Fibrin Film Fibrin gel Fibrin Micro 
threads 
Fibrin gel with 
Micro threads 
Fibrin film with 
microthreads 
Promotes 
endogenous aligned 
myogenesis 
Fibrin Micro 
threads 
Patterned 
Surface 
Micro threads 
and peptides 
Patterned 
surface and 
microthreads 
Patterned surface and 
peptides 
Release FGF-2 
throughout 
regeneration phase 
Diffusion Degradation Polymer 
Encapsulation 
Immobilization 
using Heparin 
- 
Spatiotemporal 
degradation 
“Isomorphous 
degradation” 
Chemical 
Crosslinking 
UV 
Crosslinking 
Protease 
Inhibitors 
- - 
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Figure 18: Film with microthreads and patterned surface, FGF-2 released with degradation and EDC/NHS crosslinked 
 
Table 37: Morphology chart 5 
Means 1 2 3 4 5 
Allows cellular 
survival through a 
form factor of a 
fibrin scaffold 
Fibrin Film Fibrin gel Fibrin Micro 
threads 
Fibrin gel with Micro 
threads 
Fibrin film with 
microthreads 
Promotes 
endogenous aligned 
myogenesis 
Fibrin Micro 
threads 
Patterned 
Surface 
Micro threads 
and peptides 
Patterned surface and 
microthreads 
Patterned surface 
and peptides 
Release FGF-2 
throughout 
regeneration phase 
Diffusion Degradation Polymer 
Encapsulation 
Immobilization using 
Heparin 
- 
Spatiotemporal 
degradation 
“Isomorphous 
degradation” 
Chemical 
Crosslinking 
UV 
Crosslinking 
Protease 
Inhibitors 
- - 
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4.5 Final Design  
 
Figure 19: Final Design 
The final design is a fibrin film with five uniformly-spaced fibrin microthreads (Figure 
19). For the remainder of the report, the final design will be referred to as the composite. The 
FGF-2 will be incorporated onto the scaffold with the use of heparin. The ionic bond between the 
FGF-2 and the heparin will temporarily immobilize the FGF-2 until the bond is cleaved, delaying 
the release rate (Hudalla, 2011). The scaffold will be stabilized with chemical crosslinking via 
EDC/NHS solution in order to delay degradation throughout the FGF-2 release. The team 
decided this design is best fit to achieve all of the functions and does so in a way that is user 
friendly and reproducible.  
5.0 Design Verification  
In order to determine the validity of the design team’s theoretical design, a series of 
characterization tests and experiments were performed to compare potential components of the 
final design and verify that the PFFT design was the best performing composite. Specifically, 
92 
 
compatibility tests were performed to determine if fibrin scaffold, both gels and films could be 
incorporated with fibrin microthreads to develop the composite desired for the project. 
Ultimately, the team prepared initial experiments to optimize the patterning of the scaffolds, the 
optimal protocol for the composite and the loading of the FGF-2 growth factor. Once these initial 
experiments were deemed successful, the team tested the final design for performance in the five 
project functions. In order to test the capability of the scaffold in fulfilling the functions, the 
design team designed experiments to characterize the functions. The function that is being tested 
is stated under each experiment, except for experiment 1, which is not aimed at a specific 
function but aims rather to ensure reproducibility. Protocols for the following experiments were 
retrieved from Pins’ Lab or created by the team unless otherwise specified and can be found in 
Appendix H. 
5.1 Composite Fabrication Optimization 
Function 1: Fabricated with over 90% success and require under 2 hours user labor 
The first experiment performed was to create an optimized protocol for the composite 
fabrication.  This included the creation of the scaffold with threads and the patterning step.  The 
team determined success by adjusting the protocol to find the highest yield of scaffolds possible 
which quantifies reproducibility. The variables for composite fabrication were coating the 
casting surface with Pluronics F-127 solution or not, thread attachment with the vacuum 
alignment device or hand-aligned threads and rinse times for the diH20 baths. Batches of 
composites were made testing the different variable and the yield of each batch was recorded to 
determine which was most successful. The goal of this experiment was to find a combination of 
variables that were both high yield and easy to reproduce in a timely manner.   
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Depending on the casting platform, Pins Lab has traditionally used Pluronic F-127 coating to 
create a non-stick surface for fibrin polymerization which allows easy removal. Pluronic F-127 is 
a polymer which can be made into a 1% solution with water for use of baths to coat casting 
platforms. It is highly lipophilic and prevents the fibrin from adhering to the casting platforms. 
Previously, acetyal plastic slides have been used for a casting platform but with the new 
patterned PDMS molds, the team needed to test whether Pluronic F-127 coating was a required 
step. To test this 2-3 batches (5 composites per batch) where cast on molds that were and were 
not coated with 1% Pluronic F-127 To be coated, the protocol in Appendix H. 
The yield was determined by counting the number of inact, usable films from each 5-film 
batch. Minor tears that did not impact the overall surface area of the film were considered usable. 
The results of the experiment are shown in Table 38. 
Table 38: Results from acetyl slide coating experiment 
Batch Number  No Pluronic (Yield) Pluronic Coating (Yield) 
1 3/5 5/5 
2 4/5 5/5 
3 2/5 4/5 
4 3/5 5/5 
From this experiment, the yield without coating was 60% versus 95% with the coating. The 
coating provided a noticeable increase in yield and was determined to be valuable in the 
fabrication process.  
 The incorporation of threads into a gel has been previously done using the vacuum 
alignment device in Pins’ Lab developed in a 2015 MQP Project (GXP 1201).However, the team 
tested the efficiency of hand-aligning the low five-count threads and being able to fixed 12-13 
frames per alignment attempt whereas the device only fits three to four frames. This is because 
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the total length of the 5-thread group with the device is about 3 inches, whereas manually 
aligning the original length threads yields a group with a total length of about 9-10 inches. To 
test this, average time to make composites was observed and user preference was recorded for 
each method.  
The second test was to determine the best method for aligning the threads either using a 
the vacuum device or hand aligning longer threads. The time each method took for the aligning 
and gluing steps is shown in Table 39. The batch sizes vary based on the number of composites 
needed for a particular experiment and it is important to note that with both methods, the threads 
were drawn using Lacey and wet-stretched. 
Table 39: Results for alignment method experiment 
Vacuum Device Hand Alignment 
12 composites/ 45 min 13 composites/ 25 min 
9 composites/30 min 6 composites/ 15 min 
18 composites/ 60 min 24 composites/ 35 
Average Time = 3.5 
min/composite 
Average Time = 0.54 min (35 
seconds) / composite 
The results shown that the hand alignment method is more efficient. It is on average, seven times 
faster for producing large batch sizes. All members of the team preferred this method and it is the 
final method used in the fabrication protocol. 
 Finally, incorporation of the threads into the film was a new step in which a protocol had 
not yet been developed for Pins Lab. For film fabrication, each sample was rinsed to remove 
calcium salts by submerging it in three dH2O baths for five minutes each with each bath being 15 
mL. This method was tested with the threads, along with longer times and higher volumes of 
water to ensure that the calcium ions sufficiently diffused from both the film and threads. It was 
predicted by the team that a longer time would be necessary since the threads are embedded in 
the film, providing a potential barrier to diffusion. The success of each method was determined 
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by the presence of, or lack thereof, a salt ring in the center of the composite which makes it 
brittle and crack easily. The goal was to find a method that eliminated the presence of this ring.  
The initial test performed was to see if pluronics was necessary for coating the acetyl 
slides on which the films are cast and dried. The yield was determined by counting the number of 
in-tact, usable films from each 5-film batch. Minor tares that did not impact the overall surface 
area of the film were considered usable. The results of the experiment are shown in Table 40.  
Table 40: Results from acetyl slide coating experiment 
Batch Number  No Pluronic (Yield) Pluronic Coating (Yield) 
1 3/5 5/5 
2 4/5 5/5 
3 2/5 4/5 
4 3/5 5/5 
From this experiment, the yield without coating was 60% versus 95% with the coating. The 
coating provided a noticeable increase in yield and was determined to be valuable in the 
fabrication process.  
 The second test was to determine the best method for aligning the threads: the vacuum 
device or hand aligning longer threads. The time each method took for the aligning and gluing 
steps is shown in Table 41. The batch sizes vary based on the number of composites needed for a 
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particular experiment and it is important to note that with both methods, the threads were drawn 
using Lacey and wet-stretched. 
Table 41: Results for alignment method experiment 
Vacuum Device Hand Alignment 
12 composites/ 45 min 13 composites/ 25 min 
9 composites/30 min 6 composites/ 15 min 
18 composites/ 60 min 24 composites/ 35 
Average Time = 3.5 
min/composite 
Average Time = 0.54 min (35 
seconds) / composite 
The results shown that the hand alignment method is more efficient. It is on average, seven times 
faster for producing large batch sizes. All members of the team preferred this method and it is the 
final method used in the PFFT fabrication protocol.  The third test completed to optimize the 
composite fabrication process was the rinse volume and time per sample. As previously 
mentioned, the standard for films was 15 mL per sample for five minutes each of the three times. 
To adjust this, longer times and greater volumes were tested. The yield of each variable batch 
tested was determined by the number of scaffolds which did not contain a salt ring after drying. 
To characterize the best method, any presence of a salt ring noticeable was determined to be 
unusable. The results are shown in Table 42. 
Table 42: Results from rinse time and volume experiment 
Time/rinse and Volume/scaffold Yield  
5 min and 15 mL 1/5 
10 min and 15 mL 3/5 
5 min and 25 mL 3/5 
10 min and 25 mL 5/5 
From the results, it was determined that the best method is 10 min per rinse and 25 mL per 
scaffold. For ease of use purposes, a large water bath with the same volume to scaffold ratio was 
used for a whole 5-composite batch. In other words, 125 mL was used per bath for 5 scaffolds 
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for 10 minutes. The yield remained 100% and it also saved time so it was determined to be the 
optimal rinse procedure for the protocol.  
5.2 Cellular Viability 
Function 2: Promotes cellular viability   
While fibrin is known to be a biocompatible material, it needed to be shown that the 
patterned fibrin film with threads design remains biocompatible and promotes cellular 
proliferation equally to a positive control for cell growth. In order to test the cellular viability of 
the composite scaffold, resazurin was used in vitro to measure cell viability. Resazurin is a 
molecule that is metabolized by living cells and produces a fluorescence change that can be 
quantified with a fluorescent plate reader where the fluorescent intensity directly correlates to the 
number of living cells. When added to the cells, an oxidized form of the resazurin enters the cell 
membrane and through enzymatic activity in the mitochondria it is converted to the reduced form 
(Al-Nasiry, 2007). The redox reaction occurs through electron transfer from NADPH, FADH, 
FMNH and NADH and this corresponds to the color change which goes from indigo to a pink 
hue (Al-Nasiry, 2007). To perform the assay the resazurin and media solution, which is made at 
a concentration shown in Appendix H, was added to 12-well tissue culture plates containing (1) 
composite scaffold, (2) fibrin films and (3) scaffolds with fibrin threads, as well as tissue culture 
plate (TCP) control (Figure 20). The film provides a group to compare the  composite design to 
without threads, and the threads in a scaffold group provides a group to ensure that adding fibrin 
threads to the design does not  produce any leachable materials that affect cell viability. The TCP 
wells provide a positive control to compare and ensure cell growth is equivalent for the 
composite.  At t=0 days a low-volume cell solution containing 60,500 cells was added to a 
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dehydrated composite and allowed to adhere for two hours before adding 2 mL of media to each 
well.  
 
Figure 20: Experimental design of cell viability assay 
For each trial, the solution was tested after 1 day and 4 days. The media was aspirated 
and replaced with 0.5 mL of the resazurin and media solution and incubated two hours. For each 
well sample, 100 μL was pipetted in triplicate to a 96-well plate to be read with the fluorescent 
plate reader. The protocol for the plate reader was developed by Coburn lab and reads at a 
wavelength of 580-610 nm emission while using a 540-570 nm excitation wavelength. The full 
protocol for the resazurin cell viability assay can be found in Appendix H. 
The data retrieved from the fluorescent plate was used in combination with a standard 
curve obtained using a serial dilution of cell totals. The standard curve allowed us to convert the 
fluorescent intensity to total cell numbers at a 100 μl volume for that time point. For the purpose 
of our study, cell totals based on a consistent concentration were useful when discussing the data 
but absolute cell total calculations were not necessary as we only need to ensure there is no 
statistical difference between our sample and the TCP or other groups. A total of four trials were 
completed and analyzed for results.  An ANOVA statistical test was used to compare all groups 
99 
 
for each time point. A p-value of <0.05 was considered significant. All analysis was completed 
using GraphPad software.   
The first step in this experiment was to create a standard curve that could be used to 
convert fluorescent intensity from the resazurin cell viability assay to a cell count. The results of 
the standard curve are shown in Appendix G. The R2 value of 0.9465 indicates that the trend line 
was a good linear fit for the standard curve data.  
In order to show that the cells were surviving and proliferating on the composite scaffold, 
the rezasurin assay fluorescent intensity was recorded for each sample of the composite, film, 
threads, and TCP. Each sample was loaded into the plate in triplicate, and an average reading 
was used, which was inserted into the equation shown on the standard curve graph in Appendix 
G in order to get a cell count based on the fluorescent intensity. For each trial, the data was 
graphed for the two time points, T1 which was sampled after 24 hours and T4 which was 
sampled after 4 days, as shown in Figure 21.  
 
Figure 21: Results from cell viability assay from all 3 trials 
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Figure 22: Overall results from cell viability assay 
 
The results from all trials were then averaged in order to obtain the overall results. 
Visually, it can be seen from Figure 22 that the cell counts between the composite and the other 
groups are relatively even. In order to determine whether there was a statistical difference 
between the groups, an ANOVA was performed using the data from the three trials using 
GraphPad. The negative control shown represents the wells in the test that had only resazurin and 
no cells. The composite, film, and threads had a sample size of n=16, the negative control had a 
sample size of n=6, and the TCP had a sample size of n=12. The D'Agostino & Pearson omnibus 
normality test with a confidence interval of 95% was used to determine if the samples from each 
group come from a normally distributed population. The positive control and the threads passed 
this normality test, but the composite and the film did not. It is expected that if more trials were 
performed, all groups would pass the normality test as the sample size would be higher, but time 
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restrictions on the project did not allow this. Since all of the data from Trials 2, 3 and 4 did not 
all pass the normality test, a Kruskal-Wallis non-parametric test was used. 
Table 43 shows the p-values for the comparison between each of the groups. The only 
comparisons that were considered significant according to the parameters stated in section 5.4 
were each group vs. the negative control. This means that there is no significant difference in cell 
viability between the composite, film, and threads, indicating that our design, promotes cell 
viability as well as a film, threads, and TCP.  
 
Table 43: t-test p-values 
Groups Tested Significant? 
P<0.05 
P-value 
Composite vs. Film No >0.9999 
Composite vs. Threads No >0.9999 
Composite vs. TCP No >0.9999 
Film vs. Threads No >0.9999 
Film vs. TCP No >0.9999 
Threads vs. TCP No >0.9999 
 
5.3 Degradation Study 
Function 3: Prolongs degradation to preserve partial structural integrity for two weeks 
The design should be structurally intact for the entire period of growth factor release and 
the team incorporated chemically crosslinking as a way to slow down degradation. In order to 
characterize the effect of EDC/NHS crosslinking on the film degradation time, originally, the 
tensile strength of samples was tested at various time points over seven days. Using the Instron, 
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the scaffolds were mechanically broken by tensile forces for both an uncrosslinked and 
crosslinked group at zero, three, five and seven day time points. The protocol for measuring the 
tensile strength can be found in Appendix H. 
After initial testing it was decided that this experimental protocol was too cumbersome 
and would not fit within time frame to continue. The experiment required too many samples. 
Therefore, after careful consideration, the team and the clients decided to image scaffolds over 
the span of two weeks and use ImageJ to measure the area loss due to degradation. An example 
of what was expected for crosslinked for uncrosslinked samples is shown in  
 
Figure 23: An example showing potential differences in degradation based on time for the composites that are crosslinked vs 
uncrosslinked 
The two conditions for the scaffold, crosslinked and uncrosslinked were sterilized in an 
70% ethanol bath and then placed into a sterile six-well plate. A schematic showing the expected 
difference in degradation is shown in Figure 23 and the experimental design set up is shown in 
Figure 24.  
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Figure 24: Experimental layout for degradation study where UNX = uncrosslinked composite and EDC/NHS = crosslinked 
composite using EDC/NHS solution 
Both conditions had 50,000 C2C12 cells seeded onto their surface and 2 mL of complete 
media was added to each well. The six-well plate was then placed into an incubator at 37C for 
two weeks. The media was changed every two days to ensure cell survival over two weeks. At 
specified time points, the scaffolds were imaged using the Zeiss Camera in Page’s lab. Then the 
images were analyzed using ImageJ to measure the loss due to degradation caused by cells. The 
protocol for the degradation experiment can be found in Appendix H. 
Three separate trials were performed for the degradation experiment giving a sample size 
of nine for each condition. The results were compiled and is shown in Figure 25. At the end of 
the trials, it was determined that the crosslinked composites preserved 94% of its physical 
structure meanwhile uncrosslinked composites preserved 75% of its area. A t-test was 
performed, specifically a Kolmogorov-Smirnov (KS) t-test was performed since the unpaired 
groups were compared and the distribution for each group was not normally distributed 
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(nonparametric) after testing normality. Based on the KS test, only days 10 and 14 were 
determined to be statistically significant (p<0.05).  
 
Figure 25: Average area remaining over the course of 14 days for crosslinked and uncrosslinked samples 
 
5.4 Alignment analysis  
Function 2: Promotes nuclear alignment along fibrin threads at angles <10 degrees relative to the thread 
To ensure that our composite promotes alignment along the threads, a cell solution 
containing 60,500 C2C12 mouse myoblasts was delivered to fibrin composite samples and film 
samples. The cells were allowed to adhere for a two hour incubation period before adding media. 
All groups were tested with n=3 for each trial. After four days of incubation a nuclear stain was 
used after fixing the cells to the surface of the sample. To stain for cell alignment Hoechst 33342 
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(Thermofisher), which is a DNA stain for nuclei of live or fixed cells that is imaged using 
fluorescent microscopy, was used. The dye is excited by ultraviolet lights and emits blue 
fluorescence at 460 to 490 nm. This allowed the team to analyze cellular alignment along the 
thread. The samples were fixed using at 1 mL solution of 4% paraformaldehyde for 30 minutes, 
dried, and then incubated on a shaker plate in 1 mL of 1:6,000 dilution Hoechst solution for 10 
minutes and rinsed. The samples were then imaged with 10x magnification at five regions for 
each sample near a thread to allow for analysis around the thread. The regions were 7.42 x 5.40 
mm for each image and the five regions that were generally imaged for each sample are shown in 
Figure 26.  
 
Figure 26: Cartoon depiction of the composite scaffold and the regions (outlined in red) that were imaged for each sample 
The imaging software used for the analysis was ImageJ. ImageJ is a Java-base image 
processing program that was developed by the National Institute of Health. The protocol for 
processing the raw images in ImageJ can be found in Appendix H. 
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 The analysis included defining nuclei as an oblong shape which allowed their angular 
position to be determined relative to a 0 degree thread in the image. An example of what the 
ideal nuclear alignment would look like is shown in Figure 27.  
 
Figure 27: A depiction of ideal nuclear alignment along the thread for an imaged region. The nuclei closest to the thread would 
be quantified at 0 degrees and the angle increase as they move farther away from the thread 
The images were used to analyze cellular alignment. The images were analyzed using ImageJ 
software to determine the cellular alignment of the cells in the samples. After the images were 
analyzed the data was sorted and normalized. To adjust the data to represent the absolute angle 
relative to the thread, 180° was added to angles -91 or less and 180 was subtracted from angle 
91 or greater. The absolute value of each angle was then determined, which normalized the 
range to 0 to 90.  
The data was then grouped and sorted into bins to determine the frequency of alignment 
in both the Composite and Film only samples, by portraying then in a histogram.  A higher 
percentage of cells close to 0 showed preference toward thread alignment, while a higher 
percentage of cells close to 90 showed insufficient preference toward alignment.  If the samples 
were successful in showing preference for alignment then they would be normally distributed 
around 0 with lower bin frequencies toward 90. This was compared to a film which is expected 
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to not have a no preferential orientation towards any angle. The data for the cells that had angles 
0-10 degrees from the thread angle were then analyzed and a t-test was performed on both sets of 
data. Three alignment assays were performed and the data is shown in Figure 28 for the 
composite and Figure 29 for the film. The raw data can be found in Appendix I: Raw Data Table 
for Alignment Analysis 
 
 
Figure 28: Angle frequency for composite samples 
 
Figure 29: Angle frequency for film samples 
For the composite samples, trial 1 and trial 2 showed preferential orientation towards 
increased alignment to the fibrin film. This is indicated by the higher frequency of cells located 
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at 0-10 degree angles relative to the thread. Overall for all three film trials, there was no obvious 
preferential orientation observed in the data.  
5.5 Release Characterization  
Function 3: Release of FGF-2 throughout the regeneration phase. 
In order to characterize the release of FGF-2, a sandwich ELISA assay (Human FGF-2 
Standard ABTS ELISA Development Kit; Peprotech; USA) was performed on the samples 
collected from the various test groups, with and without. This allowed the team to determine if 
the release concentrations are at levels high enough to be deemed effective by the literature, and 
more importantly matches relevant release kinetic models. The scaffolds were placed in a PBS 
bath for a series of 1-2 weeks and placed on a plate rocker at 37C. At specified time points, the 
PBS was completely removed from the vessel and frozen in a microcentrifuge tube with 1% 
Bovine Serum Albumin (BSA), while new PBS was replaced. The FGF-2 released in the 
sampled PBS was then evaluated using the ELISA, which indicated a certain optical density 
which can be then correlated to a concentration of FGF-2 using a standard curve. The protocol 
for the ELISA kit can be found in Appendix H. By monitoring the scaffold’s release over the 1-2 
week period, the release profile can be created, and the scaffold properties can be adjusted to 
either retain or release more of the FGF-2 throughout its use. This was a good initial test to 
ensure that the target release was being achieved before measuring cellular response to the 
growth factor.  
This experiment utilized two different loading methods of FGF-2 to the scaffold, as seen 
in Figure 28. One was considered “ON” while the other was considered “IN”. The “ON” scaffold 
consisted of a fibrin film, crosslinked with heparin on the surface, the FGF-2 was then placed 
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over the scaffold for 24 hours to allow for binding. This method would utilize immobilization of 
the FGF-2 by the heparin bound to the scaffold. Alternatively, the “IN” scaffolds were prepared 
by casting the FGF-2 directly inside of the scaffold with the fibrinogen, thrombin and added 
heparin. This method of loading would utilize primarily diffusion and degradation driven release 
of the growth factor out from the scaffold.  These scaffolds were then placed into PBS at 37C 
and were sampled daily for the remainder of the study.  
 
Figure 30: FGF-2 loading methods 
 
  In order to correctly characterize the release of the growth factor from the scaffolds, a 
standard curve with known concentration vs optical densities was created. The standard values 
collected were fit to a 4-parameter curve to allow for the most accurate fit. Using the standard 
curve fit, the concentrations of all the samples was determined. Release profiles for both the 
burst release period, and extended release period were created as shown in Figure 29 and Figure 
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30 respectively. 
 
Figure 31: Burst release profile from scaffold 
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Figure 32: Extended release profile from scaffold 
It was observed that both scaffold constructs, the composite with heparin and the scaffold 
without heparin, were able to sustain the release of the growth factor over the 2 week period. The 
release profiles created were then matched to zeroth, first, and second order kinetic models, 
which did not accurately match.  
5.6 FGF-2 Functional Assay  
Functions 2 and 5  
 Once the individual components of our scaffold were characterized, the scaffold as a 
whole was tested for the functionality of the FGF-2 incorporated. This test incorporated previous 
experiments including cellular viability and alignment analysis.  
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 For this experiment, the release kinetics were not measured, but instead, the cellular 
response to the scaffold and release of FGF-2 was characterized similar to the viability in Section 
5.4. The scaffolds with the incorporated growth factor were incubated with C2C12 cells for four 
days. After the four day trial, the media was aspirated and replaced with 100 μL 10x rezaurin and 
incubated two hours. For each well sample, 100 μL was pipetted in triplicate to a 96-well plate to 
be read with the fluorescent plate reader, which is all consistent with the manufacturer’s protocol 
(Thermofisher). The full protocol for the resazurin cell viability assay can be found in Appendix 
H. The absorbance measurements in the composites would be compared to the negative control 
and to the controls without the growth factor to determine if the FGF-2 increased proliferation.  
 The first trial of this experiment provided unusable results, as the negative controls 
provided an identical reading to the samples being tested. Due to time constraints, additional 
experiments were not possible. 
6.0 Final Design and Validation 
6.1 Overview of Composite Fabrication 
The following section will outline the production of composite scaffold. This information 
may be used in order to replicate the previous research. All in-depth protocols outlined in this 
section can be found in Appendix H: Composite Scaffold Fabrication. 
  The first component necessary to be made is the fibrin microthreads. The fibrin 
microthreads were extruded by using the automated biopolymer printer for fibrin microthreads 
called LACEY. Before the machine can be used, stock solutions and aliquots must be made. 
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Fibrinogen and thrombin aliquots must be made. For stock solutions, HEPES buffered saline 
(HBS) and calcium chloride must be made.  
 First, fibrinogen aliquots are made by weighing 1.00g of fibrinogen and poured into a 
50mL conical tube, then 13.6 mL must be added to creating an effective protein percentage of 
72% and a concentration of 73.5 mg/mL. The conical tube was placed on a rocker plate and 
adjusted every 30-40 minutes to allow fibrinogen to go into the solution. It was imperative to 
never shake or vortex the fibrinogen solution, as it may cause fibrinogen to bind to itself and fall 
out of solution. To allow for the fibrinogen to completely dissolve, the conical tube was 
incubated at 37C overnight. The next morning, the fibrinogen solution was separated into 1 mL 
aliquots in Eppendorf tubes bringing the concentration to 70 U/mL and stored at -20C. 
Thrombin aliquots were made by adding 25 mL of HBS to the bottle of 1 KU thrombin and 
thoroughly mixed. Afterwards, the thrombin solution was separated into 200 µL aliquots in 
Eppendorf tubes bringing the concentration to 40 U/mL and stored at -20C. 
 For the HBS stock solution, 23.83 g of HEPES was weighed out and added to 900 mL of 
diH2O to make 10X of 10 mM HBS (100mM). Afterwards, HBS was brought to a pH of 7.4 
using sodium hydroxide and hydrochloric acid. Then the final volume was brought to 1000 mL 
and stored at room temperature. To make the calcium chloride stock solution, 0.1776 g of it was 
weighed and 40 mL of diH2O was added bringing the final concentration to 40 mM. The 40 mM 
calcium chloride was then stored at 4C. 
 Once all of the solutions have been made and stored in their appropriate places, the 
preparation for extrusion was started. First, one fibrinogen and thrombin aliquot were thawed at 
room temperature. Once completely thawed, 150 µL of the thrombin and 850 µL of calcium 
chloride was added to a 2mL Eppendorf tube and thoroughly mixed. Then using two 1 mL 
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syringes, the thrombin and fibrinogen were collected into the two separate syringes. The 
thrombin and fibrinogen solutions were carefully and slowly collected to avoid air bubbles. The 
syringes were then inverted and the air bubbles were removed by saturating the tips and tapping 
the syringes. Then the syringes were adjusted to ensure equal volumes. Next, the 10X HBS stock 
solution was diluted with 450 mL of diH2O to bring the final concentration to 1X and had its pH 
adjusted to 7.4. 
 Next came the preparation of the machine which involved the syringe pump system 
which was its settings configured as explained in Appendix H. Then the blending applicator was 
set up as shown in Figure 33. The details of the individual components are explained in 
Appendix H. 
   
Figure 33: Blending applicator set up as described in steps 2 - 4. 
Afterwards, the syringe pump was set up as shown in Figure 34. After the syringe pump was set 
up, the next focus was on the extrusion tip, which was set up as shown in Figure 353 and 
according to Appendix H. 
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Figure 34: Syringe pump set up 
 
Figure 35: Extrusion head with pipette tip and polyethylene tubing set up 
The next part involved preparing the LACEY system which involved the shoes and bath set up based on 
Appendix H and Figure 36. 
 
Figure 36: Teflon pan inserted into frame on corner notches indicated by red arrows. 
Then the 1X HBS solution was poured into the Teflon pan. Next involved setting up the shoe frame so 
that it looked like Figure 37 according to Appendix H.  
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Figure 37: Shoe frame placed into machine over Teflon pan. 
 The shoes were adjusted to ensure that the HBS covered both shoes. The software set up 
which involved using a laptop and MatLab. The configuration is explained in great detail in 
Appendix H. After all the set up was complete, extrusion operation guidelines were followed in 
Appendix H and approximately 10 microthreads were extruded. After polymerization was 
completed (10 minutes), the threads were stretched in the HBS bath and then placed on the 
cardboard box as shown in Figure 38 to allow for proper drying. Typically, the fibrin 
microthreads could be stretched and placed onto the box forming two to three fully stretched 
microthreads. 
 
Figure 38: Fibrin microthreads stretched and being dried 
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 After the microthreads have dried and the frames cut, the threads are aligned and glued to 
the frame. Five microthreads were removed from the drying box with forceps and placed onto a 
clear acetyl sheet. A 1 cm width was marked out on either side of the acetyl sheet. Tape was then 
used to pick up both sides of a microthread and it was aligned between the two 1cm marks. This 
was then repeated with the other four threads, and the ends of the threads were taped down at 
each end. About 12 vellum frames were then placed under the aligned bundle of threads. Medical 
adhesive glue and a blunt needles tip were used to place glue on the edges of the frames and then 
to push the microthreads and the glue together. This was repeated for all of the frames and then 
they were left to allow the glue to dry for approximately 6 hours.  
 To create the fibrin scaffold from the frames with threads, 5 prepared frames are placed 
on PDMS after coating the PDMS in 1% Pluronics solution to prevent sticking. Fibrin gel 
solution is prepared use 670 µL fibrinogen aliquot, 150 µL PBS, 80 µL CaCl2 and 100 µL 
thrombin aliquot. From the 1 mL solution, 200 µL is pipetted directly on the center of the 
prepared frames and using a pipette tip, the frame is pushed to be completely surrounded by the 
gel. 
After creating the scaffolds, the constructs then were  cross-linked to both prolong the 
degradation and to chemically sequester the growth factor to the scaffold as well. In order to do 
this, a solution of EDC/NHS was used. Before crosslinking, the scaffolds were hydrated in 
NaH2PO4 Buffer for at least 30 minutes. This NaH2PO4 Buffer was created by mixing 0.827 g 
NaH2PO4 in 60 mL dH2O. The EDC/NHS solution, 20 ml, was created with 0.0368 g of NHS 
and 0.1073 g of EDC and 0.002 g of heparin in 20 mL of NaH2PO4 Buffer. Once properly 
hydrated using the NaH2PO4 Buffer, each scaffold was placed in 2 mL of EDC/NHS solution and 
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left at room temperature for 2 hours. When removed from the EDC/NHS solution, the scaffold 
was washed 3 times in dH2O for 5 mins each wash. After the scaffold was cross-linked with 
heparin, the scaffold was quenched using a 0.25 % solution of glycine to allow for growth factor 
binding to the heparin. In order to accomplish this, the scaffold was placed in 2 mL of 0.25% 
glycine solution for 1 hour. When removed, the scaffold was rinsed 3 times in PBS, for 5 
minutes each.  
 Once the scaffold was prepared with the proper crosslinking and binding agents, the 
growth factor, FGF-2, was loaded onto the scaffold. In order to accomplish this loading, the 
scaffold was submerged in 1 mL of a 10 ng/mL solution of FGF-2 for at least 24 hours. If 
necessary, a greater volume may be used. During this period, the scaffold and solution was 
placed on a plate rocker. Once loaded with the growth factor, the scaffold may be used in any 
desired application. 
6.2 Impact Analysis of Device 
The purpose of the following sections is to discuss the impacts of the device in areas such 
as economics, environment, health and safety, society, politics, ethics, manufacturing, and 
sustainability. Although this design is a prototype and in its first iteration, it still has the potential 
to affect the world. 
6.2.1 Economic Impact 
By designing and developing a fibrin composite scaffold, the team helped advance the 
development of a VML solution in Pins Lab towards reaching clinical viability. The scaffold 
must be scaled up before it can be viable and actually fill a muscle wound. So far, this represents 
a significant step in the right direction for future MQP teams to continue optimizing and 
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characterizing. Major challenges that need to be met before becoming clinically available include 
the further development and characterization of the design, scaling the design, FDA regulatory 
approval with animal testing and clinical trials, and final the marketing and distribution of the 
device. 
If approved by the Food and Drug Administration (FDA), it is a possible treatment that 
could become the industry gold standard, as it may overcome many limitations of current 
treatments. Another possible advantage is that this device could be more widely used and thus 
increase the number of treated patients while increasing their standard of living. The treatment 
could increase the cost of fibrinogen and thrombin since there would be a greater demand for the 
scaffold. If optimized and and allowed for implantation, the device would have some economic 
impact as a controlled of producing fibrin in mass quantities effectively would need to be 
established. In addition, the cost of hospital resources, including the implantation procedure and 
post-operational costs would need to be considered if this device were to be perfected and 
administered to patients. In theory, the device would promote the create of competitive 
companies that would try to provide a treatment similar to this. These are just some of the 
impacts on the economy caused by the scaffold.   
6.2.2 Environmental Impact 
Since the components designed during the project are still limited in research, it will not 
be advance to the clinical trial phase for some time, there are currently no environmental impacts 
directly associated with the results of the project. If the design of the fibrin composite scaffold 
was perfected and potential in vivo implantation in patients is possible, then the scaffold could 
have some potential of impacting the environment. If effective in treating VML, the scaffold 
would increase the demand of the fibrinogen and thrombin, which polymerize to form fibrin.  
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Both fibrinogen and thrombin are currently derived from bovine sources, the increase in 
demand of these two proteins may lead to an increased population of bovines. In turn, the 
demand may increase the demand for a number of resources needed to house cattle such as land, 
housing facilities, food, waste management, and increased labor force to maintain the source 
population. Any increase in energy required to maintain cattle as well as waste produced may 
significantly impact the environment. For example, sufficient land and water must be set aside 
for the increased number of bovine sources. This additional need for space may involve clearing 
trees which can severely impact the area’s natural environment. Obtaining enough food to feed 
the cattle also require additional land allocation which may further contribute to the overall 
environmental impact. The facilities needed the house the bovine sources will require electricity, 
which may require an increased use of limited natural fuel resources. Additionally, the increased 
cattle population could lead to an increase in methane production, one of the most potent 
contributors to climate change. 
 Purifying and obtaining the proteins from the source population may also present an 
impact on the environment. The chemicals used, are the facilities needed to extract the proteins 
may contribute to affecting the environment as well. Through the proper management, the 
impact of the source population can have minimized effects if properly regulated. Proper 
regulation such as using renewable energy sources or converting waste into fertilizer are 
potential ways to minimize the environmental impact. 
6.2.3 Health and Safety Impact 
 The results obtained from the project have the potential to greatly improve the health of 
patients suffering from VML, in the future. By providing other treatment options for patients, the 
patients may be able to bypass limitations of current treatments, and therefore have a better 
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standard of living. Currently continuation of extensive research is mandatory before it is safe 
enough to implant into patients. Research includes improving reliability, reproducibility, and 
further design verification. Once these tests are completed and the product is approved by the 
FDA, it will be considered safe for the majority of the population. Some possible dangers 
associated with the use of fibrin in clinical trials may surface after further understanding. Fibrin 
naturally exists in vivo as a clotting agent, the presence of fibrin in the body can pose as a risk by 
forming unexpected clots. Another issue would be tumor formation due to the use of growth 
factors, if not controlled properly. 
6.2.4 Societal Impact 
Currently, it is infeasible in the near future for the project to become applicable in vivo, 
but in the future it may pose a substantial impact on society. For instance, if the fibrin composite 
scaffold was deemed effective in treating VML, the quality of life of patients affected by VML 
my be improve. The scaffold could have the potential to help patients, such as soldiers dealing 
with post traumatic stress disorder, since patients could be fully functional. If the results of this 
project were to be optimized in the future, the use of fibrin as a scaffold material could likely 
extend to other tissue engineering applications, calling for an increase in productivity and 
efficiently of laboratory research. 
6.2.5 Political Impact 
 The project’s results currently have minimal political ramifications. The production of 
fibrin composite scaffold is still in its infancy in terms of research and initial developmental 
stages. The results produced during the project have little to no effect on the commercial or 
industrial industries. Until the scaffold becomes commercialized or the results of the project are 
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adapted and developed to further enhance the research of current tissue engineering scaffolds, 
there would be little effect on the international market, therefore major political impacts are not 
foreseeable. 
6.2.6 Ethical Impact 
 There are minimal ethical concerns associated with the results of the project. Since the 
goal of the fibrin composite scaffold is to treat patients dealing with VML, there are no direct 
ethical concerns associated with it. The only ethical concern that could be raised is the materials 
used to form fibrin. Fibrinogen and thrombin as mentioned are derived from bovine sources and 
some potential users may feel uncomfortable using materials from an animal source, even if the 
manner in which the materials were obtained was ethical. 
6.2.7 Manufacturing Impact 
 The fabrication of the fibrin composite scaffold was designed to be straightforward, easy 
to use, and reproducible. Everything is made in a lab setting and takes less than two hours to 
fabricate. Manufacturability was taken into account early on in the design process since it was a 
demanded objective. The fabrication of one of the components of the scaffold, the fibrin 
microthreads is automated. In the future, if the demand is great enough, the fabrication process 
could become completely automated therefore minimizing the manufacturing impact. 
6.2.8 Sustainability 
 The fibrin composite scaffold is composed entirely of fibrin which demands energy to 
produce, often from a bovine source. Although the materials used in the device are relatively 
sustainable, the steps and materials utilized to obtain them may not be as sustainable as it can be. 
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If the scaffold is deemed commercial viable and successful, the demand for the materials 
required may in turn allow for the processing of such materials to become more efficient. The 
demand will spark further interest and funds necessary in maximizing efficiency in becoming 
more sustainable. 
7.0 Discussion 
Through the series of tests performed to optimize the protocol, the composite was able to 
be produced at over a 90% success rate and in a user friendly manner. This protocol can possibly 
be further optimized, but for the scope of the project, the accomplished protocol was sufficient. 
Using a composite provided an improvement on the original bundle of threads in terms of how 
easy it is to manage and load them with growth factor.  
The results from the cell viability experiments allowed showed that the composite 
scaffold allows cellular viability with no significant difference compared to the positive control 
(TCP), films, and threads. This means that if implanted in a volumetric muscle deficit, cells 
would be able to survive and proliferate on the composite. In terms of how successful this would 
be in vivo, the cellular viability assay allows the team to ensure that the composite was not only 
biocompatible but also promoted cellular growth.  
The goal of the degradation experiment was to characterize the effect of using EDC/NHS 
crosslinking on the composite. The results from the degradation experiments suggest that 
chemical crosslinking the composite enhanced scaffold integrity starting after ten days. Based on 
the KS test, the t-test determined that there was indeed a significant difference between 
uncrosslinked and crosslinked composites at days 10 and 14. The statistical analysis validates the 
notion that the the EDC/NHS crosslinking reduced degradation. The experiments were only 
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carried out for 14 days but ideally it should have been to six weeks since that is how long the 
repair phase typically lasts for. Also a sample size of only 9 was used, ideally a larger sample 
size may have been more beneficial. 
The results also confirmed with literature that EDC/NHS crosslinking is an effective 
means in delaying degradation. Furthermore, the results validate the use of EDC/NHS 
crosslinking since this crosslinking method incorporates the use heparin to allow for the 
immobilization of FGF-2. Although the the EDC/NHS crosslinking enhanced scaffold 
degradation, it may have affected the mechanical properties of the scaffold, which was never 
addressed. Additionally, it has been shown that EDC/NHS crosslinking may have an adverse 
effect on cellular adhesion to the scaffold, but this was not analyzed in our project (Grasman, 
2012). 
The first two trials for the alignment experiment showed very clear preference for cellular 
alignment in the composite sample group. The third trial, however, closely resembled the control 
film data. Before staining and imaging occurred for the third trial, a large number of dead cells 
and cloudy media was observed. This may have had an effect on the alignment of the cells. 
Another factor that could have prevented the cells from aligning is the thickness of the fibrin 
film. We assume that all the samples are similar because they were created by the same 
individual and the same protocol was used, but there is a chance that some films may be thicker 
than others. This would mean that the threads are encased in a thicker layer of film, preventing 
the cells from sensing the threads. Further trials would need to be performed to further 
characterize the alignment capabilities of the composite scaffold. 
The results from the release experiments performed imply that both models with and 
without heparin are able to sustain the release of the FGF-2 over two weeks to match the repair 
phase of muscle regeneration. With the limited data collected, the release kinetics of this release 
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mechanism could not be properly modeled using the simple zero, first, and second order models. 
This is likely due to a lack of data and an over-simplified approach to the model. The system 
involving the composite includes multiple factors such as degradation, burst release, and 
different solute diffusion coefficients, which increases the complexity (Fu, 2011). In order to 
accurately represent the GF release from the composite, a model of the release profile will need 
to be developed, with these factors full taken into account.  
In addition to testing the release profile of the FGF-2 from the scaffold, the functionality 
of the growth factor was also tested, similar to the viability assay. Unfortunately, the negative 
controls for the experiment performed were invalid, and therefore no conclusions were able to be 
drawn from the initial experiment. This invalid data observed was likely due to the 
contamination of the experiment in the negative control wells. In order to further determine the 
effect of the growth factor on the cells, this experiment will need to be adjusted and performed 
again.  
8.0 Conclusions and Recommendations 
The challenge proposed to the team was to design, develop, and characterize a composite 
fibrin scaffold. Based on the revised client statement, the composite was must be able to provide 
topographical cues for cellular alignment, be easily reproducible, be user friendly, control the 
release of FGF-2 and prolong scaffold degradation. The team was able to design, create, and test 
a platform of a composite scaffold for VML. Overall the main objectives of having robust 
scaffold properties, being user friendly, promoting myogenesis, and having reproducible scaffold 
properties were achieved through the specified test methods. This was determined through the 
development of an optimized  protocol, and the use of viability assays, degradation studies, 
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alignment assays, and release studies of FGF-2. From the data we were able to conclude that our 
conceptual design is a viable option as a preliminary functional layer for the development of a 
full thickness treatment method for VML.  
Future work will require further characterization and optimization of the composite 
scaffold and increasing the binding capacity of FGF-2 to the scaffold. The platform scaffold we 
created was 10 x 10 mm, and will need to be scaled up to the size of a volumetric muscle defect. 
This can be done by layering composites and rolling them in order to increase the volume to fill 
the void in muscle. Further testing for the understanding the effect of chemical crosslinking is 
required. The degradation experiments should be carried out until the end of the repair phase 
which is six weeks. Mechanical characterization needs to be performed to determine how the 
crosslinking affected the mechanical properties of the composite.Further cell viability testing is 
required to determine the effects of crosslinking on cellular interactions. The binding capacity of 
the FGF-2 to the heparin will need to be further researched. This can be accomplished by testing 
different growth factor concentrations and performing a mass balance on the system. 
Additionally, staining of the heparin using Jaques' toluidine blue will indicate if the heparin is 
actually binding to the scaffold. In addition to binding capacity, the functionality of the growth 
factor in regards to cellular response will also need to be researched. The experiment which was 
previously developed in Section 5.6 can be used to determine if the FGF-2 increased 
proliferation.  
Further cell alignment studies would also need to be performed to allow for an increased 
sample number. This is because currently trial 3 does not line up with both trials 1 and 2. A 
longer sample time can also be used to see if the formation of myotubes can be characterized. 
Additionally, in-vivo testing in mice should be performed to determine if functional muscle can 
be restored with the composite. This can be done by using a biopsy punch to create a volumetric 
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muscle loss defect, then implanting the scaffold (Li, 2014). Ideally, the composite will promote 
better functional regeneration than what has been seen in previous clinical trials. If clinical trials 
are successful in mice, they will move on to humans. The ultimate goal of this project is to 
restore muscle functions in soldiers with debilitating VML injuries, allowing them to return to 
combat.   
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Appendices 
Appendix A: Gantt Charts 
 
Figure 39: Full year Gantt chart
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Figure 40: A-Term detailed Gantt chart 
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Figure 41: B-Term detailed Gantt chart 
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Figure 42: C-term detailed Gantt Chart
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Appendix B: Constraints Test for Developed Means 
Constraints Test For Developed Means 
   Constraints 
Function Means Money Time Availability Materials  Sterility 
  Passes (Y) / Fails (N) 
1 
Fibrin film Y Y Y Y Y 
Fibrin gel Y Y Y Y Y 
Fibrin microthreads Y Y Y Y Y 
Fibrin gel with microthreads Y Y Y Y Y 
Fibrin film with microthreads Y Y Y Y Y 
Fibrin gel with ECM proteins  N Y Y Y Y 
2 
Fibrin microthreads Y Y Y Y Y 
Patterened surface Y Y Y Y Y 
Microthreads + peptide  Y Y Y Y Y 
Microthreads + ECM proteins N Y  Y Y Y 
Patterened + ECM proteins N Y  Y Y Y 
Patterned +microthread Y Y Y Y Y 
Patterned + Peptide Y Y Y Y Y 
3 
 
 
 
Diffusion  Y Y Y Y Y 
Degradation Y Y Y Y Y 
Immobilizaition using heparin* Y Y Y Y Y 
Polymer encapsulation Y Y Y Y Y 
4 
 
UV Crosslinking Y Y Y Y Y 
Protease Inhibitors Y Y Y Y Y 
Chemical Crosslinking* Y Y Y Y Y 
 
  
142 
 
Appendix C: Pairwise Comparison Charts of clients, users, and design 
team  
Client 1: Professor George Pins 
 
 
 
User 
frien
dly 
Reprodu
cible 
composit
e 
fabricati
on 
Robust 
scaffol
d 
propert
ies 
Promote 
myogen
esis 
Promote 
angiogen
esis 
Promote 
innervat
ion 
Cost 
effici
ent 
Minimize 
environm
ental 
impact  
Sum 
User 
friendly 
 0 0 0 1 1 0.5 1 3.5 
Reproducib
le 
composite 
fabrication 
1  0.5 0.5 1 1 0.5 1 5.5 
Robust 
scaffold 
properties 
1 0.5  0.5 1 1 0.5 1 5.5 
Promote 
myogenesi
s 
1 0.5 0.5  1 1 0.5 1 5.5 
Promote 
angiogenes
is 
0 0 0 0  1 0 0 1 
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Promote 
innervation 
0 0 0 0 0  0 0 0 
Cost 
efficient 
0.5 0.5 0.5 0.5 1 1  1 5 
Minimize 
environme
ntal impact 
0 0 0 0 1 1 0  2 
 
 
Sub-Objective User Friendly  
 Minimal Preparation 
Time 
“Off the shelf” design Modular Capabilities  
Minimal Preparation 
Time 
  0.5 0 
“Off the shelf” design 0.5  1 
Modular Capabilities  0 1  
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Sub-objective Reproducible Composite Fabrication 
 Consistent Scaffold 
Properties 
Can achieve consistent functionality 
Consistent Scaffold 
Properties 
 0.5 
Can achieve consistent 
functionality 
0.5  
 
Sub-Objective Robust Scaffold Properties  
 Promotes Cell 
Alignment 
Physiologically 
Relevant Degradation 
Physiologically 
relevant stiffness 
and strength 
Promotes Cell Alignment   0.5 0.5 
Physiologically Relevant 
Degradation 
0.5  0.5 
Physiologically relevant 
stiffness and strength 
0.5 0.5  
 
Sub-objective Promote Myogenesis 
 Cell Migration Cell Proliferation Cell Differentiation 
Cell Migration  0.5 1 
Cell Proliferation 0.5  1 
Cell Differentiation 0 0  
 
Sub-objective Promote Angiogenesis 
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 Sprouting of Existing 
Blood Vessels 
Splitting angiogenesis Maturation of Blood 
Vessels 
Sprouting of Existing 
Blood Vessels 
 1 1 
Splitting angiogenesis 0  1 
Maturation of Blood 
Vessels 
0 0  
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Sub-objective Promote Innervation  
 Differentiation of 
new nerve cells 
Infiltration of 
existing nerve 
cells 
Formation of 
motor units 
Adjusting 
innervation ratio 
Differentiation of 
new nerve cells 
 0.5 1 1 
Infiltration of 
existing nerve 
cells 
0.5  1 1 
Formation of 
motor units 
0 0  1 
Adjusting 
innervation ratio 
0 0 0  
 
Sub-objective Cost Efficient 
 Can be purchased 
sustainably 
Fabrication equipment is 
inexpensive  
Can be purchased 
sustainably  
 1 
Fabrication equipment 
is inexpensive  
0  
 
Sub-objective Minimize Environmental Impact 
 Minimize Organize 
Solvent Use 
Minimize waste 
Production 
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Minimize organic 
solvent use  
 0 
Minimize waste 
production 
1  
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Client 2: Professor Jeannine Coburn  
  
User 
frien
dly 
Reproduc
ible 
composit
e 
fabricatio
n 
Robust 
scaffol
d 
proper
ties 
Promote 
myogen
esis 
Promote 
angiogen
esis 
Promot
e 
innervat
ion 
Cost 
effici
ent 
Minimize 
environm
ental 
impact  
Su
m 
User 
friendly 
x 0 0 0 0 1 1 0.5 2.5 
Reproduci
ble 
composite 
fabricatio
n 
1 x 0.5 1 1 1 1 1 6.5 
Robust 
scaffold 
properties 
1 0.5 x 1 1 1 1 1 6.5 
Promote 
myogenes
is 
1 0 0 x 0.5 1 1 1 4.5 
Promote 
angiogene
sis 
1 0 0 0.5 x 1 1 1 4.5 
Promote 
innervatio
n 
0 0 0 0 0 x 0 1 1 
Cost 
efficient 
0 0 0 0 0 1 x 0.5 1.5 
Minimize 
environm
ental 
impact 
0.5 0 0 0 0 0 0 x 0.5 
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Sub-Objective User Friendly   
Minimal Preparation 
Time 
“Off the shelf” 
design 
Modular 
Capabilities  
Minimal Preparation 
Time 
x 0 0 
“Off the shelf” design 1 x 1 
Modular Capabilities  1 0 x 
 
 
Sub-objective Reproducible Composite Fabrication  
Consistent Scaffold 
Properties 
Can achieve consistent 
functionality 
Consistent Scaffold Properties x 1 
Can achieve consistent 
functionality 
0 x 
 
Sub-Objective Robust Scaffold Properties   
Promotes Cell 
Alignment 
Physiologically 
Relevant Degradation 
Physiologically relevant 
stiffness and strength 
Promotes Cell Alignment  x 1 0.5 
Physiologically Relevant 
Degradation 
0 x 0.5 
Physiologically relevant 
stiffness and strength 
0.5 0.5 x 
 
Sub-objective Promote Myogenesis  
Cell Migration Cell Proliferation Cell Differentiation 
Cell Migration x 1 1 
Cell Proliferation 0 x 1 
Cell Differentiation 0 0 x 
 
Sub-objective Promote Angiogenesis  
Sprouting of Existing 
Blood Vessels 
Splitting 
Angiogenesis 
Maturation of Blood 
Vessels 
Sprouting of Existing 
Blood Vessels 
x 1 0.5 
Splitting Angiogenesis 0 x 0 
Maturation of Blood 
Vessels 
0.5 1 x 
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Sub-objective Promote Innervation 
 
 
 Differentiation of 
new nerve cells 
Infiltration of 
existing nerve 
cells 
Formation of 
motor units 
Adjusting 
innervation ratio 
Differentiation of 
new nerve cells 
 0 1 1 
Infiltration of 
existing nerve 
cells 
1  1 1 
Formation of 
motor units 
0 0  1 
Adjusting 
innervation ratio 
0 0 0  
 
 
Sub-objective Cost Efficient  
Can be purchased 
sustainably 
Fabrication equipment is 
inexpensive  
Can be purchased sustainably  x 1 
Fabrication equipment is 
inexpensive  
0 x 
 
Sub-objective Minimize Environmental Impact  
Minimize Organize Solvent Use Minimize waste Production 
Minimize organic solvent use  x 1 
Minimize waste production 0 x 
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User 1: Meagan Carnes  
 User 
frien
dly 
Reprodu
cible 
composit
e 
fabricatio
n 
Robust 
scaffol
d 
propert
ies 
Promote 
myogen
esis 
Promote 
angiogen
esis 
Promote 
innervat
ion 
Cost 
effici
ent 
Minimize 
environm
ental 
impact  
summa
ry 
User 
friendly 
 0 0 0 0.5 1 1 1 3.5 
Reproducib
le 
composite 
fabrication 
1  1 0.5 1 1 1 1 6.5 
Robust 
scaffold 
properties 
1 0  0.5 0.5 1 1 1 5 
Promote 
myogenesis 
1 0.5 0.5  1 1 1 1 6 
Promote 
angiogenes
is 
0.5 0 0.5 0  1 1 1 4 
Promote 
innervation 
0 0 0 0 0  1 1 2 
Cost 
efficient 
0 0 0 0 0 0  1 1 
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Minimize 
environme
ntal impact 
0 0 0 0 0 0 0  0 
 
Sub-Objective User Friendly  
 Minimal Preparation 
Time 
“Off the shelf” design Modular Capabilities  
Minimal Preparation 
Time 
  1 0.5 
“Off the shelf” design 0  0.5 
Modular Capabilities  0.5 0.5  
 
Sub-objective Reproducible Composite Fabrication 
 Consistent Scaffold 
Properties 
Can achieve consistent functionality 
Consistent Scaffold 
Properties 
 0.5 
Can achieve consistent 
functionality 
0.5  
 
Sub-Objective Robust Scaffold Properties  
 Promotes Cell 
Alignment 
Physiologically 
Relevant Degradation 
Physiologically 
relevant stiffness 
and strength 
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Promotes Cell Alignment   1 0.5 
Physiologically Relevant 
Degradation 
0   
Physiologically relevant 
stiffness and strength 
0.5 1  
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Sub-objective Promote Myogenesis 
 Cell Migration Cell Proliferation Cell Differentiation 
Cell Migration  0.5 1 
Cell Proliferation 0.5  1 
Cell Differentiation 0 0  
 
Sub-objective Promote Angiogenesis 
 Sprouting of Existing 
Blood Vessels 
Splitting angiogenesis Maturation of Blood 
Vessels 
Sprouting of Existing 
Blood Vessels 
 0.5 0.5 
Splitting angiogenesis 0.5  0.5 
Maturation of Blood 
Vessels 
0.5 0.5  
 
Sub-objective Promote Innervation 
 Differentiation of 
new nerve cells 
Infiltration of 
existing nerve 
cells 
Formation of 
motor units 
Adjusting 
innervation ratio 
Differentiation of 
new nerve cells 
 0 0 1 
Infiltration of 
existing nerve 
cells 
1  0.5 1 
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Formation of 
motor units 
1 0.5  1 
Adjusting 
innervation ratio 
0 0 0  
 
Sub-objective Cost Efficient 
 Can be purchased 
sustainably 
Fabrication equipment is 
inexpensive  
Can be purchased 
sustainably  
 1 
Fabrication equipment 
is inexpensive  
0  
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Sub-objective Minimize Environmental Impact 
 Minimize Organize 
Solvent Use 
Minimize waste 
Production 
Minimize organic 
solvent use  
 0.5 
Minimize waste 
production 
0.5  
 
 
User 2: Johanna Santos 
 User 
friend
ly 
Reproduci
ble 
composite 
fabricatio
n 
Robust 
scaffold 
properti
es 
Promote 
myogene
sis 
Promote 
angiogene
sis 
Promote 
innervati
on 
Cost 
efficie
nt 
Minimize 
environme
ntal impact  
User 
friendly 
 0 0 0.5 0.5 1 1 1 
Reproducibl
e composite 
fabrication 
1  0.5 0.5 0.5 1 1 1 
Robust 
scaffold 
properties 
1 0.5  1 1 1 1 1 
Promote 
myogenesis 
0.5 0 0  0.5 1 1 1 
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Promote 
angiogenesis 
0.5 0 0 0.5  1 1 1 
Promote 
innervation 
0 0 0 0 0  1 1 
Cost 
efficient 
0 0 0 0 0 0  0.5 
Minimize 
environment
al impact 
0 0 0 0 0 0 0.5  
 
Sub-Objective User Friendly  
 Minimal Preparation 
Time 
“Off the shelf” design Modular Capabilities  
Minimal Preparation 
Time 
  1 1 
“Off the shelf” design 0  0.5 
Modular Capabilities  0 0.5  
 
Sub-objective Reproducible Composite Fabrication 
 Consistent Scaffold 
Properties 
Can achieve consistent functionality 
Consistent Scaffold 
Properties 
 0.5 
Can achieve consistent 
functionality 
0.5  
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Sub-Objective Robust Scaffold Properties  
 Promotes Cell 
Alignment 
Physiologically 
Relevant Degradation 
Physiologically 
relevant stiffness 
and strength 
Promotes Cell Alignment   0.5 0.5 
Physiologically Relevant 
Degradation 
0.5  0 
Physiologically relevant 
stiffness and strength 
0.5 1  
 
Sub-objective Promote Myogenesis 
 Cell Migration Cell Proliferation Cell Differentiation 
Cell Migration  0.5 1 
Cell Proliferation 0.5  1 
Cell Differentiation 0 0  
 
Sub-objective Promote Angiogenesis 
 Sprouting of Existing 
Blood Vessels 
Splitting angiogenesis Maturation of Blood 
Vessels 
Sprouting of Existing 
Blood Vessels 
 0.5 0.5 
Splitting angiogenesis 0.5  0.5 
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Maturation of Blood 
Vessels 
0.5 0.5  
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Sub-objective Promote Innervation 
 Differentiation of 
new nerve cells 
Infiltration of 
existing nerve 
cells 
Formation of 
motor units 
Adjusting 
innervation ratio 
Differentiation of 
new nerve cells 
 0.5 0 1 
Infiltration of 
existing nerve 
cells 
0.5  0.5 1 
Formation of 
motor units 
1 0.5  1 
Adjusting 
innervation ratio 
0 0 0  
 
 
 
 
Sub-objective Cost Efficient 
 Can be purchased 
sustainably 
Fabrication equipment is 
inexpensive  
Can be purchased 
sustainably  
 1 
Fabrication equipment 
is inexpensive  
0  
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Sub-objective Minimize Environmental Impact 
 Minimize Organize 
Solvent Use 
Minimize waste 
Production 
Minimize organic 
solvent use  
 0 
Minimize waste 
production 
1  
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Design Team 
  
 
 
User 
friend
ly 
Reprodu
cible 
composi
te 
fabricati
on 
Robu
st 
scaff
old 
prope
rties 
Prom
ote 
myog
enesis 
Promote 
angiogene
sis 
Promote 
innervatio
n 
Cost 
efficient 
Minimize 
environme
ntal 
impact  
Sum 
User 
friendly 
 0 0 0 0 1 1 0.5 2.5 
Reprod
ucible 
compos
ite 
fabricat
ion 
1  0.5 1 1 1 1 1 6.5 
Robust 
scaffold 
properti
es 
1 0.5  1 1 1 1 1 6.5 
Promot
e 
myogen
esis 
1 0 0  0.5 1 1 1 4.5 
Promot
e 
1 0 0 0.5  1 1 1 4.5 
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angioge
nesis 
Promot
e 
innervat
ion 
0 0 0 0 0  0 1 1 
Cost 
efficien
t 
0 0 0 0 0 1  0.5 1.5 
Minimi
ze 
environ
mental 
impact 
0.5 0 0 0 0 0 0  0.5 
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Sub-Objective User Friendly  
 Minimal Preparation 
Time 
“Off the shelf” design Modular Capabilities  
Minimal Preparation 
Time 
 0 0 
“Off the shelf” design 1  1 
Modular Capabilities  1 0  
 
 
Sub-objective Reproducible Composite Fabrication 
 Consistent Scaffold 
Properties 
Can achieve consistent functionality 
Consistent Scaffold 
Properties 
 1 
Can achieve consistent 
functionality 
0  
 
Sub-Objective Robust Scaffold Properties  
 Promotes Cell Alignment Physiologically Relevant 
Degradation 
Physiologically 
relevant stiffness and 
strength 
Promotes Cell Alignment   1 0.5 
Physiologically Relevant 
Degradation 
0  0.5 
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Physiologically relevant 
stiffness and strength 
0.5 0.5  
 
 
Sub-objective Promote Myogenesis 
 Cell Migration Cell Proliferation Cell Differentiation 
Cell Migration  1 1 
Cell Proliferation 0  1 
Cell Differentiation 0 0  
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Sub-objective Promote Angiogenesis 
 Sprouting of Existing 
Blood Vessels 
Splitting 
Angiogenesis 
Maturation of Blood 
Vessels 
Sprouting of Existing 
Blood Vessels 
 1 0.5 
Splitting Angiogenesis 0  0 
Maturation of Blood 
Vessels 
0.5 1  
 
Sub-objective Promote Innervation 
 Differentiation of 
new nerve cells 
Infiltration of 
existing nerve 
cells 
Formation of 
motor units 
Adjusting 
innervation ratio 
Differentiation of 
new nerve cells 
 0 1 1 
Infiltration of 
existing nerve 
cells 
1  1 1 
Formation of 
motor units 
0 0  1 
Adjusting 
innervation ratio 
0 0 0  
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Sub-objective Cost Efficient 
 Can be purchased 
sustainably 
Fabrication equipment is 
inexpensive  
Can be purchased 
sustainably  
 1 
Fabrication equipment 
is inexpensive  
0  
 
Sub-objective Minimize Environmental Impact 
 Minimize Organize 
Solvent Use 
Minimize waste 
Production 
Minimize organic 
solvent use  
 1 
Minimize waste 
production 
0  
 
 
 
Appendix D: Summary of Pairwise Comparison Charts 
 
Main Objectives 
 Clients Users  Team  
Pins Coburn Average Santos Carnes Average   
User Friendly 3.5 4 3.75 4 3.5 3.75 2.5 
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Reproducible 
Composite 
Fabrication 
5.5 5 5.25 5.5 6.5 6 6.5 
Robust 
Scaffold 
Properties 
5.5 4.5 5 6.5 5 5.75 6.5 
Promote 
Myogenesis 
5.5 3.5 9 4 6 5 4.5 
Promote 
Angiogenesis 
1 3.5 2.25 4 4 4 4.5 
Promote 
Innervation 
0 2.5 1.25 2 2 2 1 
Cost Efficient 5 3.5 4.25 0.5 1 0.75 1.5 
Minimize 
Environmental 
Impact 
2 1 1.5 0.5 0 0.25 0.5 
 
Main Objectives: Summary  
 Clients  Users Design Team Total  
User Friendly 3.75 3.75 2.5 10 
Reproducible 
Composite 
Fabrication 
5.25 6 6.5 17.75 
Robust Scaffold 
Properties 
5 5.75 6.5 17.25 
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Promote 
Myogenesis 
9 5 4.5 18.5 
Promote 
Angiogenesis 
2.25 4 4.5 10.75 
Promote 
Innervation 
1.25 2 1 4.25 
Cost Efficient 4.25 0.75 1.5 6.5 
Minimize 
Environmental 
Impact 
1.5 0.25 0.5 2.25 
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Sub-Objective User Friendly 
 Clients Users  Team  
 Pins Coburn Average Santos Carnes Average   
Minimal 
preparation 
time 
0.5 1 0.75 2 1.5 1.75 0 
“off the 
shelf” 
design  
1.5 1.5 1.5 0.5 0.5 0.5 2 
Modular 
capabilities  
1 0.5 0.75 0.5 1 0.75 1 
 
Sub-Objective User Friendly: Summary  
 Clients  Users Design Team Total  
Minimal 
preparation time 
0.75 1.75 0 2.5 
“off the shelf” 
design  
1.5 0.5 2 4 
Modular 
capabilities  
0.75 0.75 1 2.5 
 
Sub-objective Reproducible Composite Fabrication 
 Clients Users  Team  
 Pins Coburn Average Santos Carnes Average   
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Consistent 
Scaffold 
Properties 
0.5 0.5 0.5 0.5 0.5 0.5 1 
Can achieve 
consistent 
functionality  
0.5 0.5 0.5 0.5 0.5 0.5 0 
 
Sub-objective Reproducible Composite Fabrication: Summary  
 Clients  Users Design Team Total  
Consistent 
Scaffold 
Properties 
0.5 0.5 1 2 
Can achieve 
consistent 
functionality  
0.5 0.5 0 1 
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Sub-Objective Robust Scaffold Properties 
 Clients Users  Team  
 Pins Coburn Average Santos Carnes Average   
Promotes Cell 
Alignment  
1 2 1.5 1 1.5 1.25 1.5 
Physiologically 
Relevant 
Degradation 
1 0.5 0.75 0.5 0 0.25 0.5 
Physiologically 
relevant 
stiffness and 
strength 
1 0.5 0.75 1.5 1.5 0.5 1 
 
Sub-Objective Robust Scaffold Properties: Summary  
 
 Clients  Users Design Team Total  
Promotes Cell 
Alignment  
1.5 1.25 1.5 4.25 
Physiologically 
Relevant 
Degradation 
0.75 0.25 0.5 1.5 
Physiologically 
relevant stiffness 
and strength 
0.75 0.5 1 2.25 
 
Sub-objective Promote Myogenesis 
 Clients Users  Team  
 Pins Coburn Average Santos Carnes Average   
Cell Migration 1.5 0.5 1 1.5 1.5 1.5 2 
Cell 
Proliferation 
1.5 0.5 1 1.5 1.5 1.5 1 
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Cell 
Differentiation 
0 0.5 0.25 0 0 0 0 
 
Sub-objective Promote Myogenesis: Summary  
 Clients  Users Design Team Total  
Cell Migration 1 1.5 2 4.5 
Cell Proliferation 1 1.5 1 3.5 
Cell 
Differentiation 
0.25 0 0 0.25 
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Sub-objective Promote Angiogenesis 
 Clients Users  Team  
 Pins Coburn Average Santos Carnes Average   
Sprouting of 
Existing 
Blood 
Vessels 
2 1.5 1.75 1 1 1 1.5 
Splitting 
Angiogenesis 
1 1.5 1.25 1 1 1 0 
Maturation 
of Blood 
Vessels  
0 0 0 1 1 1 1.5 
 
Sub-objective Promote Angiogenesis: Summary  
 Clients  Users Design Team Total  
Sprouting of 
Existing Blood 
Vessels 
1.75 1 1.5 4.25 
Splitting 
Angiogenesis 
1.25 1 0 2.25 
Maturation of 
Blood Vessels  
0 1 1.5 2.5 
 
Sub-objective Promote Innervation 
 Clients Users  Team  
 Pins Coburn Average Santos Carnes Average   
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Differentiation 
of new nerve 
cells 
2.5 1 1.75 1.5 1 1.25 2 
Infiltration of 
existing nerve 
cells  
2.5 2.5 2.5 2 2.5 2.25 3 
Formation of 
motor units 
1 1.5 1.25 2 2.5 2.25 1 
Adjusting 
innervation 
ratio 
0 0.5 0.25 0 0 0 0 
 
Sub-objective Promote Innervation: Summary  
 Clients  Users Design Team Total  
Differentiation of 
new nerve cells 
1.75 1.25 2 5 
Infiltration of 
existing nerve 
cells  
2.5 2.25 3 7.75 
Formation of 
motor units 
1.25 2.25 1 4.5 
Adjusting 
innervation ratio 
0.25 0 0 0.25 
 
Sub Objective Cost Efficient 
 Clients Users  Team  
 Pins Coburn Average Santos Carnes Average   
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Can be 
purchased 
sustainably  
1 1 1 1 1 1 1 
Fabrication 
equipment 
is 
inexpensive 
0 0 0 0 0 0 0 
 
Sub Objective Cost Efficient: Summary  
 Clients  Users Design Team Total  
Can be purchased 
sustainably  
1 1 1 3 
Fabrication 
equipment is 
inexpensive 
0 0 0 0 
 
Sub-objective Minimize Environmental Impact 
 Clients Users  Team  
 Pins Coburn Average Santos Carnes Average   
Minimize 
organic 
solvent use 
0 0 0 0 0.5 0.25 1 
Minimize 
waste 
production  
1 1 1 1 0.5 0.75 0 
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Sub-objective Minimize Environmental Impact: Summary  
 Clients  Users Design Team Total  
Minimize organic 
solvent use 
0 0.25 1 1.25 
Minimize waste 
production  
1 0.75 0 1.75 
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Appendix E: Weighted Sub-Objectives 
Main Objectives Weight 
Promote Myogenesis 6.5 
Reproducible Composite Fabrication 5.8 
Robust Scaffold Properties 5.6 
User Friendly 3.5 
Promote Angiogenesis 3.4 
Cost Efficient 2.3 
Promote Innervation 1.5 
Minimize Environmental Impact 0.8 
 
Sub-Objective User Friendly Weight 
“off the shelf” design  1.2 
Minimal preparation time 1 
Modular capabilities 0.8 
  
Sub-objective Reproducible Composite 
Fabrication 
Weight 
Consistent Scaffold Properties 0.6 
Can achieve consistent functionality 0.4 
   
Sub-Objective Robust Scaffold Properties  
Promotes Cell Alignment 1.4 
Physiologically relevant stiffness and strength 0.7 
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Physiologically Relevant Degradation 0.5 
 
Sub-objective Promote Myogenesis   
Cell Migration 1.4 
Cell Proliferation 1.2 
Cell Differentiation 0.1 
  
Sub-objective Promote Angiogenesis  Weight 
Sprouting of Existing Blood Vessels  1.4 
Splitting Angiogenesis 0.9 
Maturation of Blood Vessels 0.7 
 
Sub-objective Promote Innervation  Weight 
Infiltration of existing nerve cells   2.5 
Differentiation of new nerve cells 1.6 
Formation of motor units 1.6 
Adjusting innervation ratio 0.1 
  
Sub Objective Cost Efficient Weight 
Can be purchased sustainably 1 
Fabrication equipment is inexpensive 0 
  
Sub-objective Minimize Environmental Impact  Weight 
Minimize waste production 0.7 
Minimize organic solvent use 0.3 
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Appendix F: Means Evaluation Matrix 
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Appendix G: Standard Curve for Cell Viability Assay 
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Appendix H: Experiment Protocols 
Fibrinogen and Thrombin Aliquot Preparation 
 
Objective:  
Preparing fibrinogen and thrombin stock aliquots, which are used for dilution and fibrin thread creation 
 
Materials: 
Fibrinogen (82022, MP) 
Thrombin (T4648, Sigma) 
CaCl2 (MW = 110.99) - ref. ______ 
NaCl (MW = 58.44) 
HPS - ref. ______ 
 
Micropipette 
Conical tubes 
Eppendorf tubes 
 
Procedure: 
NOTE: Not all fibrinogen in product is clottable. This needs to be taken into account. Previous 
optimization of results was done with product from Sigma Aldrich (SA) 
 
SA: 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 = 75% 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ∗  96% 𝑐𝑙𝑜𝑡𝑡𝑎𝑏𝑙𝑒 
 
NOTE: Current product is from MP Biomedicals 
 
MP: 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 = 72% 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ∗ 93.6 % 𝑐𝑙𝑜𝑡𝑡𝑎𝑏𝑙𝑒 
  
NOTE: To get the % protein and % clottable, review the certificate of analysis, which comes in with the 
product. It might be different for each batch 
 
Originally, the aliquots are made to concentration of 70 mg/ml, based on SA’s procedure. Using that, 
determine the concentration of the new product needed to have an equivalent concentration of effective 
protein (EP) as SA’s aliquots. 
 
[𝑆𝐴]  ∗  (𝐸𝑃: 𝑆𝐴)  =  𝑋 ∗  (𝐸𝑃: 𝑀𝑃) 
70𝑚𝑔/𝑚𝑙 ∗  (75% ∗ 96%) = 𝑋 ∗ (72% ∗ 93.6% 
𝑋 =  79.2 𝑚𝑔/𝑚𝑙 
 
To dissolve 1000 mg: 1000/𝑋 𝑚𝑔/𝑚𝑙 =  79.2 𝑚𝑔/𝑚𝑙 
 𝑋 =  12.6 𝑚𝑙 
 
Fibrinogen Aliquot (70mg/ml) 
1. Weigh 1.00 g of fibrinogen and pour in conical tube. 
2. Measure X(specifically calculated for each batch) of Hepes buffered saline (HBS) and add to 
fibrinogen in conical tube 
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3. Place conical tube on rocker plate, adjusting position every 30-40 min until fibrinogen is no 
longer visible on the inside of the tube 
NOTE: There may be clumps visible in the solution, which is OK 
4. Measure 1 ml aliquots in eppendorf tubes and store at -20℃ 
 
Thrombin Aliquot (40U/ml) 
1. Add 25 ml HBS to bottle of 1 KU thrombin 
2. Mix well 
3. Aliquot 200 μl into eppendorf tubes and store in -20℃ 
NOTE: Final concentration should be 8 U/ 200 μl  
 
Fibrinogen and Thrombin Diluted Aliquot Preparation 
Objective: 
Preparing diluted fibrinogen and diluted thrombin aliquots for fibrin gel scaffolds 
 
Materials: 
Fibrinogen (82022, MP) Stock Solution - ref. ________ 
Thrombin (T4648, Sigma) Stock Solution - ref. ________ 
HBS - ref. _________ 
40 mM CaCl2 - ref. ________ 
PBS (can be substituted with cell media if using cells) 
PDMS - curing agent & elastomer base 
 
Eppendorf tubes 
Centrifuge tubes 
 
Procedure: 
Diluted fibrinogen solution (2X solution) (dFb solution) 
1. Pipette 137.8μL of fibrinogen stock solution into a centrifuge tube 
2. Add 862.2μL of HBS into centrifuge tube 
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● Final concentration = 11mg/mL 
NOTE: Mix gently! Try to avoid polymerization 
 
Diluted thrombin solution (2.35 U/mL) (dTh solution) 
1. Pipette 58.75μL of Thrombin stock solution into centrifuge tube 
2. Add 941.25μL HBS to the tube 
3. Mix (triturate) 
 
 
Fibrin Films and Gels Protocol  
Objective: Record current procedure for making fibrin films  
Materials:  
 Fibrinogen aliquot ((11 mg/mL) Ref #MO1:26 
 Thrombin aliquot (2.35 U/mL) Ref #MO1:26 
 40 mM CaCl2 
 PBS 
 Acetyl plastic slide  
 di H20  
 Vellum paper 
 Ruler (with millimeter markings) 
 Scissors 
 Razor Blade  
Procedures: 
 Prep of Vellum Frame for Film  
1. With vellum paper, measure a strip 30 mm wide and cut 
strip from sheet 
2. Along strip, mark every 30 mm lengthwise and cut along 
markings, creating 30x30mm squares 
3. On a hard surface, use razor blade to cut squares centers 
from the 30x30 square so that there is a 2mm thick border 
on all sides  
4. The distance from inner edge to inner edge on each frame 
should be 26mm across horizontally and vertically when 
finished 
 Prep of Fibrin Gel (from Fibrin Gel Basic Protocol – MO) 
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1. Prep Acetyl slide (sterilize with ethanol if necessary) 
2. Mix the following reagents in a centrifuge tube 
a. 2680 uL fibrinogen solution (2x solution) 
b. 320 uL CaCl2 (40mM) 
c. 600 uL PBS (or cell media if using cells) 
3. Add 400 uL thrombin solution and triturate to gently mix with other reagents in 
centrifuge tube 
4. For standard 26x26mm film frame: 
a. Pipette 1.32 mL of mixed solution onto acetyl slide with frame  
b. Use pipette tip to submerge frame edges into solution  
5. Allow 30 minutes for polymerization 
Prep of Fibrin Film 
1. Use forceps to place frame in diH2O bath (room temp) for 10 minutes 
2. Switch frame into fresh water bath for 5 minutes 
3. Switch frame into final water bath for 5 minutes  
4. Remove from water bath and place onto acetyl plastic slide to dry completely for 2-3 
hours  
 
REV 12/2015 AB 
User Manual for LACEY  
Biopolymer Printer for Fibrin Microthread Fabrication 
Terms and Definitions 
The following are terms and definitions that will be used throughout this user manual to describe key 
components of the system. 
 
Shoes  
These are the Lexan U-shaped frames with a steel mesh bottom that sit on the Teflon pan and anchor the 
ends of the threads as they are extruded and stretched in the bath.  
Shoe Sliders 
These are 3D printed parts that are placed on the long sides of the shoe frame and have holes in them that 
facilitate the insertion of the steel rods of the shoes. They move smoothly along the frame to facilitate 
controlled stretching.  
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Shoe Frame 
This is the metal frame that is used to facilitate the movement of the shoe slides and the shoes within the 
bath. After the threads are fabricated they can then be removed by lifting this frame and placing it on the 
benchtop. 
Squeegee Pieces 
Pieces of Lexan and PDMS that are sandwiched together and sit on top of the shoes to secure the ends of 
the threads during stretching and removal from the bath. 
Extrusion Head 
This is the removable printed piece with a 1mL pipette tip secured that is placed onto the machine, 
moving in both x and y directions. The polyethylene tubing is placed into the pipette tip. 
Stretch Percentage  
This is the terminology used for how far the threads are stretched. 100% is when the threads are left 
unstretched and the other percentages are stretched length based on initial length of the threads. For 
example, 200% stretch means that 6 cm threads were stretched an additional 6 cm giving a final length of 
12 cm threads.  
Strain Rate 
This is the terminology used for the rate, in mm/s, that the threads are stretched at.  
Extrusion Rate 
This is the terminology used for the rate at which the extruder head moves lengthwise to extrude the 
threads 
Teflon Pan 
This is the actual container that holds the buffer bath and in which the shoes will sit to be stretched. It is 
made of Teflon and is coated before fabrication with Pluronics to further decrease the adherence of the 
fibrin to the bottom.  
 
Solution Preparation - Stock Solutions and Aliquots 
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2.1 Fibrinogen Aliquots 
Weigh 1.00g of fibrinogen (MP Biomedicals, 08820224) and pour into 50mL conical tube  
Calculate the volume of HBS needed to have an effective protein (EP) percentage of 72% in 70 mg/mL 
(This is EP and concentration used from a previous Sigma-Aldrich fibrinogen batch that was used for 
optimization of microthreads previously) 
Determine amount of protein in fibrinogen you will be using from mpbio.com 
Navigate to “Certificate for a typical lot” for the Catalog number of the fibrinogen purchased and identify 
clottable protein percentage (highlighted in Figure 43 below) 
 
Figure 43: MP Biomedical Certificate for Fibrinogen 
Calculate the concentration needed of the fibrinogen to have 72% EP in 70 mg/ml 
Effective protein of current batch = Amount of Protein * Clottable Protein 
Example: 0.72 * 0.953 = 0.686 
Concentration needed = (70 mg/ml * .72)/(EP) 
Example: (70 * .72)/(0.686) = 73.5 mg/ml 
The amount of HBS needed for 1000mg of fibrinogen is then calculated by: HBS Volume = 
1000mg/(Concentration) 
Example: 1000mg/(73.5 mg/ml)= 13.6 ml  
Add calculated volume of HBS to conical tube. 
Place conical tube on rocker plate, adjusting the positions every 30-40 minutes until fibrinogen goes into 
solution 
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Note: Never shake/vortex fibrinogen solution! This will cause fibrinogen to fall out of solution and bind 
to itself!  
Incubate conical tube at 37°C for 24hrs to ensure fibrinogen is completely dissolved. 
After fibrinogen is dissolved, measure 1 mL aliquots into Eppendorf tubes and store at -20°C. 
2.2 Thrombin Aliquots (40 U/mL) 
Add 25 mL HBS to bottle of 1KU thrombin, mix well. 
Aliquot 200 µL into Eppendorf tubes and store at -20°C (final concentration: 8U / 200 µL). 
2.3 HEPES Buffered Saline (HBS) 10X Stock Solution 
Add 23.83g of HEPES to 900 mL of diH2O to make 10X of 10 mM HEPES buffer (100mM). 
pH to 7.4 using NaOH/HCl 
Bring final volume to 1000 mL 
Store at room temperature. 
2.4 Calcium Chloride (40 mM) 
Add 0.1776 g of CaCl2 to 40 mL of diH20. 
Store at 4°C.  
3. Solution Preparation - Preparation for Extrusion 
3.1 Pluronics Coating Bath Preparation 
Note: This should be performed each time after the pans have been washed to ensure that the threads do 
not adhere to the pan and can be stretched uniformly.  
Create a 350mL, 2% w/v F127 Pluronics solution in diH2O  
Weigh out 0.07g of F127 Pluronics 
Mix in with 350mL of diH2O, ensure that all particles are in solution as some larger particles may take 
longer to dissolve. 
Pour onto Teflon pan, let sit for 10 minutes. 
Note: Shoes should not in bath at this time.  
Remove liquid from tray and allow to air dry before using Teflon pan. 
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Do not dry with paper towel as this may remove coating. 
3.2 Fibrinogen and Thrombin 
Thaw at room temperature, one aliquot of fibrinogen and of thrombin prepared previously. 
Note: Thaw the fibrinogen aliquot for 5 min in a water bath (~37°C) to ensure that the solution is properly 
thawed and dissolved 
Using a 2mL Eppendorf tube, add 150 µL of thawed thrombin to 850 µL of calcium chloride (40mM) 
Prime two 1 mL syringes by moving the plunger several times.  
Collect all of the thrombin and fibrinogen into two separate syringes.  
Collect solutions slowly and carefully, as failure to do so may result in insoluble fibrinogen formulation.  
Invert syringe, carefully remove all bubbles and ensure that both syringes have equal volumes. 
3.3 HEPES Buffered Saline (HBS) 1X Solution 
Add 50 mL of 10X HBS stock solution with 450 mL of diH2O. 
pH to 7.4 
4. Preparation of Machine 
4.1 Syringe pump preparation 
Turn syringe pump on 
Press SELECT. 
Toggle to Table, press SELECT. 
Toggle to Bec. Dic. Plastic, press SELECT. 
Toggle to 1 cc 4.70 mm, press SELECT. 
Enter volume: 1.0 mL, press ENTER 
Enter extrusion rate: 0.225 mL/min, press ENTER 
NOTE: syringe pump will be run later in Step 5 Extrusion Procedure 
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Figure 44: Blending applicator set up as described in steps 2 - 4. 
Place blunt end needle (25 gauge, BD)(white arrow) into 0.86 mm ID polyethylene tubing(pink arrow), 
97cm in length 
Leur lock blunt end needle onto end of the blending connector 
Place each 1 mL syringe of fibrinogen (red arrow) and thrombin (yellow arrow) solutions into the back 
end of the blending applicator (orange arrow). 
Place the fibrinogen solution in the blending applicator opening with the circle on it.  
Secure syringes into end clip (green arrow). 
Secure the ends of the syringes connected to the blending applicator construct into the syringe pump and 
place syringe pump to the left of the printer on top of small table as shown. 
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Figure 45: Syringe pump set up 
Secure pipette tip into the extrusion head so that (~162) mm of the pipette is below the extrusion head. 
 
Figure 46: Extrusion head with pipette tip and polyethylene tubing set up 
Feed end of polyethylene tubing into pipette tip that is connected to extrusion head so that of the tubing is 
touching the top of the stationary shoe in the bath, approximately (~15) mm beyond the pipette tip.  
Secure the top of the tubing with tape to ensure that the tubing placement is maintained. 
Place this extrusion head set up on side until Step 5 Extrusion Procedure. 
 Shoe and bath preparation 
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Place Teflon pan into frame, ensuring that it is sitting on the lowest setting of the corner notches. By 
rotating the corner notches, it will raise and lower the pan's corners.  
 
Figure 47: Teflon pan inserted into frame on corner notches indicated by red arrows. 
Combine 50 mL of 10X HBS with 450 mL of diH2O and pH to 7.4. 
Pour 500 mL of this 1X HBS into the Teflon pan as shown below.  
 
Figure 48: Pouring HBS into Teflon pan 
Invert shoe frame on bench top so that the four feet are facing upward and the frame lies flat with shoe 
sliders positioned parallel on either side, with a slight gap between each pair on the same side.  
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Figure 49: Inverted shoe frame 
Place stainless steel rods of the shoes into holes on the shoe sliders. The shoe with the shorter rods (~3”) 
should be placed in shoe sliders closer to user with the gap of the U facing away from the user. The other 
shoe with longer rods (~4”) should be placed in the shoe sliders further away the user with the gap of the 
U facing toward the user.  
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Figure 50: Inverted shoe frame with shoes placed into shoe sliders, yellow arrows indicating sloped 
edges, red arrows indicating roughened edges. 
Secure shoes by placing clips on all four steel rods on sides closest to the bench top. 
 
Figure 51: Clip securing shoe in shoe slider. 
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Figure 52: Top view of clips securing shoes into shoe sliders. 
Revert shoe frame on bench top. 
 
Figure 53: Reverted shoe frame with shoes secured in place. 
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Place shoe frame into machine over the Teflon pan by sliding four corners into place.  
 
Figure 54: Shoe frame placed into machine over Teflon pan. 
Ensure that clips are flush against the shoe sliders to avoid any unwanted interference with the extruder. 
 
Figure 55: Clips flush against shoe sliders. 
 
Move shoe slides back and forth as necessary to ensure that HBS covers the bottom steel mesh layer top 
of both shoes.  
Move shoes to sit in left side of the bath (closest to the syringe pump and emergency stop button). 
Secure stationary shoe in place at 20 mm from the edge of the bath to the bottom of the U-shaped rough 
edge of the stationary shoe. Set screws should maintain this position, so measure this distance to ensure 
that the shoe is accurately in place. 
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 Software Set up 
These are now the instructions for setting up the software on the laptop that should be placed next to the 
machine.  
 
The program for LACEY can be run from any computer available. There are 2 software applications 
required for the LACEY program to work. The first is Java 8, which can be downloaded from 
http://www.oracle.com/technetwork/java/javase/downloads/jre8-downloads-2133155.html. The code will 
most likely work with future Java version, but if not, there is a installation program in the "Lacey system" 
folder. The second program needed is Arduino console, version 1.6.4. It can be downloaded from 
http://www.arduino.cc/en/Main/Software. It is unclear if future version will have the same language 
commands, so there is version of the current program saved on the "Lacey system" folder, from the time 
when the system and its software were created.  
 
Plug in the power cord to the machine and then connect the electronics to a USB port on the computer. 
This must be done before opening the program. The green LED on the power supply should be lit once 
plugged in. If not, check that the E-stop button has not been pressed. 
Open the program by double clicking on the file name. The window shown above should appear. On the 
lab computer the file is located in "BME - NB04" > "Local Disk(C:) > 
"FibrinPrinterControllerNullMinMax.jar". That last file is the one you will need. If you plan to use this 
program regularly it would be best to save this to your desktop. Between consecutive runs, the program 
should be closed and opened. 
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General Settings Tab
On the 
opening page of the software, select the COM port (Shown on the right hand side of the window) for the 
Arduino. In this figure, "COM6" is selected however this can be different on each computer. The "Auto. 
Configure Ports" button will try to find the Arduino when pressed. If this fails then you may need to find 
what port it is using the device manager on the computer. 
 
If the syringe pump is not connected to the computer, you must check the "Manual Pump Ctrl" box 
otherwise there will be an error later in the program. If this error shows up, close the program and restart. 
 
Change or make sure that the "Bed Length" is set to 310mm and the "Bed Width" to 150mm. This 
is reversed in the default settings for the first use! 
 
Move to the next tab to continue. 
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Extrusion Settings Tab
 
Check the "perform extrusion" first. If you just want to perform a stretching operation then make sure this 
box is unchecked  
 
Set your desired parameters from the top down. If you have used the program before then many if not all 
of the parameters will be remembered. It is important to verify each one because some numbers are 
limited by other entries. If you change a separate field it may cause additional fields to change 
unexpectedly. 
 
If a thread length of 100mm is wanted, but the program will change that value to a lower number when 
entered then check the next tab. If the "stretch amount" is set too high for that thread length then the 
original thread length is limited. In this case percent extension will need to be entered before the desired 
values can be entered. 
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Not all parameters will do things if the pump is not connected to the computer. Changing them can be 
used to notate and manually input values into the pump. 
 
Stretch Settings Tab
 
Check the perform stretch box if stretching is wanted. Set or check all parameters before moving to the 
next tab. 
 
The inputs on this page will cause changes in the previous tab. Use caution, especially if a high "stretch 
amount" has been entered because this will cause lengths in the previous tab to change. Double check the 
previous tab to make sure no changes were made to the desired parameters before moving on. 
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Run Operation Tab
 
This tab will allow you to run the set parameters by clicking "Run Operation". Clicking "OK" will move 
the machine directly to the next step. Follow instructions in 5. Machine Operation that go along with the 
on screen cues from the software. 
 
After the operation has been run close the program and unplug the machine. If multiple sets of threads are 
to be made then keep everything plugged in, but close out and restart the program. The program can not 
be run twice. Settings should be saved from the previous test, however it is good practice to check this. 
5. Extrusion Operation 
After pressing Run Operation, the machine will home the stretching and extrusion bars. Ensure that the 
extrusion head is not in place at this time. 
After hitting the next “OK” cue, the stretch bar will move the moving shoes into place and return to 
home. 
Once stretch bar is in place, you may not place extrusion head with polyethylene tubing in place as 
previously prepared in Step 4.7.  
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When directed to, start the syringe pump for extrusion, watching the flow of the fibrin through the tube. 
Once it reaches the bath is begins extruding into the buffer, press “OK” to start the movement of the 
extrusion head. 
At the end of extrusion, the head will stay in its last location move to the far end of the bath. Stop the 
syringe pump and remove the extrusion head. 
Immediately following the completion of extrusion, clean out polyethylene tubing by flushing through 
with 3-5 washes of water and 3 of air using a 10 mL syringe connected to the blending applicator. 
6. Intermediate Dry Step and Stretch 
NOTE: Follow these instructions if you would like to add an intermediate dry step to your fabrication 
process. If you would like to immediately stretch without this step, skip these instructions and follow 7. 
Stretching Operation. 
After the threads have polymerized for 10 minutes following extrusion, place the squeegee pieces on top 
of the shoes.  
Be careful to not move the shoes in the bath as this will damage the threads 
Placement of the squeegees on the shoes should be vertically down on top of the shoe.  
 
Figure 56: Squeegee pieces in place on top of extruded threads. 
Tilt the Teflon pan by turning two of the corner pieces counter-clockwise on one side of the Teflon pan 
closest to the extruded threads. 
Using either a micropipette or an aspirator, remove the liquid from the Teflon pan being careful to avoid 
contact with the threads. 
Remove the shoe frame from the bath slowly and place on the bench top for 24 hours. 
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Refill the Teflon with 500mL of diH2O at room temperature.  
Replace the shoe frame with dried threads into place over the bath, allowing the threads to rehydrate for 1 
hour.  
Restart the machine and uncheck the box at the top of the Extrusion Settings tab. Ensure that the Stretch 
Settings are set to the desired stretch percentage. 
Following the stretch, follow steps 2-4 to remove liquid from the Teflon pan. 
Tilt the Teflon pan by turning two of the corner pieces counter-clockwise on one side of the Teflon pan 
closest to the extruded threads. 
Using either a micropipette or an aspirator, remove the liquid from the Teflon pan being careful to avoid 
contact with the threads. 
Remove the shoe frame from the bath slowly and place on bench top for 24 hours. 
7. Stretching Operation 
After the threads have polymerized for 10 minutes following extrusion, place the squeegee pieces on top 
of the shoes.  
Be careful to not move the shoes in the bath as this will damage the threads 
Placement of the squeegees on the shoes should be vertically down on top of the shoe.  
 
Figure 57: Squeegee pieces in place on top of extruded threads. 
Press OK on software to initiate stretching after 10 minutes is shown on the timer. 
Tilt the Teflon pan by turning two of the corner pieces counter-clockwise on one side of the Teflon pan 
closest to the extruded threads. 
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Using either a micropipette or an aspirator, remove the liquid from the Teflon pan being careful to avoid 
contact with the threads. 
Remove the shoe frame from the bath slowly and place on bench top for 24 hours. 
8. Cleaning 
Ensure that the shoe frame and any remaining fibrin is removed from the bath. 
Ensure that polyethylene tubing is flushed as instructed previously following extrusion. 
Drain remaining liquid in bath by lifting pan out of machine and disposing of liquid in sink.  
Manually wash pan with soap, water and diH2O. 
Dispose of syringes in sharps container. 
Turn off and unplug syringe pump. 
After 24 hours and once threads removed from shoe frames, clean squeegee and shoes using soap, water 
and diH2O. 
9. Emergency Stop 
In the case that the machine is out of control, unable to be stopped with the software, and in danger of 
causing damage press this button.  
 
Figure 58: Emergency stop button highlighted by red square. 
 
This will shut down the power supply and stop the machine from moving. 
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If pressed, wait a full minute and stop the software before releasing the E-stop button. To release, turn in 
the direction of the arrow and allow to pop up. The Green LED on the power supply should be lit to 
indicate that the power supply is on. 
10. Machine Power Supply 
 
The machine has no button to turn on or off. Plugging the machine in will turn it on and the green LED on 
the power supply should be lit. If the machine is plugged in and nothing is on then check to see that the E-
stop has not been pressed down. 
 
Unplug the machine after use to prevent long-term damage. 
11. Maintenance and Modification 
11.1 Belt Tightening 
 
As the machine is used, some of the belts may increase in length. Three of the belts are fitted with 
tensioning springs. These should keep those belts at the proper tension even if they are to stretch. The two 
long top belts do not have spring tensioners. If they become noticeably loose and cause the position to slip 
during operation then the two bearings on the opposite side from the power supply can be loosened and 
slid out to increase tension.  
 
This should not be a problem for many hours of use and only needs to be checked if a problem occurs.  
207 
 
 
 
11.2 Hardware Adjustments 
 
Nearly all hardware is held in place using M5 machine screws. To adjust or tighten them, a 3mm Allen 
wrench can be used.  Careful not to over tighten these because the screws are much stronger than the 
aluminum threads.  
11.3 Printed Parts & CAD Files  
 
All files for the 3D printed parts are included in folder “Microthread ISP CAD Files”. They have been 
designed to be used with a plastic extrusion based printer and the necessary tolerances of one.  
 
The current parts are made of PLA, but ABS should also work just as well. 
 
11.4 Electronics and Control 
 
The machine is powered by a 12 volt computer power supply and controlled through an Arduino UNO 
with a GRBL shield. The software loaded onto the Arduino is a version of GRBL, an open source 
software that interprets G-code and is able to be easily downloaded from the internet. 
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G-code is a universal machine code that instructs the machine to move to coordinates and a speed to do 
so. The current (first) program on the computer generates the path in G-code and sends segments of it 
when the user prompts the program to do so.  
 
In the future, a program called "universal G-code sender" or any other similar program could be 
downloaded to control the machine by inputting custom G-code. Caution should be used because the 
software limits are only set in the current (first) computer program and not on the Arduino itself. 
 
11.5 Addition of a 4th Motor 
 
The current machine is designed for operation with three motors. The 
addition of a fourth motor (NEMA 17) is possible with the addition of an  
A4988 Stepper driver on the GRBL shield. This would also require a  
modification in the GRBL software currently on the board. 
 
12. Recommendations for Future Optimization/Troubleshooting 
12.1 Shape of end of polyethylene tubing 
Various tubing shapes were utilized with the aim of optimizing the flow of fibrin out of the tubing to 
avoid accumulation on the end of the tube and allow for consistent thread volume. By cutting the end of 
the tube to a 30 or 45 degree angle with a razor blade, this decreased the accumulation by the end of the 
tube. There was no noticeable difference between 30 and 45 degrees. With the 45 degree cut, the bottom 
of the tube was also cut to allow for limited accumulation. Even though this decreased the accumulation it 
did not completely remove it. 
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Figure 59: Extruded threads using 45 degree cut in tubing. 
 
12.2 Extrusion head speed  
By increasing or decreasing the extrusion head speed it will modify the thickness of the threads. By 
increasing the thickness this could allow threads to be less likely to break during stretching and removal.  
12.3 Volume of HBS buffer 
The team decreased the initial buffer amount from 600ml to 500ml to have less space for the threads to 
accumulate above the shoes so that they would be able to adhere better to them. 
12.4 Angle at edge of tubing 
The team attempted letting longer amounts of the tubing to be dragged for extrusion of the threads to 
simulate the angle from manual extrusion. However, this causes inconsistency with thread placement and 
a jump to occur when moving over the shoes so this would not be recommended for use with this system 
unless it can be better controlled.  
12.5 Decreasing residence time of fibrin 
By decreasing the amount of time that the fibrin spends within the tubing polymerizing, the team believes 
that this will allow a more even extrusion into the bath. This can be achieved by either decreasing the 
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length of the tubing where the fibrinogen and thrombin are mixed by having separate tubes until further 
down where a blending applicator would be located. Also this could be achieved more easily through 
increasing the rate of the syringe pump. This should be compensated for with the extrusion speed.  
12.6 Priming the tubing 
When new tubing is used for the machine, it can cause the fibrin to have inconsistent flow within the 
tubing, therefore the team suggests priming the tubing with either HBS from the bath or diH2O to remove 
any inconsistencies as possible within the tubing. 
 12.7 Different blending applicator  
Through attempts at consistent extrusion, the team observed that the fibrin had inconsistencies when 
extruded that caused breakages to the extruded threads. A potential solution to this would be changing the 
blending applicator to a different model that would allow for more mixture of the two solutions for a more 
homogenous thread composition when extruded.  
 12.8 Misaligned primary extrusion head bar 
 After multiple uses and possible bumps into the system, the primary extrusion head bar, which 
moves along the length of the bath, could become misaligned. This means that the bar is not 
perpendicular to the 2 rails on the side. This misalignment causes the bar to wheels on the bar to exert 
more resistance on the primary extrusion bar, which causes the electromotor to jam. To fix this, first, the 
belts on both sides of the primary extrusion head need to released, and the outer wheel need to rotated to 
loosen the bar. This will allow the user to readjust the loose bar, and straighten it, reducing the excess 
resistance. Once the primary extrusion bar has been realigned, fix and tighten all the loose pieces, and 
reset the system. 
14. Parts List 
All Solidworks parts and assemblies are in a folder labeled “LACEY Parts Files”. The final 3D printed 
parts are in a folder within that folder labeled "Printed Parts". Previous versions during development as 
well as STL files used to print are included as well for reference or for future modification.  
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Prepared by Meagan Carnes 
Fibrin Composite Scaffold Fabrication Protocol  
Objective: Record current procedure for making fibrin films 
Materials: 
·       Fibrinogen aliquot ((11 mg/mL) Ref #MO1:26 
·       Thrombin aliquot (2.35 U/mL) Ref #MO1:26 
·       40 mM CaCl2 
·       PBS 
·      Silicone wafer with gradient pattern 
·       di H20 
·       Vellum paper 
·       Ruler (with millimeter markings) 
·       Scissors 
·       Razor Blade 
Procedures: 
Prep of Vellum Frame for Film 
1.       With vellum paper, measure a strip 12 mm wide and cut strip from sheet 
2.       Along strip, mark every 12 mm lengthwise and cut along markings, 
creating 12x12mm squares 
3.       On a hard surface, use razor blade to cut squares centers from the 12x12 
square so that there is a 2mm thick border on all sides leaving an inner area of 
100 mm^2 
4.       The distance from inner edge to inner edge on each frame should be 
10mm across horizontally and vertically when finished 
Prep of Frame with Threads 
1. Follow protocol to make fibrin threads using Lacey 
2. After drying overnight, align 5 threads on clear plastic sheet taped at each 
end and ensure that the total width is around 9mm 
3. Place about 12 vellum frames underneath the bundle and be sure to leave 
space to cut in between each one 
4. Use medical adhesive glue and a blunt needle tip to glue the threads to each 
side of the frame 
5. Allow to dry for 1 hour or until glue is hard 
6. Starting at one end, cut frames from bundle and remove excess threads from 
the side of the frame.  
Prep of Fibrin Gel (from Fibrin Gel Basic Protocol – MO) 
1.       Prep Patterned Silicone wafer slide by soaking in 1% Pluronics F-127 in 
enough volume to cover the wafers for at least 15 min and allow to air dry 
(sterilize with ethanol if necessary[MO2] ) 
2.       Mix the following reagents in a 1.5 mL centrifuge tube 
a.       670 uL fibrinogen solution (2x solution) 
b.       80 uL CaCl2 (40mM) 
c.       150 uL PBS (or cell media if using cells) 
3.       Add 100 uL thrombin solution and titrate (at least 10x) to gently mix with other reagents in 
centrifuge tube 
4.       For a standard 10x10mm film frame: 
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a.       Pipette 200 uL of mixed solution onto silicone wafer with 
frame 
b.       Use pipette tip to submerge frame edges into solution 
5.      Allow 30 minutes for polymerization 
Prep of Fibrin Film 
1.       Use forceps to place composite in diH20 bath (room temp) for 10 
minutes 
 a. 5 scaffolds in 125 mL bath is ideal volume 
2.       Switch frame into fresh water bath for 10 minutes 
3.       Switch frame into final water bath for 10 minutes 
4.       Remove from water bath and place onto acetyl plastic slide to dry completely for 5-6 hours 
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Resazurin Cell Viability Assay Protocol 
Objective: 
Determining the cellular viability on the composite scaffold.  
 
Total time: 2 hrs 50 min  
 
Materials:  
1. Resazurin stock 
2. 1 black 96 well plate (4 samples X 3 aliquots/sample x 1 timepoint) = 12 
wells needed 
3. Media 
4. Fluorescent plate reader 
5.  
Procedure: 
1. Make resazurin stock solution and warm for 10 minutes (20 min total)  
1. Add 500 uL stock to 2.5 mL complete media (both in fridge)  
2. Mix and place in water bath for 10 min  
2. Aspirate media from samples - hold down frames with forceps and keep pasteur pipette 
away from composites (5 min) 
3. Add 600 uL resazurin solution to each sample  (5 min) 
4. Incubate plate in cell culture for 2 hours (2 hours)  
5. Transfer 100 uL from each well to a black 96 well plate in triplicate (5 min) 
6. Read fluorescence with a plate reader (20 min) 
7. Record results using fluorescence or absorbance as follows:  
 
Fluorescence: Read fluorescence using a fluorescence excitation wavelength of 540–570 nm (peak excitation is 
570 nm). Read fluorescence emission at 580–610 nm (peak emission is 585 nm).  
 
Absorbance: Monitor the absorbance of resazurin at 570 nm, using 600 nm as a reference wavelength 
(normalized to the 600 nm value).  
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Note: Fluorescence mode measurements are more sensitive. When fluorescence instrumentation is unavailable, 
monitor the absorbance of resazurin reagent. Assay plates or tubes can be wrapped in foil, stored at 4°C, and 
read within 1–3 days without affecting the fluorescence or absorbance values.  
Laser Thickness Measurements 
Objective:  
Determining the thickness of gels, films, and composites. 
 
Materials: 
Laser displacement machine 
Acetyl Slide 
Gel, film, or composite to be measured 
 
Procedure: 
 
1. Power on and screw in metal plate with four screws to ensure that plate is evenly attached 
2. “Zero” the device 
3. Place acetyl slide across all four screws to ensure stability 
4. Record readout for acetyl voltage by aiming laser where no film or gel is present  
5. Move acetyl slide where laser is on gel or film and record voltage value 
6. Repeat three times on different locations of gel or film  
NOTE: Move the gel or film to different locations on the slide, but do not move acetyl slide, or 
else calibration will not be valid. 
7. Use sheet to record measurements called “Laser Displacement Measurements” 
8. Calculate thickness using the following equation: 
𝑆𝑎𝑚𝑝𝑙𝑒 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 (μm) =  
1000 ∗ 1.7 𝑚𝑚 (𝑎𝑐𝑒𝑡𝑎𝑙 𝑠𝑙𝑖𝑑𝑒) ∗ [𝐴𝑣𝑔. (𝑉) − 𝐴𝑐𝑒𝑡𝑎𝑙 (𝑉)]
𝐴𝑐𝑒𝑡𝑎𝑙 (𝑉)
 
 
Human FGF-2 Standard ABTS ELISA Protocol 
Phase 1: Coat plate with capture antibody  
 Centrifuge vial of capture antibody  
 Reconstitute capture antibody in sterile water to concentration of 100 ug/mL. Allow to 
reconstitute for 10 min minimum  
 Centrifuge reconstituted vial for 3 minutes at max speed 
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 Dilute capture antibody with 1X PBS to conc of 1 ug/mL. Vortex. 
 Add 100 uL to ELISA plate wells 
 Seal plate 
 Incubate at 25 C overnight  
 Discard liquid, blot on clean paper towl 
 Add 300 ul of wash buffer to each well then aspirate, 4x 
 After last wash, invert plate to remove liquid  
Phase 2: Blocking non-specific binding  
 BSA used as blocking buffer, 300 uL blocking buffer to each well 
 Seal plate 
 Incubate for 1 hr at RT 
Phase 3: Specific binding of antigen  
 Prior to end of previous incubation period, centrifuge vial of FGF-2 
 Reconstitute to 1 ug/mL using 1 mL sterile water for 10 min minimum  
 Rinse plate with wash buffer 4x, invert plate  
 Centrifuge reconstituted vial for 3 min at max speed 
 Dilute to conc of 2 ng/mL with dilutent, vortex 
Standard Curve 
 Add 100 ul of dilutent to each well except 1st row  
 Add 200 ul of standatd (2 ng/mL) to first row  
 Dilute 1:2 for each standard  
 Include at least 6 blank wells with only diluent  
 Each well should have 100 ul 
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 Add samples, 100 ul to remaining wells  
 Seal plate, incubate at lease 2 hours at RT 
Phase 4: Sandwich formation  
 Centrifuge and reconstitute detection antibody in 1 mL of sterile water to 100 ug/mL 
 Wash plate 4x, invert 
 Centrifuge 3 min at max speed and dilute with diluent to 0.25 ug/mL. Vortex. 
 Immediately add 100 uL to each well 
 Seal plate, incubate at RT for 2 hr 
Phase 5: Addition of enzyme-linked avidin-hrp to the sandwich  
 Let vial of avidin that to RT 
 Wash plate 4x, invert 
 Dilute 5.5 ul avidin 1:2000 in diluent for volume of 11 mL, mix solution 
 Immediately add 100 uL to each well 
 Incubate at RT, 30 min 
Phase 6: Conversion of colorless substrate to colored solution  
 Wash after incubation, 4x, invert 
o On last wash remove wash solution from well and add 100 ul of ABTS, watch for 
color change, if none continue. If color change, continue washing. 
 Add 100 ul ABTS to each well  
 Incubate at RT for color detection  
 Check plate every 5 min up to 60 mins 
 Read plate at 405 nm – every 5 minutes for 60 min 
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EDC/NHS Crosslinking with Heparin Protocol  
Materials:  
Sodium Phosphate Monobasic Monohydrate 
N-(3-Dimethylaminopropyl)-N-Ethylcarboiimide hydrochloride (EDC) 
N-Hydro-succinimide (NHS) 
Heparin 
 Create NaH2PO4 solution and pH to 7.4  
 Hydrate scaffolds in NaH2PO4 solution for at least 30 minutes  
 Add 0.0368 g of NHS, 0.1073 g EDC, and 0.002 g heparin to 20 mL of similar buffer – for 100 
ug/mL solution of heparin 
 Submerge scaffolds in EDC/NHS + heparin solution for 2 hours at room temperature 
 Remove the scaffolds from the solution  
 Rinse 3x 5 minutes each in dH2O  
Glycine Quenching Protocol 
-Create 0.25% solution of glycine in 1x PBS 
-Submerge scaffolds completely in 2mL of glycine per scaffold, 1 hour 
-Remove the scaffolds from the glycine solution 
-Rinse each scaffold 3 times, 5 min each in PBS  
Loading of FGF-2 Protocol 
 Block 12-well plate with 2mL of 1% BSA per well for at least 1 hour 
 Reconstitute FGF-2 to a concentration of 10 ng/mL 
 Make sure solution is properly mixed by vortexing  
 Submerge each scaffold in 1mL of FGF-2 solution  
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 Place on plate rocker for 24 hours 
Instron Testing Protocol 
Prepared by Meagan Carnes  
MATERIALS:  
From Pins lab:  
 From Instron room (in baggie on top of shelving): 
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INSTRUCTIONS – SETUP: 
Make sure the INSTRON is oriented on its side, where the actuator is parallel to the table. 
Place the short spacer ring and 6-hole base plate on the bottom base of 
the instron (opposite from the the actuating side). The “T” on the base 
plate should be oriented to the top. Secure this in place with two M8 
bolts. (use a hex wrench to secure these on) 
 
On the base plate, attach the transducer-base spacer. This is attached 
with a 1’ 6M bolt. NOTE – in this picture the “T” on the base plate is 
located on the side, rather than being oriented on top. Always orient 
the T to be facing on top. 
 
Attach the 1 N load cell to the transducer-base spacer. This is done by 
CAREFULLY threading the load cell onto the spacer. Thread the 
transducer until it is snug against the spacer. 
Plug in the transducer to the back of the instron. It is pugged in where 
it says “Load cell” underneath it. 
 
Attach the custom dremel connector onto the other end of 
the load cell CAREFULLY!! 
 
T 
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Take the stage with the small “U” kink and thread on a dremel collet and dremel end. Now with these 
components on the stage, thread the other end of the dremel connecter onto the dremel end to secure the 
stage onto the connector, and thus the load cell. 
 
 
 
 
 
 
 
 
The right hand side of the set up is now complete. 
Insert the custom dremel insert into the end of the actuator 
(left hand side of the setup) 
Insert the pin through the hole of the actuator piece and the 
custom dremel insert. Use the clip to hold either end of the 
pin in place through the aligned holes of the connector and 
actuator. 
 
Tighten the gold ring on the connector until it holds the 
connecter snug in place. 
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Place a dremel collet and dremel end over the stage 
with the longer “U” bend. 
 
Thread the dremel end onto the connector 
 
 
 
 
 
 
 
 
 
 
INSTRUCTIONS – COMPUTER SETUP AND CALIBRATION: 
Switch on the back of the large white INSTRON “computer,” located under the table 
Open Instron Console on the desktop 
***NOTE:  when calibrating the load cell, you want to calibrate it with the clips sitting on the stages*** 
 
Click:  
Load 
Calibration 
Calibration Wizard 
Restore from Disk 
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VT 1N load cell 02 Jan 2014 
Uncheck Lock calibration, Save calibration data 
Check that Load primary limits are 1.05 N, and position primary limits are 29 mm 
 
Open Bluehill from Desktop 
 
Click TEST 
Method: 170615fibrinscaffolds.im_tens 
Found in: \\research.wpi.edu\PinsLab\Anthony Campagna 
 
For filename, name it the DATE the testing was done, and any distinctive features 
Name each sample by the condition and the thread number 
Input measured diameter average from hydrated threads. 
“Next” takes you to the next test 
“Return” once you are done testing 
 
“RESET” allows you to reset gauge length (distance the stages will be apart)  
 Do this at the position where the velum is sitting well aligned on the two stages, so that at the end 
of each test you can return to this starting position. The distance the stages should be apart is 
approximately 2.0 mm 
 
“RETURN” allows you to return to the set gauge length. 
SAVING FILES: 
After 10 tests have been performed, the test will prompt you to save the work. 
It will then allow you to end all testing, or continue testing with the same test method. 
________________________________ 
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TO REPOSITION STAGES: 
 
To reposition the stages so they are the correct distance apart to place a velum frame: 
 
Loosen the black knob on top left of the the Instron to allow the whole system to move on the two large 
metal rungs. DO NOT FULLY REMOVE THE BLACK KNOB FROM THE MACHINE! 
 
Manually move the system using the grey remote controller, and the black toggle button. First, the system 
will have to be switched from “0” to “1” in order to move it 
 
After it is moved to the desired distance, resecure the black knob so it is tight 
 
SETTING UP VELLUM/THREAD: 
 
The stages (grey) are positioned apart so that the vellum frame (white) is positioned accordingly, where 
none of the film (blue) is on the stages. 
Clamps (red) are then placed to secure the vellum frame in place on the stages 
Before testing, the vellum frame is cut on both sides, indicated by dotted black lines in the figure below. 
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Top view of the vellum frame positioned on the stages. Dotted lines indicate where to cut the vellum 
frame 
*All testing of scaffolds was performed hydrated and submerged in a PBS bath* 
Alignment Analysis Protocol 
 Images the samples in a similar orientation as shown below. 
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 Load image into ImageJ by either dropping the file into the ImageJ tab or opening it 
through the ImageJ system as shown below. 
 
 Through the Analyze tab, set the scale of the image. 
 
 Using the Process tab make the image binary and then add a median filter with a 5 pixel 
radius exclusion rule. 
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 These filters will produce an image similar to the one below. 
 
 Then through the Process tab make the image watershed to isolate each cell image.  
 
 This will produce an image as seen below. 
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 Then use the Analyze tab and select ‘Set Measurments’. In the pop up window select ‘fit 
ellipse’. 
  
 Then using the Analyze tab click on ‘Analyze Particles’ and select display results and 
show elipses. The size textbox and cicularity settings can be changed depending on the 
size of the cells in the image. 
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 This will produce an image as shown below and a data file output. 
 
 Select the data in the pop-up window and transfer it to excel for data analysis.  
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Degradation Analysis Protocol 
 Image the samples using the Zeiss microscope in Page’s lab for the various timepoints as shown 
below. 
 
 
 After imaging all of the samples image a picture of a ruler for a scale image as shown below. This 
will allow for setting an accurate scale in ImageJ 
 
 First load the scale image into Image as shown by either going through the open tab and 
searching for the image file or dropping the file into the ImageJ tab. Then using the straight line 
bar feature to draw a line for the known distance. Then under the analyze tab click the set scale 
option. Then enter the appropriate known distance and unit to set the scale. Ensure to set global 
so that the scale is the same when assessing the sample images. This is shown below.  
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 Now that the scale is set, open the samples as shown and using the free form line feature, draw 
around the area that was degraded on the sample as shown below.
 
 Then under the analyze tab, select measure and it will calculate the area of the drawn shape. 
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Appendix I: Raw Data Table for Alignment Analysis  
Film 
 1  2  3  4 5 6 7  8  9 10 11 Total  
Bin Cell # Cell # 
Cell 
# Cell # 
Cell 
# Cell # Cell # Cell # Cell # Cell # Cell # Cell # % 
10 473 395 28 161 802 671 840 68 388 584 991 5401 13% 
20 406 352 28 142 702 663 709 40 353 522 872 4789 12% 
30 331 324 22 159 550 761 647 51 342 505 731 4423 11% 
40 287 345 21 166 516 812 550 36 403 532 703 4371 11% 
50 265 336 18 177 452 818 474 44 398 531 647 4160 10% 
60 215 370 21 174 481 762 466 42 413 565 676 4185 10% 
70 228 323 17 143 566 809 425 37 416 483 726 4173 10% 
80 204 311 11 162 666 695 415 36 445 484 839 4268 11% 
90 239 294 21 163 758 682 475 51 492 478 942 4595 11% 
Total 2648 3050 187 1447 5493 6673 5001 405 3650 4684 7127 40365  
 
Composite 
 
Sample 
1 
Sample 
2 
Sample 
3 
Sample 
4 
Sample 
5 
Sample 
6 
Sample 
7 
Sample 
8 
Sample 
9 Total  
Bin Cell # Cell # Cell # Cell # Cell # Cell # Cell # Cell # Cell # Cell # % 
10 70 289 111 1392 368 254 395 204 136 3219 15% 
20 30 273 74 1446 296 106 349 246 140 2960 14% 
30 46 245 70 1368 310 100 327 226 138 2830 13% 
40 29 204 64 1131 268 96 318 172 135 2417 11% 
50 22 196 60 857 217 100 324 267 135 2178 10% 
60 33 177 53 812 183 63 309 195 222 2047 9% 
70 40 212 47 796 200 88 257 199 205 2044 9% 
80 31 215 55 556 190 92 399 365 203 2106 10% 
90 25 135 81 583 186 129 389 152 187 1867 9% 
Total 326 1946 615 8941 2218 1028 3067 2026 1501 21668  
 
